Page last updated: 2024-11-05

levonorgestrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13109
CHEMBL ID1389
CHEBI ID6443
CHEBI ID7630
CHEBI ID50901
SCHEMBL ID27597
MeSH IDM0025734

Synonyms (349)

Synonym
BIDD:PXR0194
MLS001074069
smr000653526
BRD-K35189033-001-03-0
gtpl2881
MLS000069491 ,
smr000059117
LMST02030119
13-ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one
norplant 2
einecs 229-433-5
brn 2391114
norgestrel [progestins]
17-beta-hydroxy-18-methyl-19-nor-17-alpha-pregn-4-en-20-yn-3-one
minivlar 30
(+-)-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(-)-
triphasil 21
e-gen-c
einecs 212-349-8
ccris 9033
hsdb 3595
levonorgestrel implants
postinor
ld norgestrel [french]
norplant
nordette 28
17alpha-ethynyl-13-ethyl-19-nortestosterone
microval
13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
follistrel
triagynon
dl-13-beta-ethyl-17-alpha-ethynyl-17-beta-hydroxygon-4-en-3-one
sh 70850
nordet
methylnorethindrone
nordette 21
18,19-dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-
ovranette
stediril 30
wy-3707
rigevidon 21+7
d-norgestrel
trinordiol 28
logynon ed
mirena
triciclor
dl-13-beta-ethyl-17-alpha-ethynyl-19-nortestosterone
microgynon 30 ed
norgestrelum [inn-latin]
ccris 6525
microgyn
microgest ed
neogynon 21
monovar
triquilar ed
trinordiol 21
norplant system in plastic container
triphasil 28
microgynon 21
microgynon 28
trifeme 28
tri-levlen 21
levora-28
neogest
fh 122-a
microlut
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-
levonova
hsdb 6483
norplant ii
18,19-dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (+-)-
ovoplex 30-150
13beta-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
ovral-lo
preven
levora-21
trigoa
microgynon cd
levonorgestrelum [inn-latin]
wy-5104
13-ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one
levlen ed
plan b
sh 850
jadelle
microlution
wy 3707
monofeme 28
19-nortestosterone, 17-ethynyl-18-methyl-
PRESTWICK3_000773
PRESTWICK_109
norgestrel-(-)-d
cas-797-63-7
PRESTWICK2_000773
BPBIO1_000932
norlevo
BSPBIO_000846
CHEBI:6443 ,
CHEBI:7630 ,
levonorgestrelum
17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one
levonelle
norgestrelum
ld norgestrel
microluton
levonorgestrel
797-63-7
C08149
(-)-norgestrel
C08153
(+-)-norgestrel
MLS000759484
18-methylnorethisterone
18-methyl-17-alpha-ethynyl-19-nortestosterone
13-beta-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one
17alpha-ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-ethynyl-18-homo-19-nortestosterone
13-ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
(-)-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
17-alpha-ethynyl-13-ethyl-19-nortestosterone
17-ethynyl-18-methyl-19-nortestosterone
DB00367
17alpha-ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
13-ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
d(-)-norgestrel
17-alpha-ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
NCGC00159349-02
skyla (tn)
levonorgestrel (jan/usp/inn)
norgestrel (jp17/usp/inn)
D00954
ovrette (tn)
D00950
mirena (tn)
norplant (tn)
(-)-norgestrel, 98%
PRESTWICK1_000773
PRESTWICK0_000773
SPBIO_002785
NCGC00159349-03
dl norgestrel
dl-norgestrel
HMS2051M08
HMS2090O06
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
norgestrel (-)-form
norgestrel, (-)-
CHEMBL1389
bay86-5028
[(-)-13-ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one
nsc-744007
[18,(17.alpha.)-(-)-]
nsc744007
HMS1570K08
HMS2097K08
N0889
(-)-17alpha-ethynyl-18-methyl-19-nortestosterone
(-)-levonorgestrel
(-)-18,19-dinor-13beta-ethyl-17beta-hydroxy-4-pregnen-20-yn-3-one
tox21_303623
cas-6533-00-2
dtxcid1016496
NCGC00257283-01
dtxcid401079284
NCGC00256735-01
dtxsid3047477 ,
tox21_303658
dtxsid3036496 ,
tox21_202872
tox21_111593
NCGC00260418-01
nsc-757251
MLS001423967
alpha-norgestrel
HMS2232H06
HMS2232K12
fh-122a
sh-850
sh-70850
CCG-100853
norgestrel [usan:usp:inn:ban:jan]
nsc 757251
unii-3j8q1747z2
3j8q1747z2 ,
BCP9000852
lng ,
bdbm50410522
lng-ius
nsc 759653
levonorgestrel [usan:usp:inn:ban]
5w7sia7yzw ,
levosert
fallback solo
intrauterine levonorgestrel
levonorgestrel implant
unii-5w7sia7yzw
plan b one-step
nsc 744007
bay 86-5028
levogel
kyleena
13-ethyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one
next choice
plan b one step
oral levonorgestrel
liletta
skyla
kurvelo component levonorgestrel
lybrel component levonorgestrel
myzilra component levonorgestrel
levonorgestrel component of seasonique
enpresse component levonorgestrel
aviane component levonorgestrel
levonorgestrel component of kyleena
plastic iud with levonorgestrel
climara pro component levonorgestrel
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-(-)-
twirla component levonorgestrel
(-)-13-ethyl-17-hydroxy-18,19-dinor-17.alpha.-pregn-4-en-20-yn-3-one
norgestimate impurity b [ep impurity]
levonorgestrel component of quasense
introvale component levonorgestrel
levonorgestrel [usp monograph]
nordette component levonorgestrel
levonorgestrel component of seasonale
levonorgestrel component of twirla
levonorgestrel [hsdb]
loseasonique component levonorgestrel
seasonale component levonorgestrel
norgestrel (-)-form [mi]
portia component levonorgestrel
quasense component levonorgestrel
afirmelle component levonorgestrel
levonorgestrel component of loseasonique
levonorgestrel [inn]
levonorgestrel component of alesse
preven component levonorgestrel
levonorgestrel [who-dd]
levonest component levonorgestrel
levonorgestrel component of levonest
triphasil component levonorgestrel
quartette component levonorgestrel
levonorgestrel [jan]
levonorgestrel component of setlakin
trivora component levonorgestrel
altavera component levonorgestrel
levonorgestrel [mart.]
seasonique component levonorgestrel
levonorgestrel component of altavera
levonorgestrel [vandf]
implant with levonorgestrel
levonorgestrel [ep monograph]
levonorgestrel [orange book]
levonorgestrel component of introvale
levonorgestrel component of preven
levlite component levonorgestrel
alesse component levonorgestrel
levonorgestrel component of levlite
elifemme component levonorgestrel
levonorgestrelum [who-ip latin]
levonorgestrel [who-ip]
lessina component levonorgestrel
levora component levonorgestrel
orsythia component levonorgestrel
opcicon one-step component levonorgestrel
marlissa component levonorgestrel
vienva component levonorgestrel
kyleena component levonorgestrel
levonorgestrel component of opcicon one-step
levonorgestrel [usp impurity]
levonorgestrel component of lybrel
levonorgestrel [usp-rs]
setlakin component levonorgestrel
levonorgestrel [usan]
levonorgestrel component of climara pro
1LHV
S1727
AKOS015894913
S5709
13beta-ethyl-17alpha-ethynyl-17-hydroxy-gon-4-en-3-one
WWYNJERNGUHSAO-XUDSTZEESA-N
13-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13beta-ethyl-17alpha-ethynyl-17beta-hydroxy-gon-4-en-3-one
HY-B0257
L-4455
NC00103
SCHEMBL27597
tox21_111593_1
NCGC00159349-05
norgestrel [usan]
norgestrel [orange book]
norgestrel [hsdb]
norgestrel [ep monograph]
norgestrel [vandf]
norgestrel component of ovral
norgestrel [jan]
cryselle component norgestrel
norgestrel [who-dd]
(+/-)-13-ethyl-17-hydroxy-18,19-dinor-17.alpha.-pregn-4-en-20-yn-3-one
ovral component norgestrel
norgestrel [mi]
norgestrel [usp-rs]
norgestrel [usp monograph]
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-(+/-)-
norgestrel component of cryselle
norgestrel [mart.]
norgestrel [inn]
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-yn-3-one
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3h-cyclopenta[a]phenanthren-3-one
HMS3649J10
OPERA_ID_552
mfcd00199013
sr-01000759218
SR-01000759218-5
levonorgestrel, united states pharmacopeia (usp) reference standard
levonorgestrel, european pharmacopoeia (ep) reference standard
EN300-122613
(1r,3as,3br,9ar,9bs,11as)-11a-ethyl-1-ethynyl-1-hydroxy-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
levonorgestrel for system suitability 2, european pharmacopoeia (ep) reference standard
levonorgestrel, pharmaceutical secondary standard; certified reference material
d(-)-norgestrel, analytical standard
HMS3714K08
levonorgestrel, british pharmacopoeia (bp) reference standard
(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3h-cyclopenta[a]phenanthren-3-one (non-preferred name)
Q416950
Z1544404028
levonorgestrel (levonelle)
levonorgestrel(levonelle)
sr-01000946725
SR-01000946725-1
HMS3886K18
AMY40476
rel-(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
levonorgestrel 100 microg/ml in acetonitrile
levonorgestrel for system suitability 2
levonorgestrel for system suitability 1
norgestrel (usp-rs)
dl-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20- yn-3-one
opill
chebi:50901
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+/-)-
norgestrel (usp monograph)
(17alpha)-dl-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3- one
norgestrel (mart.)
norgestrel (ep monograph)
(+/-)-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one

Research Excerpts

Overview

Levonorgestrel (LNG) is a progesterone receptor agonist used in both regular and emergency hormonal contraception. Its effects on the endometrium as a contraceptive remain widely unknown and under public debate. Levonorgstrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial cancer in obese women.

ExcerptReferenceRelevance
"Levonorgestrel is an EC pill, which has been only approved in Japan; it is more effective the sooner it is used after intercourse and safe without serious side effects."( [Preparation, Confidence, and Attitude to Sell Emergency Contraceptive Pills at Pharmacies: A Web Survey of Japanese Community Pharmacists].
Abe, K; Ikeda, Y; Nakayama, T; Nishimura, A; Okada, H; Suzuki, S, 2021
)
1.34
"This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use."( Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system.
Creinin, MD; Gangestad, A; Keder, LM; Olariu, AI; Teal, SB; Westhoff, CL, 2020
)
1.32
"Levonorgestrel (LNG) is a progesterone receptor agonist used in both regular and emergency hormonal contraception; however, its effects on the endometrium as a contraceptive remain widely unknown and under public debate."( Analysis of the Endometrial Transcriptome at the Time of Implantation in Women Receiving a Single Post-Ovulatory Dose of Levonorgestrel or Mifepristone.
Barrios-Hernández, AE; Durand-Carbajal, M; Larrea, F; Vega, CC, 2020
)
2.21
"Levonorgestrel is a synthetic gestagen commonly used in medicinal products for contraception."( Effects of the Gestagen Levonorgestrel in a Life Cycle Test with Zebrafish (Danio rerio).
Böhmer, W; Länge, R; Schäfers, C; Schaudien, D; Teigeler, M, 2022
)
1.75
"Levonorgestrel (LNG) is a commonly used emergency contraceptive which can effect sex hormone levels in female blood. "( Simultaneous determination of levonorgestrel and two endogenous sex hormones in human plasma based on LC-MS/MS.
Tian, Y; Wang, R; Zhang, L; Zhang, Z, 2016
)
2.17
"The levonorgestrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial cancer in obese women."( Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis.
Chino, J; Dottino, JA; Hasselblad, V; Havrilesky, LJ; Myers, ER; Secord, AA, 2016
)
2.44
"Levonorgestrel is a superior option to the Yuzpe regimen and should be promoted as the recommended ECP. "( A randomized clinical trial of two emergency contraceptive pill regimens in a Ugandan population.
Byamugisha, JK; Faxelid, E; Gemzell-Danielsson, K; Mirembe, FM; Tumwesigye, NM, 2010
)
1.8
"Levonorgestrel is an effective method for emergency contraception (EC) and is used worldwide. "( Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials.
Kapp, N; Piaggio, G; von Hertzen, H, 2011
)
2.05
"Levonorgestrel is a synthetic progesterone commonly used in pharmaceuticals (e.g., in contraceptives). "( Disrupted oogenesis in the frog Xenopus tropicalis after exposure to environmental progestin concentrations.
Berg, C; Fick, J; Norder, A; Säfholm, M, 2012
)
1.82
"Levonorgestrel is a commonly used progestin-only contraceptive that is available as subdermal (Norplant) and intrauterine implants. "( Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover.
Farmer, SE; Glew, RH; Imade, GE; Sagay, AS; Vanderjagt, DJ, 2005
)
1.77
"The levonorgestrel (LNG)-IUS is a T-shaped device that releases the progestogen LNG directly into the uterine cavity."( Medicated intrauterine systems for treatment of endometriosis-associated pain.
Muzii, L,
)
0.61
"Levonorgestrel 1.5 mg acts as an emergency contraception by delaying the LH surge and interfering with ovulation. "( Effect of single administration of levonorgestrel on the menstrual cycle.
Adeleye, OA; Arowojolu, AO; Dada, OA; Odusoga, OL; Okewole, IA; Oloyede, OA; Salu, J, 2007
)
2.06
"Levonorgestrel is a synthetic progestin, widely used in combination oral contraceptives and in single-agent "mini-pills"."( Norplant: systemic immunological complications--case report.
Brautbar, N; Campbell, A,
)
0.85
"The levonorgestrel-releasing IUD is a useful alternative mode of progestin administration for certain selected women receiving estrogen replacement therapy."( Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Apaja-Sarkkinen, MA; Kauppila, AJ; Laatikainen, TJ; Lahti, EI; Raudaskoski, TH, 1995
)
1.07
"Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use."( Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women.
Alvarez, F; Brache, V; Cochon, L; Faundes, A; Johansson, E; Kumar, N; Lovern, M; Ranta, S, 2002
)
2.01
"Levonorgestrel (LNG) is a synthetic steroid that displays potent progestational and androgenic effects but it lacks estrogen-like activity. "( Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs.
Chávez, BA; Damsky, R; García, GA; Grillasca, I; Lemus, AE; Pérez-Palacios, G; Vilchis, F, 1992
)
2.04

Effects

Levonorgestrel generally has an effect on the ovaries just during the 1st year of use. It has an inhibitory effect on sex hormone binding globulin (SHBG)

Oral levonorgestrel has antiglucocorticoid but no antioxidant activity. No information is available on the effect of the levonormestrel-releasing intrauterine system (LNG-IUS) on endothelial dysfunction. Levonormer has similar effectiveness to mid-dose or low-dose mifepristone.

ExcerptReferenceRelevance
"Levonorgestrel generally has an effect on the ovaries just during the 1st year of use."( The levonorgestrel-releasing intrauterine device.
Toivonen, J, 1994
)
1.57
"Levonorgestrel has an inhibitory effect on sex hormone binding globulin (SHBG). "( Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
Alvarez, F; Brache, V; Cochon, L; Faundes, A; Tejada, AS, 1998
)
2.01
"Oral levonorgestrel has been linked to increased cardiovascular risk, but currently, no information is available on the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on endothelial dysfunction. "( Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Hussein, AF; Selim, MF, 2013
)
1.18
"Levonorgestrel generally has an effect on the ovaries just during the 1st year of use."( The levonorgestrel-releasing intrauterine device.
Toivonen, J, 1994
)
1.57
"Levonorgestrel has been preferred over norethindrone for some time because it is effective at a dose of .150 mcg compared to 1 mg for norethindrone, but some recent research suggests that even at a much smaller dose, levonorgestrel may cause more metabolic modifications than norethindrone."( [Choosing the right synthetic progestogen].
Rozenbaum, H, 1983
)
0.89
"Levonorgestrel has similar effectiveness to mid-dose (8 trials, RR: 1.64; 95% CI: 0.82 to 3.25) or low-dose (7 trials, RR: 1.38; 95% CI: 0.93 to 2.05) mifepristone."( Interventions for emergency contraception.
Cheng, L; Ezcurra, E; Gülmezoglu, AM; Look, PF; Oel, CJ; Piaggio, G, 2004
)
1.04
"Levonorgestrel (LNG) has been recently introduced on the Danish market. "( [Levonorgestrel IUD].
Forman, A; Skajaa, K, 1994
)
2.64
"Levonorgestrel has already been available to women in progestin-only and combined oral contraceptives, but the change in delivery method has made Norplant the most effective, reversible, long term contraceptive available."( Depot levonorgestrel (Norplant) use in teenagers.
Miller, M, 1993
)
1.39
"Levonorgestrel has antiglucocorticoid but no antioxidant activity."( The effect of RU 486 and related compounds on cultured macrophage differentiation and function.
Murphy, AA; Parthasarathy, S; Roberts, CP; Santanam, N, 1996
)
1.02
"Levonorgestrel has antiglucocorticoid but no antioxidant activity."( Regulation of monocyte to macrophage differentiation by antiglucocorticoids and antioxidants.
Murphy, AA; Parthasarathy, S; Roberts, CP; Santanam, N, 1998
)
1.02
"Levonorgestrel has an inhibitory effect on sex hormone binding globulin (SHBG). "( Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
Alvarez, F; Brache, V; Cochon, L; Faundes, A; Tejada, AS, 1998
)
2.01
"The levonorgestrel system has also been used successfully as part of hormone replacement therapy, as adjuvant therapy with tamoxifen, and as an alternative to hysterectomy for women with bleeding problems."( Noncontraceptive health benefits of intrauterine devices: a systematic review.
Grimes, DA; Hubacher, D, 2002
)
0.8

Treatment

Levonorgestrel treatment did not prevent follicular growth because there was no significant difference between treatment and control animals in the size of the dominant follicle at Day 25. Treatment with levonorgstrel did not affect the expression of these endometrial receptivity markers in contrast to mifepristone.

ExcerptReferenceRelevance
"Levonorgestrel treatment did not prevent follicular growth because there was no significant difference between treatment and control animals in the size of the dominant follicle at Day 25."( Effects of levonorgestrel on ovulation and oestrous behaviour in the female tammar wallaby.
Hynes, EF; Nave, CD; Renfree, MB; Shaw, G, 2007
)
1.45
"The levonorgestrel IUD treatment can replace approx."( Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea.
Römer, T, 2000
)
1.07
"Levonorgestrel-treated monkeys had normal serum LH and FSH levels, but low serum estradiol and progesterone levels."( Treatment of endometriosis in monkeys: effectiveness of continuous infusion of a gonadotropin-releasing hormone agonist compared to treatment with a progestational steroid.
Collins, DC; Gould, KG; Kessler, MJ; Mann, DR; Smith, MM, 1986
)
0.99
"Levonorgestrel treatment resulted in a significant reduction (26%) of hepatic microsomal glycerol-3-phosphate acyltransferase specific activity."( Effects of levonorgestrel on enzymes responsible for synthesis of triacylglycerols in rat liver.
Khokha, R; Possmayer, F; Walton, PA; Wolfe, B, 1987
)
1.38
"Treatment with levonorgestrel did not affect the expression of these endometrial receptivity markers in contrast to mifepristone."( Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model.
Andersson, KL; Bentin-Ley, U; Gemzell-Danielsson, K; Lalitkumar, PG; Meng, CX, 2009
)
1.1
"Treatment with levonorgestrel decreases the incidence of endometrial neoplasia in rabbits."( Reduced incidence of rabbit endometrial neoplasia with levonorgestrel implant.
Kirk, ME; Nisker, JA; Nunez-Troconis, JT, 1988
)
0.86

Toxicity

The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use. A cohort study was performed to compare the incidence of psychiatric adverse events between groups of women who were new users of levonorogestrel.

ExcerptReferenceRelevance
" Climacteric symptoms, Kupperman index scores and potential adverse progestogen effects were recorded before treatment and three times per month during therapy."( Progestogens: therapeutic and adverse effects in early post-menopausal women.
Christiansen, C; Marslew, U; Riis, B, 1991
)
0.28
" Despite the overall high level of acceptability, some important variations were found with respect to the sociodemographic characteristics, effectiveness, satisafction, and adverse experiences between the 2 groups of acceptors in the study centers."( Evaluation of safety, efficacy, and acceptability of NORPLANT implants in Sri Lanka.
Balogh, SA; Basnayake, S; Thapa, S,
)
0.13
" Neither clinical, functional nor morphological investigations revealed toxic side effects of the drugs on the liver, the kidneys, the bone marrow, or on blood clotting function."( Toxicity of the progestagen STS 557 compared to levonorgestrel in beagles after oral administration for 6 months.
Güttner, J; Hillesheim, HG; Hoffmann, H; Oettel, M, 1982
)
0.52
"Weight gain was the most frequently observed side-effect of Norplant in adolescents in this study."( Adolescents and Norplant: preliminary findings of side effects.
Davis, P; Hendon, A; Kozlowski, KJ; Rickert, VI, 1995
)
0.29
" The most frequent side effect was weight gain in 21 women (36."( [Norplant and its side effects].
Habib, ND; Joachim, A; Kato, K; Nielsen, P, 1995
)
0.29
" They wanted to ascertain whether insertion of Norplant in the immediate postpartum period was safe and well-tolerated."( Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance.
Harrison, FN; Laurent, S; Phemister, DA, 1995
)
0.29
"To describe serious adverse events in Norplant users from reports submitted to the Food and Drug Administration's (FDA) MedWatch Spontaneous Reporting System."( Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Green, L; Wysowski, DK, 1995
)
0.29
"Reports of certain serious adverse events in Norplant users in the United States from February 1991 to December 1993 were reviewed and analyzed."( Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Green, L; Wysowski, DK, 1995
)
0.29
" The most frequent side effect reported by both adolescents (71%) and adults (53%) was abnormal menstrual bleeding."( Patient satisfaction and side effects with levonorgestrel implant (Norplant) use in adolescents 18 years of age or younger.
Berenson, AB; Wiemann, CM, 1993
)
0.55
" About 49% of Norplant acceptors experienced at least 1 side effect in the first 6 months, primarily menstrual disorders, headache, vertigo, and nausea."( Acceptance, efficacy, and side effects of Norplant implants in four counties in north China.
Fang, H; Qiu, S; Smith, HL; Tu, P, 1997
)
0.3
" In 15,279 woman-months of experience accumulated with Norplant implants and 14,092 with Norplant-II implants, there were few adverse events reported."( A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II.
Alvarado, G; Bassol, S; Canto-de-Cetina, T; del Carmen Cravioto, M; Fuziwara, JL; Garza-Flores, J; Navarrete, T; Oropeza, G; Palma, Y; Pérez-Palacios, G; Santos-Yung, R; Valencia, J, 1997
)
0.3
" There were no serious adverse events related to treatment, and most adverse events were those commonly observed in clinical trials with oral contraceptives."( A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Albring, M; Bannemerschult, R; Brill, K; Fox, P; Hanker, JP; Wünsch, C, 1997
)
0.48
"4% of women discontinued OC use due to adverse events."( A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Albring, M; Bannemerschult, R; Brill, K; Fox, P; Hanker, JP; Wünsch, C, 1997
)
0.48
" There were indications, however, that both steroids were toxic to endometrial cells at concentrations of approximately 5 micrograms/ml, and both drugs showed signs of potential teratogenicity at 10 micrograms/ml."( In vitro cytotoxicity and teratogenicity of norethisterone and levonorgestrel released from hollow nylon monofilaments.
Gard, PR; Malhi, JS; Ostad, SN, 1998
)
0.54
" The frequency and pattern of adverse experiences were comparable for desogestrel 75 micrograms/day and levonorgestrel 30 micrograms/day."( A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progest
, 1998
)
0.71
"Desogestrel 75 micrograms/day is a reliable and safe progestogen-only pill with a contraceptive efficacy superior to levonorgestrel 30 micrograms/day."( A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progest
, 1998
)
0.71
"This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon; these aspects are compared for Implanon and Norplant, the six-capsule implant containing levonorgestrel."( An integrated analysis of nonmenstrual adverse events with Implanon.
Urbancsek, J, 1998
)
0.48
" There were no serious adverse effects."( Safety and effectiveness of hormonal postcoital contraception: a prospective study.
Armengol, J; Aura, M; Calaf, J; Cuberas, N; Espinós, JJ; Senosiain, R; Vanrell, C, 1999
)
0.3
"The combination of ethinylestradiol and levonorgestrel in low doses is an effective and safe method of postcoital contraception."( Safety and effectiveness of hormonal postcoital contraception: a prospective study.
Armengol, J; Aura, M; Calaf, J; Cuberas, N; Espinós, JJ; Senosiain, R; Vanrell, C, 1999
)
0.57
" The 2 most common adverse events cited as reasons for discontinuation were headache (2% of subjects) and metrorrhagia (2%)."( Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).
Archer, DF; DelConte, A; Maheux, R; O'Brien, FB, 1999
)
0.52
" The occurrence of adverse events was recorded at each visit."( Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.
Coney, P; DiGiovanna, JJ; Harrison, DD; Langley, RG; Washenik, K, 2001
)
0.31
" Adverse events were typical of hormonal contraception, and most were mild-to-moderate in severity and not treatment limiting."( Efficacy and safety of a transdermal contraceptive system.
Creasy, GW; Fisher, AC; Lenihan, JP; Meador, ML; Shangold, GA; Smallwood, GH, 2001
)
0.31
" The major side effect was irregular bleeding."( Efficacy and side effects of Norplant use in Thai women above the age of 35 years.
Intharasakda, P; Taneepanichskul, S, 2001
)
0.31
" Application-site reactions, vaginal hemorrhage, and breast pain were the most common adverse events reported with transdermal E2/LNG."( Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled t
Shulman, LP; Uhl, K; Yankov, V,
)
0.37
" Using the contraceptive pill administered by vaginal route is a safe method with fewer side effects and more acceptability when compared with the oral route."( Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route.
Faghihzadeh, S; Lamyian, M; Rajaei, L; Ziaei, S, 2002
)
0.31
" About 36% of Norplant users and 15% of Uniplant users reported non-menstrual adverse events, the commonest ones being pain/itching at the insertion site, unexplained low abdominal pains and clinically diagnosed pelvic inflammatory disease (PID)."( Nonmenstrual adverse events associated with subdermal contraceptive implants containing normegestrel and levonorgestrel.
Arowojolu, AO; Ladipo, OA, 2003
)
0.53
" There were no other serious adverse events reported."( Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Janssens, D; Vrijens, M; Weyers, S; Wildemeersch, D, 2005
)
0.56
" The simple and safe insertion procedure could be an advantage for use by nonspecialist providers such as nurses, midwives, general practitioners, and for those not inserting intrauterine devices regularly."( Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Janssens, D; Vrijens, M; Weyers, S; Wildemeersch, D, 2005
)
0.56
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Results suggest that drospirenone possesses a generally well-accepted side effect profile and resembles comparator oral progestogens in conferring endometrial protection with no significant effect on weight."( A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone.
Shulman, LP, 2006
)
0.53
"The analysis of adverse events revealed two crucial points for acceptability, compliance and continuation: poor cycle control and disturbance of sexual intercourse due to vaginal dryness and loss of desire."( Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.
Cagiano, R; Sabatini, R, 2006
)
0.33
" The most common side effect was intermenstrual spotting during the first 6 months, and 18 patients (28."( Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia.
Agarwal, N; Kriplani, A; Lal, S; Singh, BM, 2007
)
0.6
" However, a higher incidence of minor adverse effects such as breast tenderness and nausea were demonstrated when compared to oral contraceptive containing with ethinyl estradiol (EE) 30 microg and levonorgestrel 150 microg."( Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years.
Boonyarangkul, A; Taneepanichskul, S, 2007
)
0.53
" Safety assessments included physical examinations, laboratory evaluations and adverse event records."( Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
Archer, DF; Ballagh, SA; Grubb, GS; Kovalevsky, G, 2009
)
0.62
" Pearl index, adverse event (AE) incidence and bleeding profiles were assessed."( Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Apter, D; Constantine, GD; Emerich, J; Greven, K; Grubb, GS; Klasa-Mazurkiewicz, D; Melis, GB; Spaczynski, M; Spielmann, D; Teichmann, A, 2009
)
0.69
"Continuous LNG 90 mcg/EE 20 mcg was shown to be a safe and effective OC in this direct comparison to a cyclic OC."( Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Apter, D; Constantine, GD; Emerich, J; Greven, K; Grubb, GS; Klasa-Mazurkiewicz, D; Melis, GB; Spaczynski, M; Spielmann, D; Teichmann, A, 2009
)
0.69
"9%) prematurely discontinued the study: five due to an adverse event and seven due to other reasons (inclusive of loss to follow-up)."( Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study.
Boubli, L; Gemzell-Danielsson, K; Heikinheimo, O; Inki, P; Kunz, M; O'Flynn, M, 2010
)
0.61
" Cycle control and adverse events reported with this regimen were similar to those reported with other low-dose OCs."( The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
Kroll, R; Margolis, M; Reape, KZ, 2010
)
0.36
" In addition, the regimen was well tolerated and incidence of adverse events were consistent with what has been reported with other low-dose OCs."( The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
Kroll, R; Margolis, M; Reape, KZ, 2010
)
0.36
"Oral contraceptive pills (OCPs) are one of the most effective reversible and accessible contraceptives, and patient acceptance for their use depends partly on the unfavorable adverse effects."( A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran.
Kashanian, M; Shahpourian, F; Zare, O, 2010
)
0.64
" In light of these changes in regimens, clinicians may be seeking evidence that the new regimens are safe and will not result in unexpected adverse events."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
" We evaluated incidence of reported adverse events (AEs), rates of study discontinuation, and reported bleeding patterns."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
"This study demonstrated that the AE profile of the 91-day extended-regimen OC over 4 years was similar to that seen in the 1-year clinical trials, with no unexpected adverse events."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
" Primary end points included bleeding profile and adverse events."( Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Constantine, GD; Fortier, MP; Grubb, GS; Mirkin, S; Reid, RL; Smith, L, 2010
)
0.62
" Adverse events were comparable to cyclic OC regimens, except unscheduled vaginal bleeding."( Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Constantine, GD; Fortier, MP; Grubb, GS; Mirkin, S; Reid, RL; Smith, L, 2010
)
0.62
"Ulipristal acetate (UPA), a selective progesterone receptor modulator, when taken as a single 30-mg dose, is safe and effective for emergency contraception up to 5 days (120 h) following unprotected intercourse."( Ulipristal acetate: a new emergency contraceptive that is safe and more effective than levonorgestrel.
Fine, PM, 2011
)
0.59
"Describe characteristics, compliance, efficacy, and side effect profile of adolescents and young women who use intrauterine contraception (IC)."( Intrauterine contraception in adolescents and young women: a descriptive study of use, side effects, and compliance.
Correia, N; Lara-Torre, E; Spotswood, L; Weiss, PM, 2011
)
0.37
"5% of women reported at least one adverse event after taking E-LNG-ECP, and no serious adverse events were reported."( Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial.
Chen, QJ; Cheng, LN; Kang, JZ; Luo, YF; Wang, RP; Xiang, WP; Zhang, DK, 2011
)
0.67
"The study found that E-LNG-ECP was effective, safe and well tolerated as an OTC drug."( Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial.
Chen, QJ; Cheng, LN; Kang, JZ; Luo, YF; Wang, RP; Xiang, WP; Zhang, DK, 2011
)
0.67
"Pearl index, bleeding profile, ease/pain of placement/removal, adverse events."( A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
Apter, D; Gemzell-Danielsson, K; Schellschmidt, I, 2012
)
0.6
" During 3 years, 10 subjects in the LNG-IUS12 (2 women), LNG-IUS16 (3 women), and Mirena (5 women) groups reported serious adverse events, possibly related to study treatment."( A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
Apter, D; Gemzell-Danielsson, K; Schellschmidt, I, 2012
)
0.6
" Main outcome measures were adverse maternal and infant effects and continuation of breastfeeding."( Levonorgestrel used for emergency contraception during lactation-a prospective observational cohort study on maternal and infant safety.
Gilad, O; Klinger, G; Merlob, P; Polakow-Farkash, S; Stahl, B; Yogev, Y, 2013
)
1.83
" Maternal adverse effects were mainly vaginal bleeding, which was less frequent in the study vs."( Levonorgestrel used for emergency contraception during lactation-a prospective observational cohort study on maternal and infant safety.
Gilad, O; Klinger, G; Merlob, P; Polakow-Farkash, S; Stahl, B; Yogev, Y, 2013
)
1.83
" We conclude that antenatal insertion of subdermal contraceptive implants is very likely to be safe and ethically defensible where access to contraceptive services is poor."( Antenatal contraception - simple, feasible, but is it safe and ethical in resource-poor environments?
Compaore, G; Filippi, V; Meda, N; Pittrof, R; Somé, DA, 2013
)
0.39
" Overall low rates of adverse effects such as pain, bleeding, infection and perforation, are documented to occur in all studies regardless of the timing or route of IUC insertion."( Immediate post-partum initiation of intrauterine contraception and implants: a review of the safety and guidelines for use.
Black, KI; Mwalwanda, CS, 2013
)
0.39
" No serious adverse events were reported, and vaginal bleeding patterns were generally acceptable."( A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel.
Bahamondes, LG; Fine, PM; Ginde, SY; Halpern, V; Lendvay, A; Raymond, EG; Taylor, DJ; Wheeless, A, 2014
)
0.62
" Although the regimen was safe and generally acceptable, the study was challenged by slow enrollment and curtailed person-years of follow-up, resulting in poor precision for the estimated treatment effect."( A single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel.
Bahamondes, LG; Fine, PM; Ginde, SY; Halpern, V; Lendvay, A; Raymond, EG; Taylor, DJ; Wheeless, A, 2014
)
0.62
" Study outcomes were: one-year cumulative pregnancy and discontinuation rates; rates of insertion and removal complications; adverse event and side effect rates; reasons for discontinuation; and implant acceptability and satisfaction with clinic services."( Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: results from Kenya and Pakistan.
Azmat, SK; Chen, M; Feldblum, PJ; Hameed, W; Kuria, S; Lendvay, A; Otieno-Masaba, R; Shaikh, BT; Steiner, MJ; Wheeless, A, 2014
)
0.4
" Four serious adverse events occurred in Kenya and none occurred in Pakistan; one SAE (an ectopic pregnancy) was possibly related to Sino-implant (II)."( Effectiveness, safety and acceptability of Sino-implant (II) during the first year of use: results from Kenya and Pakistan.
Azmat, SK; Chen, M; Feldblum, PJ; Hameed, W; Kuria, S; Lendvay, A; Otieno-Masaba, R; Shaikh, BT; Steiner, MJ; Wheeless, A, 2014
)
0.4
" Efficacy was measured using the Pearl Index and the life-table method; safety and tolerability were assessed through reported adverse events (AEs)."( Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Howard, B; Hsieh, J; Kaunitz, AM; Portman, DJ; Ricciotti, N; Weiss, H, 2014
)
0.65
" Here, we reported one case of acute urticaria following Mirena® implantation to increase the awareness of possible adverse side effects associated with Mirena®."( Acute urticaria as a side effect of the Mirena® (levonorgestrel-releasing intrauterine system): a case report.
Chen, X; Wu, X; Zhu, H, 2014
)
0.66
" The main side effect was frequent menstrual irregularities."( A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception.
Al-Amin, MM; Rahman, MM; Reza, HM; Shohel, M; Uddin, MM; Zaman, A, 2014
)
0.63
"Treatment-emergent adverse events of 2% or greater in the LNG/EE contraceptive patch were nasopharyngitis (5."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42
"The LNG/EE contraceptive patch and combination oral contraceptives were well tolerated and associated with similar treatment-emergent adverse event incidences in obese and nonobese women."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42
"The LNG20 intrauterine system is highly effective and safe over 3 years of use in nulliparous and parous women."( Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Creinin, MD; Eisenberg, DL; Schreiber, CA; Teal, SB; Turok, DK; Westhoff, CL, 2015
)
0.68
"A new 52-mg levonorgestrel-releasing intrauterine system is effective and safe for nulliparous and parous women for at least 3 years."( Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
Creinin, MD; Eisenberg, DL; Schreiber, CA; Teal, SB; Turok, DK; Westhoff, CL, 2015
)
1.05
"31, respectively), safe and well tolerated."( The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Apter, D; Gemzell-Danielsson, K; Hauck, B; Nelson, A; Rosen, K; Rybowski, S; Schmelter, T, 2015
)
0.62
"LNG-IUS 8 and LNG-IUS 13 were highly effective, safe and well tolerated regardless of age or parity."( The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
Apter, D; Gemzell-Danielsson, K; Hauck, B; Nelson, A; Rosen, K; Rybowski, S; Schmelter, T, 2015
)
0.62
" To determine whether LNG, UPA or COC (Yuzpe) ECPs are safe for women with certain characteristics or medical conditions, we searched the PubMed and Cochrane databases for articles published from date of inception until May 2015 pertaining to the safety of LNG, UPA or Yuzpe ECP use."( Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception.
Curtis, KM; Jatlaoui, TC; Riley, H, 2016
)
0.78
" There were three reported severe adverse events and 102 other mild adverse events (most common were headache, nausea, abdominal and pelvic pain), with high recovery rate."( A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.
Bahamondes, L; Bahamondes, MV; Bartfai, G; Bito, T; Festin, MP; Gosavi, A; Habib, N; Kapp, N; Nguyen, TM; Singh, K; Thamkhantho, M, 2016
)
0.64
" Among women with medical conditions, no evidence was identified for the outcomes of interest, including serious adverse events or outcomes related to medical conditions."( The safety of Sino-implant (II) for women with medical conditions or other characteristics: a systematic review.
Curtis, KM; Phillips, SJ; Steyn, PS, 2016
)
0.43
"Evidence among healthy women suggests SI (II) is safe and had health outcomes similar to those of other levonorgestrel implants."( The safety of Sino-implant (II) for women with medical conditions or other characteristics: a systematic review.
Curtis, KM; Phillips, SJ; Steyn, PS, 2016
)
0.65
" We included studies of Cu-IUD or LNG-IUD users comparing IUD-specific (perforation, expulsion) and other contraceptive-related (infection, removal/cessation due to bleeding/pain and other adverse events) outcomes for breastfeeding vs."( The safety of intrauterine devices in breastfeeding women: a systematic review.
Berry-Bibee, EN; Curtis, KM; Jamieson, DJ; Jatlaoui, TC; Tepper, NK; Whiteman, MK, 2016
)
0.43
" Seven studies suggested that risks for other adverse events were similar or lower among breastfeeding vs."( The safety of intrauterine devices in breastfeeding women: a systematic review.
Berry-Bibee, EN; Curtis, KM; Jamieson, DJ; Jatlaoui, TC; Tepper, NK; Whiteman, MK, 2016
)
0.43
"Overall, risks for adverse events among IUD users, including expulsion, pain and removals, were similar or lower for breastfeeding women vs."( The safety of intrauterine devices in breastfeeding women: a systematic review.
Berry-Bibee, EN; Curtis, KM; Jamieson, DJ; Jatlaoui, TC; Tepper, NK; Whiteman, MK, 2016
)
0.43
"The objective was to determine the association between use of intrauterine devices (IUDs) by young women and risk of adverse outcomes."( The safety of intrauterine devices among young women: a systematic review.
Curtis, KM; Jatlaoui, TC; Riley, HEM, 2017
)
0.46
"Overall evidence suggests that the risk of adverse outcomes related to pregnancy, perforation, infection, heavy bleeding or removals for bleeding among young IUD users is low and may not be clinically meaningful."( The safety of intrauterine devices among young women: a systematic review.
Curtis, KM; Jatlaoui, TC; Riley, HEM, 2017
)
0.46
" Secondary outcomes included 3-year cumulative failure rate, treatment-emergent adverse events (TEAEs), discontinuation rate, bleeding profile and placement pain."( A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan, G; Kang, S; Lukkari-Lax, E; Ren, M; Roth, K; Shin, S; Weisberg, E, 2017
)
0.68
"9% due to adverse events."( A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan, G; Kang, S; Lukkari-Lax, E; Ren, M; Roth, K; Shin, S; Weisberg, E, 2017
)
0.68
" Providers were asked how safe they thought copper and levonorgestrel (LNG) IUDs were in postpartum women (very safe, safe, unsafe, very unsafe, and unsure)."( Healthcare Provider Attitudes of Safety of Intrauterine Devices in the Postpartum Period.
Curtis, KM; Jamieson, DJ; Mandel, MG; Marchbanks, PA; Rauh-Benoit, LA; Tepper, NK; Whiteman, MK; Zapata, LB, 2017
)
0.7
"To compare expulsions and adverse events (AEs) between immediate and delayed insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) following medical termination of pregnancy (MTOP)."( Expulsions and adverse events following immediate and later insertion of a levonorgestrel-releasing intrauterine system after medical termination of late first- and second-trimester pregnancy: a randomised controlled trial.
Heikinheimo, O; Korjamo, R; Mentula, M, 2017
)
0.91
", ulipristal acetate pills, levonorgestrel pills, and the copper-IUD), carry only mild side effects and serious adverse events are essentially unknown."( The safety of available and emerging options for emergency contraception.
Lee, JK; Schwarz, EB, 2017
)
0.75
" The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database."( Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Abe, J; Fukuda, A; Hane, Y; Hasegawa, S; Hatahira, H; Hirade, K; Kinosada, Y; Matsui, T; Motooka, Y; Naganuma, M; Nakamura, M; Sasaoka, S; Takahashi, Y, 2017
)
0.46
" For invertebrates, potential chronic toxicity was predicted in 53% of streams, punctuated in 12% of streams by acutely toxic exposures."( Complex mixtures of dissolved pesticides show potential aquatic toxicity in a synoptic study of Midwestern U.S. streams.
Hladik, ML; Mahler, BJ; Moran, PW; Nakagaki, N; Norman, JE; Nowell, LH; Sandstrom, MW; Schmidt, TS; Shoda, ME; Stone, WW; Van Metre, PC, 2018
)
0.48
"3%) and discomfort due to bleeding alterations and other adverse effects (25."( Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
Castillo Cañadas, AM; García Santos, F; Gómez García, MT; González de Merlo, G; González Mirasol, E; López Del Cerro, E; Serrano Diana, C, 2018
)
0.48
"A cohort study was performed to compare the incidence of psychiatric adverse events between groups of women who were new users of levonorgestrel-releasing and non-hormonal intrauterine devices."( Cohort Study of Psychiatric Adverse Events Following Exposure to Levonorgestrel-Containing Intrauterine Devices in UK General Practice.
Kurz, X; Morales, D; Pinheiro, L; Slattery, J, 2018
)
0.92
" We assessed safety by adverse events, colposcopy, vaginal microbiota, epithelial integrity, mucosal histology and immune cell numbers and phenotype, cervicovaginal [CV] cytokines and antimicrobial proteins and changes in systemic laboratory measurements, and LNG and TFV pharmacokinetics in multiple compartments."( Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D, 2018
)
0.68
" Potential barriers to IUC use in nulliparous women, particularly concerns around infection, significantly higher rates of device expulsion and adverse effects on fertility, do not appear to be justified."( Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review.
Bateson, D; Butcher, BE; Foran, T; Kovacs, G; O'Connor, V, 2018
)
0.48
" Discontinuation for adverse events occurred in 322 (18."( Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System.
Chen, BA; Creinin, MD; Kimble, T; Olariu, AI; Teal, SB; Turok, DK, 2019
)
0.77
" A minority of respondents correctly classified the progestin-only pill, depot medroxyprogesterone acetate, the etonogestrel implant, the levonorgestrel intrauterine system and the copper intrauterine device as safe to use during lactation [14/56 (25%), 24/56 (43%), 27/56 (48%), 19/55 (35%) and 9/55 (16%), respectively]."( An exploratory study of the perception of contraceptive safety and impact on lactation among postpartum nurses at Women and Infants Hospital in 2017.
Allen, RH; Cohen, KE; Has, P; Matteson, KA, 2019
)
0.72
"In 2017, concerns regarding adverse events (AEs) associated with the Mirena levonorgestrel intrauterine device were largely echoed in the media in France."( Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.
Béné, J; Bosco-Lévy, P; Gouraud, A; Gouverneur, A; Langlade, C; Miremont-Salamé, G; Pariente, A; Pérault-Pochat, MC, 2019
)
1.02
"To evaluate the efficacy and adverse effects of levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis."( [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis].
Chen, Z; Yang, H; Zhang, L; Zhang, X, 2019
)
1.05
" The efficacy and adverse effects were assessed."( [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis].
Chen, Z; Yang, H; Zhang, L; Zhang, X, 2019
)
0.8
"Mirena is effective and safe in the long term management of adenomyosis, but about one third patients may require further treatment because of the expulsion or ineffectiveness of Mirena."( [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis].
Chen, Z; Yang, H; Zhang, L; Zhang, X, 2019
)
0.8
" Main outcome measure The survey focused on the utilization of emergency contraceptives without a prescription in Germany, and on the pharmacists' experiences with (potential) problems and concerns regarding safe use."( Trends in dispensing oral emergency contraceptives and safety issues: a survey of German community pharmacists.
Freudewald, L; Ganso, M; Said, A; Schulz, M, 2019
)
0.51
"There is unmet need for male contraceptive options, but a recent injectable combination male contraceptive trial was terminated early due to adverse events (AEs)."( Assessing safety in hormonal male contraception: a critical appraisal of adverse events reported in a male contraceptive trial.
Abbe, C; Roxby, AC, 2020
)
0.56
" Adverse event rates remain low through 6 or more years of use."( Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system.
Creinin, MD; Gangestad, A; Keder, LM; Olariu, AI; Teal, SB; Westhoff, CL, 2020
)
0.8
"This levonorgestrel 52 mg IUS is a highly effective and safe contraceptive over 6 years of use."( Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system.
Creinin, MD; Gangestad, A; Keder, LM; Olariu, AI; Teal, SB; Westhoff, CL, 2020
)
1.32
"The levonorgestrel 52 mg IUS shows high 6-year contraceptive efficacy and a low rate of adverse events through 6 or more years of use."( Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system.
Creinin, MD; Gangestad, A; Keder, LM; Olariu, AI; Teal, SB; Westhoff, CL, 2020
)
1.36
"To systematically review the literature to determine if extended use of intrauterine devices, including the copper or levonorgestrel intrauterine device, beyond approved durations is effective and safe for preventing pregnancy."( Effectiveness and safety of extending intrauterine device duration: a systematic review.
Curtis, KM; Gaffield, ME; Roe, AH; Smith, RA; Ti, AJ; Whitehouse, KC, 2020
)
0.77
" Safety outcomes included adverse events and side effects that led to discontinuation."( Effectiveness and safety of extending intrauterine device duration: a systematic review.
Curtis, KM; Gaffield, ME; Roe, AH; Smith, RA; Ti, AJ; Whitehouse, KC, 2020
)
0.56
"The available evidence suggests that rates of pregnancy, adverse events, and discontinuation owing to side effects during the first 2 years of extended use of the 52 mg levonorgestrel intrauterine device and the T380A copper intrauterine device are low and comparable to rates during approved duration of use."( Effectiveness and safety of extending intrauterine device duration: a systematic review.
Curtis, KM; Gaffield, ME; Roe, AH; Smith, RA; Ti, AJ; Whitehouse, KC, 2020
)
0.75
"This systematic review and meta-analysis aimed to summarize current evidence regarding the adverse events, and their prevalence, reported during the use of oral levonorgestrel emergency contraceptives."( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.
Leelakanok, N; Methaneethorn, J, 2020
)
0.99
"Four electronic databases and the US FDA Adverse Event Reporting System (FAERS) Public Dashboard were searched."( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.
Leelakanok, N; Methaneethorn, J, 2020
)
0.8
"A total of 47 articles were included in this systematic review, from which it was shown that most of the adverse reactions were common and not serious."( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.
Leelakanok, N; Methaneethorn, J, 2020
)
0.8
"The most common adverse effects of levonorgestrel were not serious."( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.
Leelakanok, N; Methaneethorn, J, 2020
)
1.07
" There were 39 serious adverse events (SAEs); SAEs believed to be directly related to IUC use (n = 7) comprised 3 pelvic inflammatory disease (PID) cases and 4 pregnancies with IUC in place with no discernible trend by IUC arm."( Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Chen, PL; Hoover, DR; Jones, HE; Langwenya, N; Myer, L; Petro, G; Todd, CS, 2020
)
0.84
" The LNG-IUS appears to be a safe contraceptive with regard to HIV disease and may be a highly acceptable option for WLHIV."( Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Chen, PL; Hoover, DR; Jones, HE; Langwenya, N; Myer, L; Petro, G; Todd, CS, 2020
)
0.84
"The LNG-IUS is safe for women with hematologic disorders."( Safety and bleeding patterns of the levonorgestrel 52-mg intrauterine system among women with thrombosis or coagulopathy.
Bahamondes, L; Brull, EP; Fernandes, A; Juliato, CRT; Monteiro, I, 2020
)
0.83
" Sociodemographic and clinical baseline variables were measured, as well as patient perception of bleeding and the frequency of failure, amenorrhea, need for hysterectomy and adverse events, over a 12-month follow-up period."( [Safety and acceptability of the 52 mg levonorgestrel-releasing intrauterine system in women with abnormal uterine bleeding in an ambulatory care center in Bogotá, Colombia, 2012-2016].
Sandoval-Vivas, P, 2020
)
0.83
" A subjective perception of improvement in terms of bleeding volume and frequency of leave of absence or visits to the emergency department was found; 90 % of the patients had amenorrhea, and 6 % experienced adverse events."( [Safety and acceptability of the 52 mg levonorgestrel-releasing intrauterine system in women with abnormal uterine bleeding in an ambulatory care center in Bogotá, Colombia, 2012-2016].
Sandoval-Vivas, P, 2020
)
0.83
"The 52-mg levonorgestrel-releasing intrauterine system is a safe option for the management of abnormal uterine bleeding in women with normal uterine size and no submucosal endometrial abnormalities."( [Safety and acceptability of the 52 mg levonorgestrel-releasing intrauterine system in women with abnormal uterine bleeding in an ambulatory care center in Bogotá, Colombia, 2012-2016].
Sandoval-Vivas, P, 2020
)
1.23
" Food and Drug Administration's Adverse Event Reporting System by couse of CYP3A4-inducing drugs and route of administration for levonorgestrel and etonogestrel/desogestrel."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.83
" This study provides evidence from an Adverse Event Reporting System that CYP3A4-inducing medications increase the risk of unintended pregnancy for oral and implant contraceptives but not intrauterine or vaginal devices."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.62
"LNG-IUS for >5 years as a postoperative maintenance therapy for endometriosis patients is an effective and feasible treatment that shows significant effect on pain reduction with less systemic side effect compared with other types of treatment."( Long-term efficacy and safety of levonorgestrel-releasing intrauterine system as a maintenance treatment for endometriosis.
Jung, SH; Jung, YW; Kim, HY; Lee, KH; Lee, M; Song, HJ; Song, SY; Yoo, HJ, 2022
)
1
" We also evaluated bleeding outcomes and adverse events."( Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.
Jensen, JT; Kroll, R; Lukkari-Lax, E; Schulze, A; Serrani, M; Wahdan, Y, 2022
)
0.98
" We found treatment-emergent adverse events in 249 of 362 participants (68."( Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.
Jensen, JT; Kroll, R; Lukkari-Lax, E; Schulze, A; Serrani, M; Wahdan, Y, 2022
)
0.98
" Safety was assessed by adverse events and changes from baseline in mucosal histology and immune mediators."( Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N, 2022
)
0.92
" Adverse events were those expected."( Bleeding profile and safety of a levonorgestrel 13.5 mg intrauterine device versus Nova T copper 380 mm
Bailón-Queiruga, M; Calaf-Alsina, J; Estadella-Tarriel, J; Gich-Saladich, I; Llurba-Olivé, E; Perelló-Capó, J, 2023
)
1.19
" After literature screening, data extraction and quality evaluation, effective rate, recurrence rate, pregnancy rate and adverse reaction rate were used as outcome indicators to evaluate the efficacy and safety of drugs."( Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis.
Ma, R; Mao, H; Wang, L; Xu, H; Zhang, L; Zhao, R; Zheng, Y, 2023
)
0.91
" Adverse reaction rate: the application of dienogest, leuprolide, danazol, gestrinone, mifepristone and LNG-IUS after EMT fertility preservation surgery was higher than that of placebo."( Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis.
Ma, R; Mao, H; Wang, L; Xu, H; Zhang, L; Zhao, R; Zheng, Y, 2023
)
0.91

Pharmacokinetics

The pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel (L-NOG) at an initial rate of 27 micrograms/24 h were studied in a group of 12 normally menstruating women during 90 days of continuous use. Serum concentration profiles and pharmacokinetics parameters (cmax, tmax, A UC24, AUC24,. AUC0-00, MRT) were obtained following administration of two combined oral contraceptives.

ExcerptReferenceRelevance
" This was derived from the pharmacokinetic parameters which were obtained after single dose administration."( Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle.
al-Yacoub, G; Fuhrmeister, A; Kuhnz, W, 1992
)
0.61
" At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
al-Yacoub, G; Fuhrmeister, A; Kuhnz, W, 1992
)
0.61
"Serum concentration profiles and pharmacokinetic parameters (cmax, tmax, AUC24, AUC0-00, MRT) of ethinylestradiol (EE2) and levonorgestrel (LNG) were obtained following administration of two combined oral contraceptives."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.76
"Serum concentration profiles and pharmacokinetic parameters of ethinyl estradiol (EE2) and levonorgestrel (LNG) were obtained after administration of 2 combined oral contraceptives (OCs)."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.77
" This increase was due to an increased dose of LNG according to the triphasic dose regimen, a concomitantly ethinylestradiol-induced increase in SHBG and due to pharmacokinetic accumulation, since LNG had a terminal half-life of approximately 28."( Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive.
al-Yacoub, G; Kuhnz, W, 1991
)
0.6
" Blood samples were collected at the end of each treatment month, assayed for EE and the half-life of elimination (Tel) and bioavailability (area under the serum concentration-time curve, AUC) calculated."( Intrasubject variability in the pharmacokinetics of ethynyloestradiol.
Fotherby, K, 1991
)
0.28
" The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1."( Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol.
Chiang, ST; Lobo, RA; Stanczyk, FZ; Woutersz, TB, 1990
)
0.5
"A pharmaceutical and pharmacokinetic study was carried out on levonorgestrel tablets from two different sources (Hungarian- and Chinese-made)."( Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel.
Fotherby, K; He, CH; Liao, DL; Matlin, SA; Shi, YE; Van Look, PF; Vince, PM; Xu, JQ; Zhu, YH, 1990
)
0.73
" This wide variability in the pharmacokinetic parameters, problems that arise in the derivation and interpretation of the parameters, the biologic significance of most of these parameters, and their lack of correlation with pharmacodynamic responses severely limit the usefulness of pharmacokinetic studies of the gestagens."( Pharmacokinetics of gestagens: some problems.
Fotherby, K, 1990
)
0.28
" The mean half-life of elimination, usually calculated using two-compartment open modeling, ranged from 8 to 18 hours."( Pharmacokinetics of gestagens: some problems.
Fotherby, K, 1990
)
0.28
" The predictive value of single-dose administration for the pharmacokinetic behavior of a progestin during long-term treatment was investigated for two triphasic oral contraceptives."( Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
Kuhnz, W, 1990
)
0.54
"Biotransformation, pharmacologic, and pharmacokinetic studies of norgestimate and its metabolites indicate that 17-deacetyl norgestimate, along with the parent drug, contributes to the biologic response."( Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites.
Flor, S; Hahn, DW; Kafrissen, ME; McGuire, JL; Phillips, A; Tolman, EL, 1990
)
0.28
" These differences in serum concentrations are determined by the different pharmacokinetic behaviour of the gestagens, which in turn is largely determined by their binding to serum proteins."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: (1) maximum serum concentration, (2) time to maximum serum concentration, (3) total area under the serum concentration versus time curve, and (4) serum half-life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: maximum serum concentration, time to maximum serum concentration, total area under the serum concentration vs time curve, and serum 1/2 life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
"Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women."( Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
Back, DJ; el-Raghy, I; Fathalla, M; Makeram, M; Orme, ML; Osman, F; Salem, H, 1986
)
0.27
" The volume of distribution was not significantly different in patients and controls; thus there was a tendency (nonsignificant) for the elimination half-life and area under curve after the intravenous dose to be less in the women with cystic fibrosis."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.27
"6 ml/hr/kg and the half-life was 19."( Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.
D'Ambrosio, R; Gardner, MJ; Jusko, WJ; Kanarkowski, R; Tornatore, KM, 1988
)
0.51
" The clearance of levonorgestrel was significantly lower in chronic OC users (mean elimination half-life of 30 hours) than in single-dose subjects (mean elimination half-life of 23 hours)."( Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.
D'Ambrosio, R; Gardner, MJ; Jusko, WJ; Kanarkowski, R; Tornatore, KM, 1988
)
0.84
" The time to peak (tmax) was significantly longer and the peak concentration (Cmax) significantly reduced following vaginal administration."( Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration.
Back, DJ; Grimmer, SF; Orme, ML; Rogers, S; Stevenson, PJ, 1987
)
0.56
" It was found that the levonorgestrel decay rate after implant removal can be entirely accounted assuming one half-life of 42 +/- 16 h (mean +/- SD; range 13 to 62 h)."( Clearance of levonorgestrel from the circulation following removal of NORPLANT subdermal implants.
Cárdenas, H; Croxatto, HB; Díaz, S; Johansson, ED; Larsson, M; Pavez, M, 1988
)
0.95
"Pharmacokinetic and pharmacodynamic effects of a vaginal ring releasing 20 micrograms/day levonorgestrel (L-NOG) have been studied in 15 women."( Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel.
Feng, DD; Xiao, BL; Zhang, XL, 1985
)
0.72
" Plasma levels of levonorgestrel at various intervals after dosing were analysed by a specific radioimmunoassay and its pharmacokinetic parameters were computed."( Pharmacokinetics of levonorgestrel in Indian women.
Madhavan Nair, K; Narasinga Rao, BS; Prema, K; Sivakumar, B, 1983
)
0.92
" Measurement by radioimmunoassay of plasma levonorgestrel has been used to compare the pharmacokinetic parameters of the drug after oral and intravenous administration in both control and liver-affected animals."( Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel.
Gommaa, AA; Osman, FH, 1983
)
0.76
" had any significant effect on plasma concentrations of EE2 or levonorgestrel or on any pharmacokinetic parameter determined."( Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine.
Back, DJ; Breckenridge, AM; Grimmer, SF; Orme, ML; Purba, HS, 1984
)
0.51
" Neither drug given 1 hour before the OC had any significant effect on pharmacokinetic concentrations of EE2 or levonorgestrel or on any pharmacokinetic parameter determined."( Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine.
Back, DJ; Breckenridge, AM; Grimmer, SF; Orme, ML; Purba, HS, 1984
)
0.48
" Significance of dose-dependent pharmacokinetic studies is discussed."( Effect of dose on the pharmacokinetics of levonorgestrel in the rat during the rapid elimination phase following subcutaneous administration.
Lindberg, MC; Mitra, SB; Naqvi, RH, 1984
)
0.53
"The pharmacokinetic and pharmacodynamic effects of vaginal devices releasing levonorgestrel (L-NOG) at a constant rate (in vitro release: approximately 20 micrograms/day) were studied in a group of 20 normally menstruating women during a period of 90 days of continuous use."( Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Diczfalusy, E; Johannisson, E; Landgren, BM; Masironi, B, 1982
)
0.72
" The mean maximum plasma levonorgestrel concentrations (Cmax), time to Cmax (tmax) and area under the plasma time-concentration curves (AUC(0,t)) did not differ between subjects given tenidap or placebo."( An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates, PE; Mesure, R, 1995
)
0.59
" There was no appreciable difference in mean maximum plasma levonorgestrel concentrations (Cmax), time to Cmax (tmax), and area under the plasma time-concentration curves (AUC[0,t]) between the tenidap group and the placebo group."( An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates, PE; Mesure, R, 1995
)
0.53
" Following single dose administration, a mean terminal half-life of 22 h was observed for LNG."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels i
Jütting, G; Kuhnz, W; Staks, T, 1994
)
0.61
" The mean terminal half-life for LNG was 22 hours."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels i
Jütting, G; Kuhnz, W; Staks, T, 1994
)
0.61
"Published values for the serum concentrations and pharmacokinetic parameters of levonorgestrel after administration of various doses of levonorgestrel alone or with ethinylestradiol are reviewed."( Levonorgestrel. Clinical pharmacokinetics.
Fotherby, K, 1995
)
1.96
"The pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel (L-NOG) at an initial rate of 27 micrograms/24 h were studied in a group of 12 normally menstruating women during 90 days of continuous use (i."( Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms/24 hours: a pilot study.
Aedo, AR; Cekan, SZ; Johannisson, E; Landgren, BM, 1994
)
0.75
" Mean Cmax and AUC values for norgestrel decreased by 12% and 10%, respectively, when administered with ABT-761."( Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
Awni, WM; Dube, LM; O'Dea, RF; Wong, SL, 1998
)
0.51
" These were assayed for ethinyloestradiol and levonorgestrel and the resulting data used to derive pharmacokinetic data for these steroids."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.57
"The mean AUC(0,24 h), Cmax and tmax for ethinyloestradiol and the mean AUC(0, 24 h) and Cmax for levonorgestrel during ziprasidone co-administration were not statistically significantly different from corresponding values occurring during placebo co-administration."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.52
"The findings of this study suggest that, based on pharmacokinetic and tolerability data, ziprasidone may be co-administered with ethinyloestradiol and levonorgestrel without loss of contraceptive efficacy or increased risk of adverse events."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.51
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.73
" There was no evidence of a pharmacokinetic interaction between tolterodine and the steroid hormones in the oral contraceptive used, nor did the oral contraceptive show any relevant pharmacokinetic interaction with tolterodine."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.51
"The plasma concentration-time curves and pharmacokinetic parameters of ethinyl estradiol and levonorgestrel were not statistically different during concomitant treatment with either levetiracetam or placebo."( Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
Janik, F; Levy, RH; Ragueneau-Majlessi, I, 2002
)
0.53
"Unlike oral contraceptives, HRT is not likely to have clinically significant pharmacokinetic interaction with selegiline."( Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Anttila, M; Laine, K; Nyman, L; Palovaara, S, 2002
)
0.54
" The clearance and volume of distribution of LNG decreased and the terminal half-life increased after repeated daily administration, compared with single administration."( A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Blode, H; Endrikat, J; Gerlinger, C; Kuhnz, W; Rosenbaum, P, 2002
)
0.53
"This paper discusses the pharmacokinetics of the vaginal application of levonorgestrel (LNG); its effect on the foundation of the ovary, and a pharmacokinetic comparison of oral administration and vaginal application of LNG, in order to develop a steroid contraceptive for external use and to identify the appropriate dosage."( [Pharmacokinetic and pharmacodynamic studies on vaginally administered levonorgestrel].
He, CH, 1991
)
0.75
"The mean values of the pharmacokinetic parameters AUC and Cmax of ethinylestradiol and levonorgestrel after multiple-dose treatment with losigamone or placebo were quite similar and met the criteria for bioequivalence."( Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
Dienel, A; Klement, S; Müller, F, 2004
)
0.55
" This study assessed the effect of alosetron co-administration on pharmacodynamic markers of contraceptive efficacy, on the pharmacokinetics of estrogen and progesterone OC components, and on the activity of biochemical markers for the risk of thrombosis."( Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
Ameen, VZ; Baidoo, CA; Campanella, C; Kersey, KE; Koch, K; Manzo, JA, 2004
)
0.32
" Comparable systemic exposure of EE and 17-DNE in the presence and absence of dexloxiglumide suggests that dexloxiglumide treatment is unlikely to interfere with the safety and efficacy of oral contraceptives based on the analysis of the resulting pharmacokinetic profile."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
" Interestingly, the half-life of levonorgestrel was shorter after oral administration (25 hours vs."( Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route.
Devoto, L; Espinoza, A; Fuentes, A; Kohen, P; Palomino, A; Ranta, S; von Hertzen, H, 2005
)
0.86
"The aim of this study was to evaluate the effect of solifenacin on the pharmacokinetic (PK) parameters of an oral contraceptive (OC) containing ethinyl estradiol (EE) and levonorgestrel (LNG)."( Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Krauwinkel, WJ; Kuipers, ME; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME; Visser, N, 2005
)
0.74
"To assess the pharmacokinetic and pharmacodynamic effects of co-administration of a combined oral contraceptive (ethinyloestradiol plus levonorgestrel) and lamotrigine."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.54
"Of the 22 enrolled subjects, 16 had evaluable pharmacokinetic data."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
"A clinically relevant pharmacokinetic interaction was observed during co-administration of a combined oral contraceptive and lamotrigine."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
" There was a trend for a larger volume of distribution divided by bioavailability (V/F), but there was no significant difference in the half-life of levonorgestrel in adolescents relative to adults (p=."( Pharmacokinetics of single-dose levonorgestrel in adolescents.
Darney, P; Harper, CC; Kim, L; Liu, CY; Raine, TR; Sambol, NC, 2006
)
0.82
" The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416."( Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route.
Ding, WX; Fu, Q; Piao, HS; Qi, XR, 2007
)
0.57
"This was a randomized double-blind pharmacokinetic study conducted in 12 subjects enrolled at two centers."( Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.
Brache, V; Croxatto, H; Faundes, A; Kumar, N; Kumar, S; Maguire, R; Montero, JC; Phillips, D; Salvatierra, AM; Sitruk-Ware, R, 2007
)
0.57
"7 nmol/L and Tmax was 12."( Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.
Brache, V; Croxatto, H; Faundes, A; Kumar, N; Kumar, S; Maguire, R; Montero, JC; Phillips, D; Salvatierra, AM; Sitruk-Ware, R, 2007
)
0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The validated LC-MS/MS method was successfully used in a pharmacokinetic study in healthy female volunteers after oral administration of 25 mg mifepristone tablet."( Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study.
Bi, HC; Chen, X; Huang, M; Huang, ZY; Tang, C; Zhong, GP, 2009
)
0.55
"This was a randomized, cross-over, pharmacokinetic study including an abstinence arm and an arm in which couples engaged in sexual intercourse between 2 and 4 h after gel application."( Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.
Brache, V; Cochón, L; Croxatto, H; Faundes, A; Kumar, N; Maguire, R; Muñoz, C; Schiappacasse, V; Sitruk-Ware, R; Sivin, I, 2009
)
0.61
" Pharmacokinetic parameters presented large variability between subjects, but excellent reproducibility within each subject."( Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.
Brache, V; Cochón, L; Croxatto, H; Faundes, A; Kumar, N; Maguire, R; Muñoz, C; Schiappacasse, V; Sitruk-Ware, R; Sivin, I, 2009
)
0.61
" The LNG half-life was significantly longer in the obese group (52."( Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
Cameron, JL; Carlson, NE; Cherala, G; Edelman, AB; Jensen, JT; Munar, MY; Stanczyk, FZ; Stouffer, RL, 2009
)
0.35
" Pharmacokinetic (PK) monitoring was conducted on Days 1, 21, 84 and 91."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" We sought to assess the pharmacodynamic effects of CBZ on breakthrough bleeding and ovulation during oral contraceptive (OC) use."( Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding.
Davis, AR; Stanczyk, FZ; Westhoff, CL, 2011
)
0.37
" Pharmacokinetic parameters were evaluated on cycle day 21, and endogenous hormones assayed on cycle days 1, 7, 14 and 21."( Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.
Butler, K; Teng, R, 2011
)
0.6
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
"This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate 250 mcg."( Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2012
)
0.94
" Single- (Day 8) and multiple-dose (Day 22) pharmacokinetic profiles were assessed for each treatment period."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
" Single-dose oral contraceptive administration 30 minutes after exenatide resulted in mean (90% CI) Cmax reductions of 46% (42-51%) and 41% (35-47%) for EE and LV, respectively."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive bioavailability and trough concentrations; however, for oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"Healthy HIV-negative subjects underwent 12 hr intensive pharmacokinetic (PK) sampling following single dose LNG alone and after 14 days of EFV."( Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.
Carten, ML; Cu-Uvin, S; Kiser, JJ; Kwara, A; Mawhinney, S, 2012
)
0.61
"This study compares the pharmacokinetic profile, adhesion and safety of the AG200-15 Agile Patch (AP), a novel contraceptive patch releasing low-dose ethinyl estradiol (EE) and levonorgestrel (LNG), during wear under external conditions of heat, humidity and exercise versus normal activities."( Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.58
" Blood samples were collected for pharmacokinetic evaluations."( Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.39
" This study determined whether application of the AP to three different anatomical sites (lower abdomen, buttock and upper torso) influences the pharmacokinetic profile of EE and levonorgestrel (LNG)."( Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.58
" For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites."( Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.39
" The pharmacokinetic parameters of area under the concentration-time curve (AUC), maximum steady-state plasma drug concentration (Cmax ), and time to maximum concentration (tmax ) were measured for the OC components and lacosamide."( Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello, W; Rosenkranz, B; Schmid, B; Wierich, W, 2013
)
0.6
" In each of the 31 volunteers who completed the trial (through cycle 3), pharmacodynamic assessment showed progesterone serum concentration was <5."( Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello, W; Rosenkranz, B; Schmid, B; Wierich, W, 2013
)
0.6
" There were no relevant changes in the time to reach peak levels (t (max,ss)) or terminal elimination half-life (t (½,ss)) of EE and LNG between test and reference treatments."( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013
)
0.61
" An analysis of variance (ANOVA) was used to test for differences between pharmacokinetic parameters of 30 μg ethinylestradiol and 150 μg levonorgestrel following ESL+OC and OC alone, and 90% confidence intervals (90%CI) for the ESL+OC/OC alone geometric mean ratio (GMR) were calculated."( Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.
Almeida, L; Falcão, A; Gama, H; Nunes, T; Soares-da-Silva, P; Vaz-da-Silva, M, 2013
)
0.81
" A high pharmacokinetic variability between volunteers was observed, but no statistical association of pharmacokinetic parameters was found within the studied CYP3A4/5 polymorphisms."( [Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study].
Cáceres, D; Catalán, J; Gaete, L; Miranda, C; Moreno, I; Quiñones, L; Roco, Á; Saavedra, I; Sasso, J; Tamayo, E; Tchernitchin, AN,
)
0.37
"Two open-label, randomized, two-period, crossover studies were performed to determine the safety, delivery rates, and pharmacokinetic properties of a combination estradiol (E2)/levonorgestrel (LNG) transdermal delivery system (TDS)."( Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Bourg, D; Bourg, L; Harrison, LI; Karara, AH; Melikian, AP; Morrison, D; Poola, N; Zurth, C, 2014
)
0.82
" A population pharmacokinetic (PK) model for EE was developed using nonlinear mixed-effects modeling to characterize the PK profile of EE administered in Quartette and other extended-regimen LNG/EE COCs."( A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Bond, M; Darwish, M; Fiedler-Kelly, J; Grasela, T; Hsieh, J; Ricciotti, N, 2014
)
0.4
"Pooled pharmacokinetic and pharmacodynamic analyses of phase II and III studies."( Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.
Apter, D; Gemzell-Danielsson, K; Hauck, B; Rosen, K; Zurth, C, 2014
)
0.68
"To determine if increasing the hormone dose or eliminating the hormone-free interval improves key pharmacokinetic (PK) alterations caused by obesity during oral contraceptive (OC) use."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2."( Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Elgadi, M; Huang, F; Lang, B; Sabo, JP, 2015
)
0.62
"We evaluated the potential pharmacokinetic interaction between pradigastat, a potent and selective diacylglycerol acyltransferase 1 inhibitor, and Levora-28®, a combination oral contraceptive (COC) containing 30 μg ethinylestradiol (EE) and 150 μg levonorgestrel (LVG)."( Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
Bhansali, S; Chen, J; Majumdar, T; Meyers, C; Neelakantham, S; Rebello, S; Sunkara, G; Trusley, C, 2015
)
0.6
" Plasma concentrations of EE and LNG were measured up to 72 hours post administration, and the PK parameters Cmax and AUClast were estimated using noncompartmental methods."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.62
"In conclusion, EE PK was unchanged, whereas Cmax and AUClast of LNG were 19% and 32% lower, respectively, when given with mavoglurant Further investigation regarding the impact on contraceptive efficacy is warranted."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.62
" This study was aimed to describe the pharmacokinetic characteristics of this new combination contraceptive tablet in female Chinese volunteers."( Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers.
Ding, L; Geng, T; Liu, X; Sun, C; Wu, Y; Xin, X, 2016
)
0.66
"This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus-infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20)."( Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016
)
0.68
" The total LNG Cmax for obese subjects following ECx1 (5."( Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.
Blue, SW; Cherala, G; Edelman, AB; Erikson, DW; Jensen, JT, 2016
)
0.69
"Obesity adversely impacts both the total and free Cmax levels of LNG EC and this likely explains its lack of efficacy in obese women."( Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.
Blue, SW; Cherala, G; Edelman, AB; Erikson, DW; Jensen, JT, 2016
)
0.69
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.64
" Mean half-life was similar in the presence and absence of tofacitinib: 13."( Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
Alvey, CW; Krishnaswami, S; Menon, S; Petit, W; Riese, R; Shi, H; Wang, R, 2016
)
0.43
" Confusing in some of the literature is that a few studies have reported erroneously calculated pharmacokinetic parameters after multiple dosing of oral contraceptives."( Clarification of contraceptive drug pharmacokinetics in obesity.
Jusko, WJ, 2017
)
0.46
" These studies evaluated the safety and pharmacokinetic interactions between elbasvir (EBR) and grazoprevir (GZR) and ethinyl estradiol/levonorgestrel (EE/LNG)."( No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Butterton, JR; Caro, L; Feng, HP; Guo, Z; Huang, X; Ma, J; Mangin, E; Marshall, WL; O'Reilly, TE; Panebianco, D; Talaty, J; Yeh, WW, 2017
)
0.85
"To investigate clinically applicable dose-adjustment strategies to overcome the known drug-drug interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK) modelling-based approach."( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018
)
0.89
" TFV pharmacodynamic activity was measured by evaluating CV fluid [CVF] and tissue for antiviral activity using in vitro models."( Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D, 2018
)
0.68
" Blood samples for pharmacokinetic profiling of laquinimod, EE and LNG were collected on day 21 and day 22 of Cycles 1 and 3 pre-dose and multiple times post-dose."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.71
"The combination of COC and laquinimod treatment was found to be safe, tolerable, and devoid of any noticeable pharmacokinetic interaction."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.71
" The harmonic mean terminal half-life for ethinylestradiol (7."( The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Feng, T; Friedman, A; Mohamed, MF; Othman, AA; Trueman, S, 2019
)
0.75
" Mean bioavailable LNG Cmax was lower in obese (7."( Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index.
Jusko, WJ; Molins, EAG; Natavio, M; Nelson, A; Stanczyk, FZ, 2019
)
0.8
"This is a multi-center, open label, phase 2 pharmacokinetic study performed at the University Hospital of Linköping and the Clinical Trials Center, Department of Obstetrics and Gynecology, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden."( Pharmacokinetics of Oral Levonorgestrel in Women After Roux-en-Y Gastric Bypass Surgery and in BMI-Matched Controls.
Ärlemalm, A; Böttiger, Y; Brynhildsen, J; Carlsson, B; Fagerberg-Silwer, J; Ginstman, C; Kopp Kallner, H, 2020
)
0.86
" We could not find any significant pharmacokinetic differences between the groups, suggesting that oral levonorgestrel may be used in non-obese women after Roux-en-Y gastric bypass once a stable body weight has been reached."( Pharmacokinetics of Oral Levonorgestrel in Women After Roux-en-Y Gastric Bypass Surgery and in BMI-Matched Controls.
Ärlemalm, A; Böttiger, Y; Brynhildsen, J; Carlsson, B; Fagerberg-Silwer, J; Ginstman, C; Kopp Kallner, H, 2020
)
1.08
" Serial blood samples were collected for pharmacokinetic analysis."( Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive.
Christmann, R; Naik, H; Tidemann-Miller, B; Versavel, M; Zhao, Y, 2020
)
0.56
"The pharmacokinetic (PK) evaluation in a subpopulation indicated that the steady-state concentration of plasma LNG was markedly lower in the participants in the USA compared to those in Japan suggesting non-compliance in the US participants which may explain a clearly higher Pearl Index (PI) in USA (8."( Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure.
Elliesen, J; Höchel, J; Kohnke, A; Mellinger, U; Nave, R; Schmitz, H, 2020
)
0.87
"An integrated population pharmacokinetic (popPK) analysis of data from over 3400 individuals in ten clinical studies with six different LNG-releasing contraceptives (four long-acting reversible contraceptives [LARCs: LNG-IUS 8, 12, and 20, initially releasing LNG 14, 17."( Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route.
Apter, D; Bitzer, J; Höchel, J; Hofmann, BM; Merz, M; Reinecke, I; Serrani, M, 2020
)
0.83
"To assess pharmacodynamic and pharmacokinetic outcomes of a novel copper (Cu) intrauterine system (IUS) releasing ulipristal acetate (UPA) in healthy women."( Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study.
Aprem, AS; Bagchi, IC; Blithe, DL; Brache, V; Cochon, L; Kannan, A; Kumar, N; Lansiaux, M; Loeven, D; Merkatz, R; Plagianos, M; Sitruk-Ware, R; Sussman, H; Tejada, AS; Vieira, CS; Williams, AR, 2021
)
0.62
" Pharmacokinetic data from 15 patients were analysed."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.93
"Two separate, parallel, three-group, non-randomized, pharmacokinetic studies evaluated either etonogestrel or levonorgestrel in women receiving rilpivirine- or darunavir-based ART compared with women without HIV (control group)."( Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Byakika-Kibwika, P; Chappell, CA; Fletcher, CV; Jeppson, J; Kaboggoza, J; Kyohairwe, I; Lamorde, M; Mbabazi, L; Musaazi, J; Nakalema, S; Nakijoba, R; Nassiwa, S; Pham, M; Scarsi, KK; Siccardi, M; Walimbwa, SI; Winchester, L, 2022
)
1.26
" Modeled TFV pharmacodynamic antiviral activity was evaluated in vaginal and rectal fluids and cervicovaginal tissue ex vivo."( Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N, 2022
)
0.92
"This study employed population pharmacokinetic (popPK) models to predict levonorgestrel (LNG) and ethinyl estradiol (EE) exposure after dosing with the transdermal contraceptive TWIRLA® (LNG/EE TDS) as a 12-week extended regimen in a healthy female population."( Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
Archer, DF; Korner, P; Lohmer, LRL; Pirone, J; Previtera, M; Stanczyk, FZ, 2022
)
1.27
"We estimated in vivo levonorgestrel (LNG) release rates and LNG plasma/serum concentrations for LNG-IUS 52mg up to 8 years of use with a population pharmacokinetic (popPK) approach using data from the Mirena Extension Trial (MET) and earlier clinical trials."( Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.
Hofmann, BM; Jensen, JT; Lukkari-Lax, E; Post, TM; Reinecke, I, 2023
)
1.58
" Levonorgestrel pharmacokinetic parameters were compared between groups using geometric mean ratios (GMR) with 90% confidence intervals."( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023
)
2.1
"5 mg to 3 mg improves levonorgestrel pharmacokinetic exposure in participants receiving either efavirenz-based antiretroviral regimens or rifampicin-containing tuberculosis therapy."( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023
)
1.5
" In this study, we report the findings from pharmacokinetic (PK) analyses undertaken with an LNG-IUS (LNG-IUS 8) modified with an additional reservoir containing indomethacin (IND)."( Development of an Intrauterine Device Releasing Both Indomethacin and Levonorgestrel During the First Months of Use: Pharmacokinetic Characterization in Healthy Women.
Ahola, M; Fels, LM; Hofmann, BM; Klein, S; Lindenthal, B; Pihlaja, J, 2023
)
1.14

Compound-Compound Interactions

The study concluded that 8 mg/kg testosterone buciclate would provide adequate androgen replacement when combined with 4mg/kg levonorgestrel butanoate as a putative male contraceptive regimen.

ExcerptReferenceRelevance
" Na+,K+ co-transport, measured as the ouabain-resistant, frusemide-sensitive component of 86Rb+ influx, and Na(+)-Na+ countertransport, measured as the ouabain-resistant, phloretin-sensitive component of 22Na+ influx, were both increased in women taking, on days 1-21 of their cycle, ethinyloestradiol (30-50 micrograms) combined with norethisterone (1000 micrograms or 500-1000 micrograms) for 3 or 6 months."( Effects of oral contraceptives containing oestrogen combined with norethisterone or levonorgestrel on erythrocyte cation transport in normal women.
Baber, R; Flemming, CL; Johnston, H; Jones, M; Monaghan, JC; Pinkerton, G; Stokes, GS, 1992
)
0.51
" The four groups receiving hormone replacement therapy were given 2 mg estradiol valerate equivalents (E), either sequentially combined with 75 micrograms levonorgestrel (E/LNG), 10 mg medroxyprogesterone acetate (E/MPA), or 150 micrograms desogestrel (E/DG), or continuously combined with 1 mg cyproterone acetate (E/CPA)."( Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Christiansen, C; Haarbo, J; Hassager, C; Jensen, SB; Riis, BJ, 1991
)
0.48
" In combination with EE, however, DG seems to counteract the effects of EE to a lesser extent than NORG, as judged particularly from the effects on TG and PL in serum and VLDL."( The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins.
Crona, N; Samsioe, G; Silfverstolpe, G, 1985
)
0.27
" In combination with EE, however, DG seems to be less "anti-oestrogenic" than NORG, as judged from the higher apo-AI and SHBG values after the combination DG + EE compared to those after NORG + EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.27
" In combination with EE, however, DG seems to be less antiestrogenic than NORG, as judged from the higher apo-AI and SHBG values after the combination of DG EE compared to those after NORG & EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.27
" It was concluded that 8 mg/kg testosterone buciclate would provide adequate androgen replacement when combined with 4 mg/kg levonorgestrel butanoate as a putative male contraceptive regimen."( A non-human primate study (baboon; Papio hamadryas) to determine if a long-acting progestogen, levonorgestrel butanoate, combined with a long-acting androgen, testosterone buciclate, can suppress spermatogenesis: I. Dose-finding study.
Butnev, VU; Goncharov, NP; Katzia, GV; Matikainen, T; Richkor, EG; Waites, GM, 1995
)
0.72
"3), were included in a single-center, non-comparative study to investigate the effect on inhibition of ovulation of an oral contraceptive containing 20 micrograms ethinylestradiol in combination with 100 micrograms levonorgestrel."( Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.
Brill, K; Feichtinger, W; Kindermann, C; Spona, J; Wünsch, C, 1996
)
0.71
" Women were randomized to either cyclical treatment with 2 mg of oral estradiol valerate in combination with 250 micrograms of levonorgestrel for the last ten days (Cyclo Progynova) or continuously with 2 mg estradiol valerate orally in combination with a 20 micrograms per 24 hour levonorgestrel releasing intrauterine device."( Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
Andersson, K; Mattsson, LA; Rybo, G; Samsioe, G; Stadberg, E,
)
0.61
"Our purpose was to compare the effects of a new estradiol-releasing vaginal ring with an oral progestin versus the efficacy, safety and acceptability of an intrauterine device releasing levonorgestrel combined with estradiol, delivered transdermally from a patch."( A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Antoniou, D; Antoniou, G; Giannikos, L; Kalogirou, D; Kalogirou, O; Karakitsos, P,
)
0.52
" One dose-reduced preparation contained 20 microg ethinylestradiol (EE) in combination with 100 microg levonorgestrel (LNG) (20/100) was compared with the reference preparation which contained 30 microg EE in combination with 150 microg LNG (30/150)."( A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density.
Düsterberg, B; Endrikat, J; Felsenberg, D; Gerlinger, C; Land, K; Mih, E; Schmidt, W, 2004
)
0.73
"To evaluate the acceptability and endometrial safety of a novel intrauterine drug delivery system, FibroPlant-levonorgestrel (LNG), combined with estrogen therapy (ET) in 150 peri- and postmenopausal women, followed-up for at least 3 years."( Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
de Wever, N; Janssens, D; Pylyser, K; Schacht, E; Wildemeersch, D, 2005
)
0.91
" In the majority of women, treatment with the FibroPlant-LNG intrauterine system (IUS), combined with ET, was initiated during the perimenopausal transitional phase to establish a smooth transition to menopause and suppress the endometrium to prevent endometrial proliferation and bleeding."( Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
de Wever, N; Janssens, D; Pylyser, K; Schacht, E; Wildemeersch, D, 2005
)
0.7
"To perform a pilot study of the effects on the breast by low-dose intrauterine progestogen combined with estrogen."( Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.
Azavedo, E; Lundström, E; Olovsson, M; Skoog, L; Söderqvist, G; Svane, G; von Schoultz, B; von Schoultz, E, 2006
)
0.55
"Women were treated with a low-dose intrauterine system releasing 20 microg/24 hours of levonorgestrel in continuous combination with 2 mg of oral E2 valerate."( Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.
Azavedo, E; Lundström, E; Olovsson, M; Skoog, L; Söderqvist, G; Svane, G; von Schoultz, B; von Schoultz, E, 2006
)
0.77
"Treatment with injectable testosterone undecanoate (TU) alone or in combination with oral levonorgestrel (LNG) resulted in marked decreases in sperm concentrations."( Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptive.
Cui, Y; Guo, X; Hikim, AS; Huo, R; Jia, Y; Lue, YH; Qian, L; Sha, J; Swerdloff, RS; Tong, J; Wang, C; Wang, X; Zhou, Z; Zhu, H; Zhu, Y, 2008
)
0.77
"To evaluate the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) combined with GnRH analogue (GnRH-a) in the treatment of adenomyosis with uterine body enlargement."( [Effect of levonorgestrel-releasing intrauterine system combined with GnRH analogue for treatment of large adenomyosis].
Gan, XQ; Ke, PQ; Wang, JH; Wang, NN; Zheng, QQ; Zheng, Z, 2010
)
1.05
"LNG-IUS combined with GnRH analogue injection can be effective in the treatment of adenomyosis with dysmenorrhea and hypermenorrhea."( [Effect of levonorgestrel-releasing intrauterine system combined with GnRH analogue for treatment of large adenomyosis].
Gan, XQ; Ke, PQ; Wang, JH; Wang, NN; Zheng, QQ; Zheng, Z, 2010
)
0.75
" The exposure of ethinylestradiol and levonorgestrel was similar when Microgynon® 30 was administered with or without dalcetrapib; for ethinylestradiol the geometric mean ratio %, (90% confidence interval (CI)) for AUC0-24 and Cmax were 92 (86 - 98) and 105 (95 - 115) and for levonorgestrel 92 (88 - 96) and 93 (87 - 99), respectively."( No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Anzures-Cabrera, J; Derks, M; Young, A, 2012
)
0.65
"The objective of this study was to evaluate the effect of three contraceptive pills containing ethinylestradiol (EE) (20 or 30 mcg) in combination with drospirenone (DRSP) and levonorgestrel (LNG) on plasma concentration of adhesion molecules vascular cell adhesion molecule -1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.91
"A cross-sectional study was conducted with 72 participants (18-30 years old) distributed into three groups that used oral contraceptives containing EE 20 or 30 mcg combined with DRSP 3 mg or EE 30 mcg/LNG 150 mcg for at least 6 months."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.72
" To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interaction study of fingolimod with ethinylestradiol/levonorgestrel was performed in healthy female volunteers."( Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David, OJ; den Daas, I; Emotte, C; Jakab, A; Meiser, K; Ocwieja, M; Schmouder, R; Wemer, J, 2012
)
0.57
"To comment on the acceptability and potential health benefits of the continuous use of the levonorgestrel-releasing intrauterine system (LNG-IUS), combined with estrogen substitution, for seamless transition through the menopause, in women with climacteric symptoms."( Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience.
Wildemeersch, D, 2013
)
0.61
"The combination of intrauterine progestogen delivery to suppress the endometrium, in combination with systemic estrogen, is highly acceptable resulting in a high continuation of use due to the absence of side effects and erratic bleeding in the large majority of women."( Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience.
Wildemeersch, D, 2013
)
0.39
"The study suggests that parenteral estrogen replacement therapy combined with intrauterine progestogen delivery for endometrial suppression in the perimenopause is highly practical and beneficial, providing enhanced quality of life."( Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience.
Wildemeersch, D, 2013
)
0.39
"Electrospun drug-eluting fabrics have enormous potential for the delivery of physicochemically diverse drugs in combination by controlling the underlying material chemistry and fabric microarchitecture."( Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.
Blakney, AK; Jiang, YH; Krogstad, EA; Woodrow, KA, 2014
)
0.4
" Finally, we showed that the drug-loaded nanofibers are noncytotoxic and that the antiviral activity of TFV is preserved through the electrospinning process and when combined with LNG."( Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.
Blakney, AK; Jiang, YH; Krogstad, EA; Woodrow, KA, 2014
)
0.4
"The aim of the study was to evaluate the efficacy of different dosages of estetrol (E4) combined with one of two progestins in suppressing the pituitary-ovarian axis and ovulation in healthy premenopausal women."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.64
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.64
"The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH)."( Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Cao, D; Lang, J; Shen, K; Yang, J; Zhou, H, 2017
)
0.91
"To investigate clinically applicable dose-adjustment strategies to overcome the known drug-drug interaction (DDI) between levonorgestrel and efavirenz, using a physiologically based pharmacokinetic (PBPK) modelling-based approach."( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018
)
0.89
" Conversely, increased-dose levonorgestrel in combination with either 600 or 400 mg of efavirenz was sufficient to restore levonorgestrel concentrations to levels similar to those observed in the 150 mg levonorgestrel control group 48 weeks post-implant-placement (efavirenz:control geometric mean ratio = 0."( Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
Back, DJ; Darin, KM; Fletcher, CV; Lamorde, M; Owen, A; Rajoli, RKR; Roberts, O; Scarsi, KK; Siccardi, M, 2018
)
0.98
" Two hundred sixteen patients were randomized to the treatment group with IVRs releasing LNG 40 μg/day alone or in combination with ATZ 300 μg/day, 600 μg/day, or 1050 μg/day for 12 weeks."( Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial.
Höchel, J; Klein, S; Mellinger, U; Nave, R; Schmitz, H, 2019
)
0.77
"To evaluate the clinical efficacy and safety of adenomyomectomy using "H" type incision combined with Mirena (LNG-IUS) in the treatment of adenomyosis."( Clinical efficacy of adenomyomectomy using "H" type incision combined with Mirena in the treatment of adenomyosis.
Gao, Y; Jiang, J; Li, D; Shan, S; Shi, B; Zhao, X, 2019
)
0.51
" A drug-drug interaction study to evaluate the potential effect of FIL on the pharmacokinetics (PK) of the oral contraceptive levonorgestrel (LEVO)/ethinyl estradiol (EE) was conducted."( Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
Ampaw, L; Anderson, K; Begley, R; Kearney, BP; Mathias, A; Qin, A; Watkins, TR; Weng, W, 2021
)
1.04
"To evaluate the clinical efficacy and safety of laparoscopic adenomyomectomy combined with intraoperative replacement of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of symptomatic adenomyosis."( Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness.
Sun, F; Xu, H; Yang, Y; You, M; Yu, Y; Zhang, Y, 2021
)
1.09
" A total of 52 patients with symptomatic adenomyosis were treated by laparoscopic adenomyomectomy combined with intraoperative replacement of LNG-IUS from January 2015 to July 2018."( Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness.
Sun, F; Xu, H; Yang, Y; You, M; Yu, Y; Zhang, Y, 2021
)
0.88
"Laparoscopic adenomyomectomy combined with intraoperative replacement of LNG-IUS is a novel and effective conservative surgical procedure for symptomatic adenomyosis treatment."( Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness.
Sun, F; Xu, H; Yang, Y; You, M; Yu, Y; Zhang, Y, 2021
)
0.88
" Due to its widespread use and CYP3A4-mediated metabolism, there is concern regarding drug-drug interactions (DDIs), particularly a suboptimal LNG exposure when co-administered with CYP3A4 inducers, potentially leading to unintended pregnancies."( Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021
)
0.92
"Levonorgestrel containing combination oral products and implants containing levonorgestrel or etonogestrel were prone to CYP3A4-inducing drug-drug interactions that may increase contraceptive failures."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
2.06
"The progestin components of hormonal contraceptives are susceptible to drug-drug interactions, but this susceptibility is influenced by route of administration."( Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
Brown, J; Cicali, B; Schmidt, S; Sunaga, T, 2021
)
0.62
"To evaluate the clinical outcomes of transvaginal ultrasound-guided radiofrequency ablation (RFA) combined with a levonorgestrel-releasing intrauterine system (LNG-IUS) for the treatment of symptomatic uterine adenomyosis."( Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment.
Guo, R; Hai, N; Hou, Q, 2021
)
1.07
"Patients with symptomatic uterine adenomyosis treated with ultrasound-guided RFA in combined with an LNG-IUS from January 2013 to January 2016 and followed up for 3 years after treatment were selected."( Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment.
Guo, R; Hai, N; Hou, Q, 2021
)
0.86
"Ultrasound-guided RFA combined with an LNG-IUS might be a simple, safe and effective alternative for the treatment of symptomatic adenomyosis."( Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment.
Guo, R; Hai, N; Hou, Q, 2021
)
0.86
"The objective of this study was to investigate the efficacy of high-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone agonist or levonorgestrel-releasing intrauterine system (LNG-IUS) in treating dysmenorrhea in patients with severe adenomyosis."( High-Intensity Focused Ultrasound Combined With Gonadotropin-Releasing Hormone Agonist or Levonorgestrel-Releasing Intrauterine System in Treating Dysmenorrhea of Severe Adenomyosis.
Liu, G; Shao, L; Wang, H; Xu, Y; Zhou, Z,
)
0.55
" Patients were divided into H (received HIFU alone), H-G (received HIFU combined with gonadotropin-releasing hormone agonist), and H-L (received HIFU combined with LNG-IUS) groups."( High-Intensity Focused Ultrasound Combined With Gonadotropin-Releasing Hormone Agonist or Levonorgestrel-Releasing Intrauterine System in Treating Dysmenorrhea of Severe Adenomyosis.
Liu, G; Shao, L; Wang, H; Xu, Y; Zhou, Z,
)
0.35
" However, HIFU combined with LNG-IUS improves the therapeutic effect for a longer period."( High-Intensity Focused Ultrasound Combined With Gonadotropin-Releasing Hormone Agonist or Levonorgestrel-Releasing Intrauterine System in Treating Dysmenorrhea of Severe Adenomyosis.
Liu, G; Shao, L; Wang, H; Xu, Y; Zhou, Z,
)
0.35
"To investigate the clinical effect of high intensity focused ultrasound (HIFU) ablation combined with gonadotropin-releasing hormone agonist (GnRH-a) and levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of adenomyosis patients who failed to respond to drug therapies."( Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results.
Dai, Y; Jin, P; Peng, Y; Wen, C; Yang, X; Yu, G, 2021
)
0.82
"A total of 47 patients with adenomyosis who had failed to respond to drug therapies and had no fertility desires were treated with HIFU combined with GnRH-a and LNG-IUS."( Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results.
Dai, Y; Jin, P; Peng, Y; Wen, C; Yang, X; Yu, G, 2021
)
0.62
"This was an open-label, two-period, fixed-sequence, drug-drug interaction study."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.93
" For patients with adenomyosis who refuse surgery and are not candidates for the use of LNG-IUS, an ENG-releasing implant combined with endometrial ablation may be an effective alternative."( Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports.
Cheng, L; Nie, LK; Zhang, PH; Zou, HL, 2022
)
0.72
"Hormonal contraceptives are among the most effective forms of reversible contraception, but many other compounds, including some antiretrovirals, have clinically meaningful drug-drug interactions (DDIs) with hormonal contraceptives."( A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Ankrom, W; Brimhall, D; Fillgrove, KL; Gravesande, KN; Iwamoto, MN; Jackson Rudd, D; Matthews, RP; Stoch, SA; Zhang, S, 2021
)
0.83
"The results of this trial support the use of LNG/EE contraceptives in combination with islatravir without dose adjustment."( A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Ankrom, W; Brimhall, D; Fillgrove, KL; Gravesande, KN; Iwamoto, MN; Jackson Rudd, D; Matthews, RP; Stoch, SA; Zhang, S, 2021
)
0.83
"To investigate the effect of hysteroscopy surgery combined with Mirena on postoperative adverse reactions and recurrence rate of endometrial polyps (EP)."( Effect of Hysteroscopic Polypectomy Combined with Mirena Placement on Postoperative Adverse Reactions and Recurrence Rate of Endometrial Polyps: Based on a Large-Sample, Single-Center, Retrospective Cohort Study.
Feng, W; Shen, Y; Yang, J; Yi, J, 2022
)
0.72
"A case-control study was performed to explore the efficacy and adverse reactions of Mirena combined with hysteroscopy when treating AUB."( Evaluation of the Efficacy and Adverse Reactions of Mirena Combined with Hysteroscopic Surgery When Treating AUB: Based on a Retrospective Cohort Study.
Shao, L; Teng, Y; Yang, Z, 2022
)
0.72
"Hysteroscopy combined with Mirena when treating perimenopausal AUB can remarkably enhance the related symptoms, regulate the level of sex hormones, and remarkably reduce the amount of menstrual bleeding."( Evaluation of the Efficacy and Adverse Reactions of Mirena Combined with Hysteroscopic Surgery When Treating AUB: Based on a Retrospective Cohort Study.
Shao, L; Teng, Y; Yang, Z, 2022
)
0.72
"To evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with the levonorgestrel intrauterine system (LNG-IUS) for adenomyosis."( Efficacy of high-intensity focused ultrasound combined with LNG-IUS for adenomyosis: a systematic review and meta-analysis.
Fan, LX; Li, RN; Pang, LL; Wen, Y; Yang, LL; Zhao, TT, 2023
)
1.13
"We searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases from their inception to Nov 20, 2021 for relevant articles that compared HIFU combined with LNG-IUS vs."( Efficacy of high-intensity focused ultrasound combined with LNG-IUS for adenomyosis: a systematic review and meta-analysis.
Fan, LX; Li, RN; Pang, LL; Wen, Y; Yang, LL; Zhao, TT, 2023
)
0.91
"To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility."( Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Cao, D; Chen, J; Cheng, N; Peng, P; Shen, K; Wang, J; Yang, J; Yu, M; Zhang, Y; Zhou, H, 2022
)
1.15
"To investigate the clinical value of Mirena (levonorgestrel intrauterine sustained release system) combined with gonadotropin-releasing hormone agonist (GnRH-a) in patients with endometriosis, 80 patients with endometriosis (March 2019 ~ March 2020) were selected as the research object."( Effect of Mirena intrauterine device combined with GNRH-A on endometriosis, sex hormone level and carbohydrate antigen 125.
Fenghua, Y; Guan, L; Juan, S; Rong, S, 2022
)
0.98
" In the control group, 34 patients were treated with HIFU alone, 29 patients with HIFU combined with mifepristone, 10 patients with HIFU combined with LNG-IUS."( Clinical evaluation of high-intensity focused ultrasound ablation combined with mifepristone and levonorgestrel-releasing intrauterine system to treat symptomatic adenomyosis.
Dong, G; Li, Y; Ma, Q; Mu, Y; Song, S; Yang, L; Zhu, H, 2023
)
1.13
" This combination therapy demonstrates superior efficacy to treatment with HIFU alone, HIFU combined with mifepristone, and HIFU combined with LNG-IUS."( Clinical evaluation of high-intensity focused ultrasound ablation combined with mifepristone and levonorgestrel-releasing intrauterine system to treat symptomatic adenomyosis.
Dong, G; Li, Y; Ma, Q; Mu, Y; Song, S; Yang, L; Zhu, H, 2023
)
1.13
"To determine if double-dose levonorgestrel emergency contraception (EC) in combination with efavirenz or rifampicin, 2 drugs known to decrease levonorgestrel exposure, resulted in similar pharmacokinetics compared to standard-dose levonorgestrel EC without drug-drug interactions."( Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E, 2023
)
1.48
"To compare the treatment efficacies of high-intensity focused ultrasound (HIFU), HIFU combined with gonadotrophin-releasing hormone agonist (GnRH-a), and HIFU combined with GnRH-a and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis."( Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis.
Chuang, LT; Jeng, CJ; Otgontuya, A; Shen, J; Wu, TN, 2023
)
1.1
" This study was to investigate the effect of HIFU combined with the LN-IUS on adenomyosis."( Effects of high-intensity focused ultrasound combined with levonorgestrel-releasing intrauterine system on patients with adenomyosis.
Cai, Y; Cao, Q; Gao, B; Hao, X; Ren, C; Sun, Y; Wu, Y; Xu, F, 2023
)
1.15

Bioavailability

The comparative bioavailability was carried out on levonorgestrel tablets. Absorption and bioavailability of the Hungarian-made tablets were greater as evidenced by higher serum concentrations.

ExcerptReferenceRelevance
" The results indicate that OCBZ, like most antiepileptic drugs (AEDs), decreases the bioavailability of EE and LNG, perhaps by affecting metabolism or protein binding."( Possible interaction between oxcarbazepine and an oral contraceptive.
Haring, P; Klosterskov Jensen, P; Menge, GP; Saano, V; Svenstrup, B,
)
0.13
" In both cases, the in vitro mucosal conjugation rose while the in vivo bioavailability fell (4."( The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease.
Back, DJ; Ellis, A; Gilmore, IT; Grimmer, SF; Orme, ML; Tjia, JF, 1992
)
0.28
" Blood samples were collected at the end of each treatment month, assayed for EE and the half-life of elimination (Tel) and bioavailability (area under the serum concentration-time curve, AUC) calculated."( Intrasubject variability in the pharmacokinetics of ethynyloestradiol.
Fotherby, K, 1991
)
0.28
" WHO is conducting dose reduction trials and studies of bioavailability in various national populations."( Long-acting hormonal contraceptives for women.
Garza-Flores, J; Hall, PE; Perez-Palacios, G, 1991
)
0.28
" Absorption and bioavailability of the Hungarian-made tablets were greater as evidenced by higher serum concentrations of levonorgestrel, a greater area under the concentration-time curve during the first 24 hours, and a more marked suppressive effect on SHBG levels."( Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel.
Fotherby, K; He, CH; Liao, DL; Matlin, SA; Shi, YE; Van Look, PF; Vince, PM; Xu, JQ; Zhu, YH, 1990
)
0.7
" Another common parameter, mean pharmacokinetic bioavailability of LNG (as calculated by the area under the curve method), ranged from 20 to 35 ng/ml/hour in patients given 150 mcg of LNG with 30 mcg of ethinyl estradiol."( Pharmacokinetics of gestagens: some problems.
Fotherby, K, 1990
)
0.28
" Levonorgestrel was well absorbed and the serum levels remained almost constant throughout treatment."( Effects of treatment with oestradiol/levonorgestrel on bone, lipoproteins and hormone status in postmenopausal women.
Beastall, G; Farish, E; Fletcher, CD; Gray, CE; Hart, DM; Lindsay, R, 1989
)
1.46
"The bioavailability of ethinyloestradiol and levonorgestrel has been studied in 5 young women with an ileostomy following surgery for ulcerative colitis and compared to that in 5 control subjects."( The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy.
Back, DJ; Cowie, A; Gilmore, I; Grimmer, SF; Orme, ML; Tjia, J, 1986
)
0.79
"The bioavailability of contraceptive steroids was studied in 12 women who were given an antacid and a contraceptive pill simultaneously."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
" Apparently, self-dosing with this antacid will not affect bioavailability of oral contraceptive steroids."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
" For bioavailability study, blood samples were collected twice weekly for a period of one month in the first cycle in 8 women."( Bioavailability of levonorgestrel from intravaginal rings in women of low income groups.
Madhavan Nair, K; Narasinga Rao, BS; Prema, K; Sivakumar, B, 1986
)
0.6
"The relative bioavailability of levonorgestrel (LNG) and ethinyl estradiol (EE) administered concomitantly both as an oral tablet and as a solution was assessed in a randomized two-period crossover study in 24 healthy women."( The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
Chiang, S; Goebelsmann, U; Hoffman, D; Woutersz, T, 1986
)
0.84
"The relative bioavailability of levonorgestrel (LNG) and ethinyl estradiol (EE) administered concomitantly both as an oral tablet and as a solution was assessed in a randomized 2-period crossover study in 24 healthy women."( The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
Chiang, S; Goebelsmann, U; Hoffman, D; Woutersz, T, 1986
)
0.84
" Phase II studies typically provide an opportunity to examine issues of efficacy and safety in a clinical target population and often permit a determination of the dose and dose intervals which will be most appropriate for that particular population and allow for a more definitive evaluation of the pharmacokinetics and, perhaps, bioavailability of a particular formulation."( Clinical evaluation of drugs used in fertility regulation.
Siemens, AJ, 1986
)
0.27
" In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.27
" The bioavailability of ethinyl estradiol was significantly greater in women with cystic fibrosis (76."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.27
"The relative bioavailability of levonorgestrel (LNG) and ethinylestradiol (EE2) administered as a conventional tablet (150/30) or capsule has been assessed in a randomized two-period crossover study in 9 healthy volunteer women."( The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form.
Back, DJ; Cohen, M; Elstein, M; Killick, SR; Shenoy, N; Stevenson, PJ, 1987
)
0.84
"9 female volunteers, aged 18-38 years participated in this study contrasting the bioavailability of levonorgestrel (LNG) and ethinylestradiol (EE2)."( The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form.
Back, DJ; Cohen, M; Elstein, M; Killick, SR; Shenoy, N; Stevenson, PJ, 1987
)
0.77
" The pharmacokinetic parameters of levonorgestrel in control mice showed some similarity to those observed in human subjects, save the systemic bioavailability which was about 67% in mice compared to 100% in humans."( Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel.
Gommaa, AA; Osman, FH, 1983
)
0.77
" However, very little is known concerning the bioavailability and plasma levels of unmetabolized gestagens in the animal species used for chronic toxicity testing and pharmacological investigation."( Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys.
Düsterberg, B; Hümpel, M; Speck, U, 1981
)
0.5
" Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose."( The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette.
Back, DJ; Bates, M; Breckenridge, AM; Hall, JM; MacIver, M; Orme, ML; Park, BK; Rowe, PH, 1981
)
0.57
" In addition, the initial absorption rate and removal half-life of L-NOG were assessed in 7 subjects using the devices for a period of 8 days only."( Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Diczfalusy, E; Johannisson, E; Landgren, BM; Masironi, B, 1982
)
0.49
" Basic pharmacokinetic parameters of levonorgestrel were calculated and from the ratio of the AUC values obtained after both administrations, the bioavailability of norgestimate-derived levonorgestrel was calculated."( Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women.
Blode, H; Kuhnz, W; Mahler, M, 1994
)
0.86
" Overall, these findings suggest that progestogen-related bleeding abnormalities are related to the bioavailability of estrogen and progesterone receptors in the endometrium rather than histological changes."( The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti, W; Leepipatpaiboon, S; Niruttisard, S; Pruksananonda, K; Reinprayoon, D; Triratanachat, S; Wannakrairot, P, 1996
)
0.29
"In a randomized, single dose, open crossover study in 24 healthy women, aged between 20 and 28 years, the relative bioavailability of the test product Mini 30 (0."( Bioavailability study with 2 different levonorgestrel-containing drugs in women.
Farker, K; Hoffmann, A; Lautenschlager, M; Mellinger, U; Nagel, U; Nassr, N; Zimmermann, H, 1997
)
0.57
" This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones."( Contraceptive vaginal rings.
Harwood, B; Mishell, DR, 2001
)
0.31
"To ascertain the nasal bioavailability of Levonorgestrel and change formulation components to provide long-term effective concentrations of the drug in blood."( Nasal delivery of levonorgestrel for contraception: an experimental study in rats.
Misra, A; Shahiwala, A, 2004
)
0.92
" Bioavailability was improved from 29."( Nasal delivery of levonorgestrel for contraception: an experimental study in rats.
Misra, A; Shahiwala, A, 2004
)
0.66
"The purpose of these studies was to achieve desired bioavailability after pulmonary administration of Levonorgestrel (LN) and to provide prolonged effective concentration of the drug in plasma and to reduce reported side effects of orally administered drug."( Pulmonary absorption of liposomal levonorgestrel.
Misra, A; Shahiwala, A, 2004
)
0.82
"Separate crossover studies compared the bioavailability of oral vs."( Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration.
Hahn, PM; Kives, S; Reid, RL; Stanczyk, FZ; White, E, 2005
)
0.61
" The comparative bioavailability was carried out on levonorgestrel tablets (0."( Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel.
Chompootaweep, S; Leepipatpibul, S, 2004
)
0.81
" The comparative bioavailability of the two products was determined by the analysis of variance (ANOVA) for two way crossover design."( Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel.
Chompootaweep, S; Leepipatpibul, S, 2004
)
0.56
"There was a statistically significant higher total plasma clearance divided by the bioavailability (CL/F) of levonorgestrel in adolescents compared to adults, resulting in lower maximum and average total plasma concentrations."( Pharmacokinetics of single-dose levonorgestrel in adolescents.
Darney, P; Harper, CC; Kim, L; Liu, CY; Raine, TR; Sambol, NC, 2006
)
0.83
" Bioavailability of levonorgestrel with minipills was comparable to that with levonorgestrel tablets."( Pharmacokinetics of a single oral dose of 1.5-mg levonorgestrel when administered as 750-mug tablets or as 30-microg minipills.
Devoto, L; Espinoza, A; Fuentes, A; Muñoz, A; von Hertzen, H, 2007
)
0.92
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" Nestorone is well absorbed transdermally from a gel as well as from a metered dose transdermal system (MTDS) that sprays an invisible film on the skin."( Parenteral administration of progestins for hormonal replacement therapy.
Nath, A; Sitruk-Ware, R, 2009
)
0.35
" Moreover, because endogenous gonadal hormones modulate both BDNF expression and serotonin biosynthesis and bioavailability and regulate brain functions like affective and cognitive functions, we proposed to evaluate the effects of a treatment with paroxetine, an SSRI, in a group of postmenopausal women and to clarify the possible relationship between paroxetine, plasma BDNF levels, and climacteric symptoms."( Paroxetine increases brain-derived neurotrophic factor in postmenopausal women.
Bucci, F; Casarosa, E; Cubeddu, A; Genazzani, AR; Giannini, A; Luisi, M; Luisi, S; Merlini, S; Pluchino, N, 2010
)
0.36
"05) increased relative bioavailability of steroidal hormones compared to control."( In vivo absorption of steroidal hormones from smart polymer based delivery systems.
Chen, S; Oak, M; Pederson, D; Singh, J, 2010
)
0.36
" No clinically relevant reduction in bioavailability of ethinyl estradiol/levonorgestrel occurred."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.81
"Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum concentration (Cmax)."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"Exenatide did not alter the bioavailability nor decrease daily trough concentrations for either oral contraceptive component."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive bioavailability and trough concentrations; however, for oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated."( Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
Flint, A; Hartvig, H; Jensen, CB; Jensen, L; Kapitza, C; Nosek, L, 2015
)
0.62
" The use of chitosan and β-GP together with HP-β-CD inclusion compounds was shown to enhance the bioavailability of LNG transdermally."( Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization.
Chen, H; Lin, S; Pan, X; Peng, T; Quan, G; Ran, H; Wang, L; Wang, Q; Wu, C; Yao, G; Zhang, Q, 2017
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG) In the presence of fingolimod, ethinylestradiol pharmacokinetics were unchanged.

ExcerptRelevanceReference
"The effects of two differing dosage schedules of ethinyloestradiol and levonorgestrel, taken cyclically as oral contraceptives, on blood pressure, body mass, blood glucose and serum triglycerides were measured."( The effect of cyclical administration of levonorgestrel and ethinyloestradiol on blood pressure, body mass, blood glucose and serum triglycerides.
Bloch, B, 1979
)
0.76
"0 hours after dosing with their OCS on days 5, 6, 7 and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.28
"0 hours after dosing with OCs on days 5, 6, 7, and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH, and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.28
" These results indicate that these changes are related to the dosage and estrogen-progestogen ratio of the preparation."( A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
Holck, S; Loke, DF; Ng, CS; Ratnam, SS; Samsioe, G, 1990
)
0.49
" A further complication is the multiplicity of pharmacological effects elicited by the gestagens and each of these effects is likely to have its own dose-response relationship."( Potency and pharmacokinetics of gestagens.
Fotherby, K, 1990
)
0.28
" This even occurs with those methods which do not usually suppress ovulation, but the disturbance is generally less severe with lower dosage systems."( Menstrual changes associated with progestogen-only contraception.
Fraser, IS, 1986
)
0.27
" Studies of the oral contraceptives in current use show that the coagulation effects depend on the dosage of estrogen and the type of progestogen used in combination."( Coagulation effects of oral contraception.
Bonnar, J, 1987
)
0.27
" One of the main objects of the study was to determine whether the lower dosage would be sufficient to prevent the development of endometrial hyperplasia."( Clinical experience with a low-dose combination of estradiol valerate and levonorgestrel. Double-blind comparative study between SH D 386 F and Cyclabil. Effects on symptoms, lipids and endometrial condition.
Fredricsson, B; Hirt, M; Lagrelius, A; Weintraub, L, 1986
)
0.5
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
" It is very difficult to show a correlation of ambiguous side effects such as depression and mood changes and the dosage level."( Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol.
Goldzieher, JW, 1983
)
0.51
" Plasma levels of levonorgestrel at various intervals after dosing were analysed by a specific radioimmunoassay and its pharmacokinetic parameters were computed."( Pharmacokinetics of levonorgestrel in Indian women.
Madhavan Nair, K; Narasinga Rao, BS; Prema, K; Sivakumar, B, 1983
)
0.92
" This finding demonstrates that postcoital STS 557 in the chosen dosage does not suppress ovulation."( STS 557 as an interceptive in baboons.
Goncharov, NP; Komor, A; Oettel, M; Schubert, K, 1983
)
0.27
"In the present study the Authors consider whether estroprogestins at low dosage may influence the basal levels of plasma Prolactin in a group of patients subdivided on the basis of their different ways of life."( Prolactin plasma levels and oral contraceptives at low dosage.
Dessole, S; Firinu, C; Milia, S; Piras, G, 1983
)
0.27
"In this study, the authors considered whether estroprogestins at low dosage may influence the basal levels of plasma prolactin (PRL) in a group of patients subdivided on the basis of different lifestyle."( Prolactin plasma levels and oral contraceptives at low dosage.
Dessole, S; Firinu, C; Milia, S; Piras, G, 1983
)
0.27
" Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively."( Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture.
Bayard, F; Jozan, S; Kreitmann, B, 1981
)
0.26
" The results indicate that hormonal contraception of the low dosage type may be administered to women with previously impaired glucose tolerance in pregnancy without any deterioration of the glucose metabolism post partum."( Low dosage oral contraception in women with previous gestational diabetes.
Kühl, C; Mølsted-Pedersen, L; Skouby, SO, 1982
)
0.26
"Scanning electron microscopy and a capillary tube sperm penetration test were used to study the cervical mucus of women using a triphasic oral contraceptive supplying a varying dosage of estrogen and gestagen during the cycle."( Ultrastructure of cervical mucus and sperm penetration during use of a triphasic oral contraceptive.
Myklebust, RU; Ulstein, M, 1982
)
0.26
" Protection is ensured with a low drug dosage and no estrogen, and fertility is readily reversible once the implants are removed."( Subdermal contraceptive implants.
Croxatto, H; Diaz, S; Peralta, O, 1995
)
0.29
"01) suggest that a hypercoagulable state persists in low dosage OC users."( Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.
Donnez, J; Grandjean, P; Lavenne, E; Schlit, AF, 1995
)
0.29
" This points out that the compound dosage form can clinically alleviate the irregular bleeding caused by the administration of LNG alone."( [Study on compound levonorgestrel microspheres].
Guo, R; Lu, B, 1993
)
0.61
"The dosage of ethinylestradiol used in emergency contraception is very shortlived and this study shows no effect on clotting factors."( Clotting factors after emergency contraception.
Taberner, D; Webb, A, 1993
)
0.29
" Overall, the two IUDs had similar effects on the endometrium, indicating that the LNG dosage was not responsible for the morphological alterations."( A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ.
Gu, Z; Luo, H; Wu, S; Zhang, G; Zhu, P; Zhu, X, 1995
)
0.29
" The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effects, which tend to be in the category of 'nuisance' rather than hazardous, and gradually diminish after the first few months of use."( A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Guillebaud, J; Sturridge, F, 1996
)
0.9
"Estrogen-progestin combination oral contraceptives (COCs) are well tolerated, offer high reliability, convenience, and ready availability, but require strict adherence to dosing guidelines."( Contraceptive options for the 1990s.
McGuffey, EC,
)
0.13
" However, the subdermal levonorgestrel systems release a lower dosage of steroid and avoid the first pass through the liver that occurs with oral administration."( A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system.
Harper, MA; Meis, PJ; Steele, L,
)
0.65
" No additional research has been conducted on the timing or dosage of the estrogen-progestogen method, but some dose-effectiveness studies have been performed on mifepristone."( Emergency contraception: is it time to change method?
Webb, A, 1999
)
0.3
" We hypothesized that a combination of physiologic exogenous testosterone and lower dosage LNG would result in uniform severe oligoazoospermia or azoospermia in normal men but would cause fewer adverse metabolic side effects."( A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
Anawalt, BD; Bebb, RA; Bremner, WJ; Matsumoto, AM,
)
0.48
"Combined oral contraceptives show clear differences in effect on the tissue factor-initiated coagulation test of activated protein C resistance, which is dependent on the presence and dosage of levonorgestrel."( Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.
de Maat, MP; Heinemann, LA; Kluft, C; Schramm, W; Spannagl, M, 1999
)
0.85
"Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system."( [New forms of hormonal contraception].
Buicu, C; Gaspard, U; van den Brûle, F, 2000
)
0.48
"Two dosage forms were tested: the first 11 women received a 3-cm long coaxial fibrous delivery system, delivering approximately 10 microg per day of LNG; the remaining 19 women in the study received a 4-cm long delivery system, delivering approximately 14 microg per day."( Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
Schacht, E; Wildemeersch, D, 2000
)
0.56
" Steroids were delivered by silicone elastomer implants placed subdermally except for oral dosing in 1 experiment."( The roles of estrogen and progestin in producing deciduosarcoma and other lesions in the rabbit.
Didolkar, AK; Jänne, OA; Nash, HA; Sundaram, K; Zook, BC,
)
0.13
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.73
" Once-a-week transdermal E2/LNG, therefore, offers an effective and convenient formulation, the dosing of which can be individualized according to the needs of each patient."( Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled t
Shulman, LP; Uhl, K; Yankov, V,
)
0.37
" Serial blood samples were drawn over 72 h after dosing in a fasting state."( Pharmacokinetics of levonorgestrel 0.75 mg tablets.
Duncan, G; Gabelnick, H; Kook, K, 2002
)
0.64
"Marketing of an intravaginal ring that releases a progestagen at low dosage willbegin in 1985."( Progestagen-releasing vaginal rings--an update.
Elstein, M; Nuttal, ID; Spencer, BE, 1985
)
0.27
" A comparison of the pharmacodynamics of administering Postinor through two different media shows that oral administration led to faster effects, but the dosage may need to be reduced to preserve the contraceptive effect while reducing the impact of the drug on the body."( [Pharmacokinetic and pharmacodynamic studies on vaginally administered levonorgestrel].
He, CH, 1991
)
0.51
" Since the levels of HDL between the OC I and OC II groups did not differ significantly, there is no advantage to a reduced dosage of estrogen and progestogen."( The influence of high- and low-dose hormonal contraceptives on HDL and total cholesterol levels.
Novacan Hudnik, S; Pretnar Darovec, A,
)
0.13
" In general, the lowest effective dose of any drug, including contraceptives, is the best practice, but as the dosage is decreased from 50 mcg, cycle control is less effective though side effects are minimized; therefore, reliance on bleeding patterns is necessary for deciding an individual's dosage schedule."( The choice of the dose of oestrogen in a combined oral contraceptive.
Smith, M, 1978
)
0.26
" Pharmacodynamic studies indicate that the dosing interval can be changed from daily oral administration to nasal administration once every 2 days without changing the dose."( Nasal delivery of levonorgestrel for contraception: an experimental study in rats.
Misra, A; Shahiwala, A, 2004
)
0.66
" Hence, the pulmonary delivery is expected to reduce frequency of dosing and systemic side effects associated with oral administration of LN."( Pulmonary absorption of liposomal levonorgestrel.
Misra, A; Shahiwala, A, 2004
)
0.6
" The results show that this effect depends on dosage of the progestin."( Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin.
Ahotupa, M; Hakonen, T; Rauramo, I; Skouby, SO; Vasankari, TJ, 2004
)
0.32
" However, the dosing interval is inconvenient for those taking the first dose in the afternoon."( A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception.
Cheng, L; Ding, J; Fan, S; Ho, PC; Jing, X; Li, S; Ng, EH; Ngai, SW, 2005
)
0.56
" Radiational receptor analysis was made to measure the estrogenic effect of Kalirui and Trinordiol on Compared with the control group, the three dosage groups of homemade (Kalirui) rabbit uterus."( [Experimental study on estrogenic function of triphasic contraceptive tablets].
Fan, A; Yang, F; Zhang, M; Zhou, G; Zhou, S; Zhu, L, 2003
)
0.32
"75 mg levonorgestrel in dosage 1 or 2 pills after non-protected sexual contact."( [Emergency contraception with levonorgestrel in adolescents].
Shentov, B; Tanchev, S, 2004
)
1.09
"250 mg per 7-day phase, respectively) for 5 days (days 17-21) concurrently with either 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21) or matching placebo during 2 consecutive 28-day OC dosing cycles."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
" We hypothesized that intramuscular T enanthate 100 mg weekly plus a very low dosage of oral LNG would effectively suppress spermatogenesis in normal men without inducing weight gain or HDL suppression."( Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
Amory, JK; Anawalt, BD; Bremner, WJ; Coviello, AD; Herbst, KL; Matsumoto, AM; Page, ST,
)
0.37
" Following an initial dose-response trial, queens were assigned to one of four treatments: (1) antide, two 6 mg/kg injections 15 days apart (n = 8 cats); (2) levonorgestrel, six silastic rods (36 mg levonorgestrel/rod) implanted for 30 days (n = 8); (3) control injections (n = 5); and (4) control implants (n = 5)."( Short term suppression of follicular recruitment and spontaneous ovulation in the cat using levonorgestrel versus a GnRH antagonist.
Brown, JL; Howard, JG; Ottinger, MA; Pelican, KM; Wildt, DE, 2005
)
0.75
" Three dosage levels of CNT (0."( [Compound nylestriol tablet to prevent bone loss in osteoporotic rats].
Chen, ZN; Dai, RC; Li, HD; Liao, EY; Liu, SP; Liu, XJ; Luo, XH; Sun, RY; Wu, XP, 2004
)
0.32
" A dosage adjustment for lamotrigine may need to be considered when these agents are co-administered."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
" continuous oral contraceptive (OC) dosing regimens, to explore follicular development during the hormone-free interval (HFI) and to examine follicular development following OC discontinuation."( Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use.
Birtch, RL; Olatunbosun, OA; Pierson, RA, 2006
)
0.33
"To estimate whether progestin type or estrogen dose influences bleeding patterns, adverse effects, or satisfaction with combined oral contraceptives dosed continuously."( Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman, AB; Jensen, JT; Koontz, SL; Nichols, MD, 2006
)
0.33
" Forty female Sprague-Dawley rats were divided into two groups: an experimental group received daily ethinylestradiol and levonorgestrel in a dosing model designed to simulate a typical oral contraception regime in humans, while a control group received daily oral placebo."( Reproductive hormone effects on strength of the rat anterior cruciate ligament.
Huber, P; Schmale, GA; Seidel, K; Simonian, P; Tencer, A; Woodhouse, E, 2007
)
0.55
" Women refrained from nursing for 72 h after dosing and fed their infants with milk frozen beforehand."( Levonorgestrel pharmacokinetics in plasma and milk of lactating women who take 1.5 mg for emergency contraception.
Bouyer, J; Caviedes, R; Forcelledo, ML; Gainer, E; Lillo, S; Massai, R; Reyes, V; Villarroel, C, 2007
)
1.78
" This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 microg and ethinyl estradiol 20 microg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year."( Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms.
Archer, DF; Jensen, JT, 2008
)
0.62
"This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG)."( Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt, HJ; Makalová, D; Mansour, D; Mellinger, U; Parke, S, 2009
)
0.73
" Although providers are generally following the most recent dosing guidelines, opportunities to prescribe EC to adolescent girls with complaints other than sexual assault seem to be missed."( Patient characteristics and provider practice patterns for emergency contraception in a pediatric emergency department.
Dowd, MD; Miller, MK; Patel, S, 2010
)
0.36
" The vast majority (97%) of the respondents were aware of the dosing schedule of the available ECP."( Knowledge and attitudes of pharmacists regarding over-the-counter emergency contraception in South-Eastern Hungary.
Bártfai, G; Szöllosi, AP; Szucs, M, 2010
)
0.36
" Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" Evidence was limited on optimal dosage or duration of treatment for GnRHas."( Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.
Brown, J; Hart, RJ; Pan, A, 2010
)
0.36
" Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.85
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
" Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein."( The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Chong, CL; Davis, J; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.55
" Young patients with histologically confirmed Grade 1 endometrioid adenocarcinoma that is presumably confined to the endometrium, who desired to preserve their fertility potential, undergo levonorgestrel-releasing intrauterine system insertion and are administered medroxyprogesterone acetate at a dosage of 500 mg/day concurrently."( Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
Hong, SR; Kim, JW; Kim, MK; Lee, TS; Nam, BH; Seong, SJ; Suh, KS, 2012
)
0.82
"The pharmacokinetics of EE and LNG at steady state based on the primary endpoints of area under the steady-state plasma concentration-time curve during a dosage interval τ (AUC(τ,ss)) and maximum steady-state plasma concentration during a dosage interval (C (max,ss)) were the main outcome measures."( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013
)
0.61
" The hazard ratio (HR) from Cox proportional hazards models was used to assess the VTE relative risk (RR) with drospirenone compared with levonorgestrel, adjusted by a propensity score used to control for baseline co-morbidity and stratified by EE dosage and user-type (new/current)."( Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013
)
0.59
"The objective of this multicentre, randomised, double-blind study was to compare a combined oral contraceptive (COC) containing oestradiol valerate/dienogest (E2V/DNG) administered in a dynamic dosing regimen with a monophasic COC containing ethinyloestradiol/levonorgestrel (EE/LNG), with regard to their ability to reduce the frequency and intensity of headache and pelvic pain in women with hormone withdrawal-associated symptoms (HWAS)."( Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas, G; Mellinger, U; Merki-Feld, GS; Parke, S; Serrani, M, 2013
)
0.57
"Obese [body mass index (BMI)≥30 kg/m(2)], ovulatory, otherwise healthy, women received an OC containing 20 mcg ethinyl estradiol (EE)/100 mcg levonorgestrel (LNG) dosed cyclically (21 days active pills with 7-day placebo week) for two cycles and then were randomized for two additional cycles to the following: continuous cycling (CC, a dose neutral arm using the same OC with no hormone-free interval) or increased dose (ID, a dose escalation arm using an OC containing 30 mcg EE/150 mcg LNG cyclically)."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.6
"Both increasing the OC dose and continuous dosing appear to counteract the impact of obesity on key OC PK parameters."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" Although the impact of these changes on OC efficacy is still under debate, PK parameters can be normalized in obese users by continuous dosing or increasing to a low-dose pill."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" The primary outcome measure was the area under the concentration-time curve over a dosing interval of τ = 24 h (AUCτ) for EE and LNG plasma levels."( No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
Dienel, A; Heger-Mahn, D; Klipping, C; Pabst, G; Schläfke, S, 2014
)
0.61
"Combined with a progestin, E4 adequately suppresses ovarian activity, particularly when given at a dosage above 10 mg/day."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.64
" Dosing occurred during the follicular phase."( Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.
Blue, SW; Cherala, G; Edelman, AB; Erikson, DW; Jensen, JT, 2016
)
0.69
" A marketed dosing regimen of estradiol valerate with dienogest (E2V/DNG) served as reference since it contains (like E4) a natural oestrogen."( Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA).
Apter, D; Beekman, L; Coelingh Bennink, HJ; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y, 2016
)
0.43
"Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs)."( Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology.
Brimer, A; Devlin, B; Major, I; McConville, C, 2016
)
0.67
" Outcomes included changes in symptoms, hospitalization, suicide and modifications in medication regimens such as increase or decrease in dosage or changes in type of drug."( Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review.
Berry-Bibee, EN; Curtis, KM; Nanda, K; Pagano, HP; Zapata, LB, 2016
)
0.43
" Confusing in some of the literature is that a few studies have reported erroneously calculated pharmacokinetic parameters after multiple dosing of oral contraceptives."( Clarification of contraceptive drug pharmacokinetics in obesity.
Jusko, WJ, 2017
)
0.46
" The LNG-IUS was removed in six patients and of these, two experienced clinical improvement with lower fluconazole dosage requirements and three experienced complete resolution of symptoms."( Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device.
Fischer, G; Nguyen, Y, 2018
)
0.73
" We also included data from 2 subjects who experienced rupture prior to COC dosing in the analysis."( Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study.
Edelman, AB; Hennebold, JD; Jensen, JT; McCrimmon, S; Messerle-Forbes, M; O'Donnell, A, 2018
)
0.48
"Laquinimod is an orally dosed immuno-modulator currently under development for Huntington's disease (HD)."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.71
" To avoid unintended pregnancy in the pretreatment period, the dosage used should, ideally, also be effective for contraception and the pretreatment period should be kept as short as possible."( Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Gemzell-Danielsson, K; Kopp Kallner, H; Papaikonomou, K; Söderdahl, F, 2018
)
0.74
" Recent advisories from the United Kingdom regarding daily dosing of ulipristal for fibroids emphasize the need for more safety data."( Pericoital contraception.
Blumenthal, PD; Cahill, EP, 2018
)
0.48
" PK blood samples were taken before dosing and before IVR replacement or removal (days 28, 56, and 84)."( Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial.
Höchel, J; Klein, S; Mellinger, U; Nave, R; Schmitz, H, 2019
)
0.77
"Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type."( Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
Adeyanju, OA; Olatunji, LA, 2019
)
0.51
" Here, we describe the design and report in vivo characterization of a levonorgestrel-releasing gastric resident dosage form in pigs."( A once-a-month oral contraceptive.
Bajpayee, A; Bensel, T; Brooks, S; Collins, J; Gwynne, D; Hayward, A; Hua, T; Kirtane, AR; Langer, R; Lopes, A; Ma, L; Stanczyk, FZ; Tamang, SM; Traverso, G; Wahane, A; Wainer, J, 2019
)
0.75
" No hormonal dosage or imaging is indicated to make a diagnosis of menopause in a classic situation."( [How to diagnose menopause? Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Rousset-Jablonski, C, 2021
)
0.62
" The most common regiments are the following progestins: megestrol acetate (MA) and medroxyprogesterone acetate (MPA) taken orally with a daily dosage of 160 mg-320 mg for MA and 250 mg-600 mg for MP."( Uterine sparing management in patients with endometrial cancer: a narrative literature review.
George, M; Kalantaridou, S; Papadimitriou, S; Paschopoulos, M; Tsonis, O; Zisi, M; Zygouris, D, 2022
)
0.72
"To investigate the effect of different oral dosages of levonorgestrel (LNG) on ovarian activity and to identify the lowest dosage at which no ovulation occurred."( Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel.
Duijkers, IJM; Klipping, C; Kochhar, PS; Oettel, M; Osterwald, H; Rautenberg, T; Schug, BS, 2022
)
1.19
"115 mg per day was the lowest effective dosage for consistent ovulation inhibition."( Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel.
Duijkers, IJM; Klipping, C; Kochhar, PS; Oettel, M; Osterwald, H; Rautenberg, T; Schug, BS, 2022
)
0.95
"This study employed population pharmacokinetic (popPK) models to predict levonorgestrel (LNG) and ethinyl estradiol (EE) exposure after dosing with the transdermal contraceptive TWIRLA® (LNG/EE TDS) as a 12-week extended regimen in a healthy female population."( Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
Archer, DF; Korner, P; Lohmer, LRL; Pirone, J; Previtera, M; Stanczyk, FZ, 2022
)
1.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
contraceptive drugA chemical substance that prevents or reduces the probability of conception.
progestinA synthetic progestogen.
synthetic oral contraceptiveAn oral contraceptive which owes its effectiveness to synthetic preparation.
female contraceptive drugA chemical substance or agent with contraceptive activity in females.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency56.23410.044717.8581100.0000AID485294
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency43.64123.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.24460.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency24.54120.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency5.80240.004110.890331.5287AID504466
USP1 protein, partialHomo sapiens (human)Potency89.12510.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency24.54120.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency20.96180.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency13.58920.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency2.50830.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency30.20720.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency58.70050.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency25.94480.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.54040.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.58860.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.09140.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency13.01840.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency43.34130.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency54.94100.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency30.24080.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.23760.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency12.30180.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency16.78420.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.69950.023723.228263.5986AID743223; AID743241
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency19.95260.016525.307841.3999AID602332
thyroid stimulating hormone receptorHomo sapiens (human)Potency45.23160.001628.015177.1139AID1224895; AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency29.368119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency43.64120.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency120.05300.039147.5451146.8240AID1224845
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency16.36010.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency100.00003.548119.542744.6684AID743266
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency0.89130.794321.275750.1187AID624246
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.08900.000323.4451159.6830AID743065; AID743067
DNA polymerase betaHomo sapiens (human)Potency100.00000.022421.010289.1251AID485314
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency23.15900.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.37480.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency10.10300.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency20.31480.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency2.81840.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.92400.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency12.30180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency30.70020.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.92400.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency48.55770.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency48.55770.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Progesterone receptorHomo sapiens (human)EC50 (µMol)0.00100.00010.40478.2000AID1893228; AID1893229
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (239)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (83)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1893228Agonist activity at human PR-alpha expressed in U2OS cells by PathHunter assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1893229Agonist activity at human PR-beta expressed in U2OS cells by PathHunter assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)1983Journal of steroid biochemistry, Nov, Volume: 19, Issue:5
Binding of progestagens to receptor proteins in MCF-7 cells.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)2003Maturitas, Dec-10, Volume: 46 Suppl 1Classification and pharmacology of progestins.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,578)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990524 (11.45)18.7374
1990's988 (21.58)18.2507
2000's1155 (25.23)29.6817
2010's1379 (30.12)24.3611
2020's532 (11.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 124.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index124.73 (24.57)
Research Supply Index8.67 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index237.92 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (124.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,004 (20.84%)5.53%
Reviews616 (12.79%)6.00%
Case Studies272 (5.65%)4.05%
Observational60 (1.25%)0.25%
Other2,866 (59.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (255)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Special Drug Use Investigation of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea [NCT02475356]601 participants (Actual)Observational2015-08-04Completed
A Randomized, Cross-over, Clinical Trial to Assess the Prevention of Ovulation Achieved by Single Intra-vaginal Administration of 0.75 mg Levonorgestrel (LNG) Gel (Levogel) as Compared to 1.5 mg Oral LNG [NCT01286948]Phase 120 participants (Actual)Interventional2011-01-31Completed
International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levon [NCT01295294]Phase 4187 participants (Actual)Interventional2011-03-31Completed
Levonorgestrel-releasing Intrauterine System: A Emerging Tool for Conservative Treatment of Pain and Bleeding After Tubal Ligation [NCT04663568]2 participants (Actual)Interventional2020-12-01Terminated(stopped due to No fund was obtained for buying the hormonal IUD)
Reducing Racism and Discrimination in Schools: Comprehensive Prevention Services [NCT05189769]1,020 participants (Anticipated)Interventional2019-05-15Enrolling by invitation
A Phase 1, Randomized, Open Label, 2-Way Crossover Study To Assess The Effect Of Multiple Dose CP-690,550 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids In Healthy Female Subjects [NCT01137708]Phase 120 participants (Actual)Interventional2010-06-30Completed
Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006) [NCT01234818]Phase 280 participants (Anticipated)Interventional2010-11-30Recruiting
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT05282940]Phase 136 participants (Actual)Interventional2022-02-26Completed
Cycle Planning With OCP in GnRH Antagonists Cycles Versus Long Protocol in Good Prognosis IVF Patients [NCT01157754]115 participants (Actual)Interventional2009-06-30Completed
Open-label, Randomized, Crossover Study to Compare the Bioavailability of One Coated Tablet of Opxion® (Levonorgestrel 1.5 mg From Bayer de Mexico) vs. Two Tablets of Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers [NCT01096485]Phase 124 participants (Actual)Interventional2009-02-28Completed
A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC) [NCT01297179]Phase 130 participants (Actual)Interventional2008-10-31Completed
A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contrac [NCT02616146]Phase 32,016 participants (Actual)Interventional2015-12-01Terminated(stopped due to Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.)
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia [NCT03241888]Phase 2/Phase 3180 participants (Actual)Interventional2017-07-04Completed
An Open-label, Randomized, Parallel Group Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) [NCT01044056]Phase 424 participants (Actual)Interventional2004-03-31Completed
KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method [NCT03182140]1,134 participants (Actual)Observational2017-07-06Completed
Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index [NCT02689804]Phase 434 participants (Actual)Interventional2015-07-10Completed
A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-04965842 ON THE PHARMACOKINETICS OF SINGLE-DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE SUBJECTS [NCT03662516]Phase 117 participants (Actual)Interventional2018-09-26Completed
Patient Compliance With Long-Acting Reversible Contraception Administration Immediately and Early Postpartum Versus Interval Postpartum [NCT03305081]45 participants (Actual)Interventional2014-10-22Terminated
Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis [NCT03778359]5,000 participants (Actual)Observational2005-01-01Completed
An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol [NCT03547024]Phase 114 participants (Actual)Interventional2018-06-08Completed
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo. [NCT01569113]Phase 476 participants (Actual)Interventional2012-03-31Completed
A Phase I Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile of a Single Injection of Levonorgestrel Butanoate (LB) for Female Contraception [NCT02173808]Phase 116 participants (Actual)Interventional2011-05-31Completed
Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir With and Without Levonorgestrel Among Women in Western Kenya [NCT03762382]Phase 250 participants (Anticipated)Interventional2018-12-12Active, not recruiting
Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period: A Prospective, Randomized Pilot Study of Three Time Intervals [NCT01088178]45 participants (Anticipated)Interventional2009-11-30Recruiting
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia: A Non-Inferiority Study [NCT04897217]Phase 30 participants (Actual)Interventional2023-06-30Withdrawn(stopped due to PI decision)
MiCo - Mirena or Conventional Medical Treatment for Menorrhagia (MA0901) [NCT01085487]1,211 participants (Actual)Observational2009-04-30Completed
The Influence of Oral Contraceptives on Mood, Sexuality and Economic Behavior [NCT02257671]400 participants (Anticipated)Interventional2012-02-29Recruiting
Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers [NCT03709355]Phase 156 participants (Actual)Interventional2018-11-14Completed
Pharmacoepidemiological Study (Drug Utilization Study) of JAYDESS Use in Routine Clinical Practice in Sweden [NCT02349815]10,000 participants (Actual)Observational2017-01-01Completed
Multi-center, Open-label, Uncontrolled Study to Assess Contraceptive Efficacy and Safety of Mirena During Extended Use Beyond 5 Years in Women 18 to 35 Years of Age Including a Subgroup Evaluation of Treatment Effect on Heavy Menstrual Bleeding [NCT02985541]Phase 3364 participants (Actual)Interventional2016-12-22Completed
The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding [NCT02326922]Phase 1/Phase 261 participants (Actual)Interventional2014-06-30Completed
Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone [NCT02235662]Phase 186 participants (Actual)Interventional2014-10-31Completed
The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial. [NCT04385667]Phase 2/Phase 3143 participants (Actual)Interventional2020-05-20Completed
A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg [NCT03537768]Phase 41,200 participants (Anticipated)Interventional2018-07-12Recruiting
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins [NCT01291004]Phase 1206 participants (Actual)Interventional2011-01-31Completed
Results of Intrauterine Levonorgestrel Use for the Patients With Isthmocele Suffering From Postmenstrual Spotting Without Fertility Desire [NCT04872244]30 participants (Actual)Interventional2019-11-03Completed
HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC [NCT02038335]451 participants (Actual)Observational2014-02-28Completed
Experimental Study Examining Mirena IUD Insertion and Estimating Rates of Expulsion Immediately After Placental Delivery. [NCT01230242]4 participants (Actual)Interventional2010-09-07Terminated(stopped due to Suspended to determine if Mirena device could be charged to patient insurance)
CCN009: A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate the Effects on the Mechanisms of Contraceptive Efficacy and, Secondarily, to Assess the Pharmacokinetic Profile and Safety of Two Progestin-only Patches Containing Different [NCT01166412]Phase 1/Phase 2121 participants (Actual)Interventional2010-12-31Completed
Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial [NCT02158845]Phase 444 participants (Actual)Interventional2010-02-28Completed
Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant [NCT03353012]Phase 460 participants (Actual)Interventional2018-01-01Completed
Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women [NCT01320917]Phase 488 participants (Anticipated)Interventional2009-02-28Active, not recruiting
A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma [NCT00788671]Phase 269 participants (Actual)Interventional2008-11-03Active, not recruiting
A Cross-sectional, Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess® as Their Contraceptive Method - The JULIA Study. [NCT02574715]1,039 participants (Actual)Observational2015-09-18Completed
Plan B® 1.5 Emergency Contraception Actual Use Study in Adolescents [NCT00777556]Phase 3343 participants (Actual)Interventional2008-10-31Completed
A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06700841 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS [NCT04267250]Phase 118 participants (Actual)Interventional2020-08-24Completed
A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of DR-105 and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females [NCT00924560]Phase 21,361 participants (Actual)Interventional2009-06-30Completed
A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs) [NCT02550067]7,830 participants (Actual)Interventional2015-12-14Completed
Levonorgestrel Releasing Intrauterine Device (Mirena) in Idiopathic Menorrhagia [NCT00868153]1,125 participants (Actual)Observational2004-08-31Completed
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia [NCT05903131]Phase 296 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Effects of St. John's Wort on Levonorgestrel [NCT00131885]Phase 436 participants (Actual)Interventional2005-08-31Completed
Pharmacokinetics of the Levonorgestrel-only Emergency Contraception Regimen in Normal-weight, Obese and Extremely Obese Users: a Pilot Study [NCT02104609]26 participants (Actual)Observational [Patient Registry]2013-04-30Completed
A Randomized Controlled Pilot Study of Polyethylene Glycol Loxenatide Plus LNG-IUS in Women With Endometrial Atypical Hyperplasia [NCT05172999]Phase 2/Phase 328 participants (Anticipated)Interventional2022-01-08Recruiting
An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects [NCT02159131]Phase 120 participants (Actual)Interventional2014-08-31Completed
Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review [NCT02414919]13,880 participants (Actual)Observational2015-04-01Completed
[NCT00551616]Phase 32,221 participants (Actual)Interventional2007-04-30Completed
A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies [NCT03557619]Phase 112 participants (Anticipated)Interventional2019-07-30Recruiting
Intrauterine Contraception for Adolescents Aged 14 to 18: A Multi-center Randomized Controlled Feasibility Trial of Levonorgestrel-releasing Intrauterine System Compared to the Copper T 380A [NCT00653159]Phase 423 participants (Actual)Interventional2007-07-31Completed
Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs [NCT00461253]25,565 participants (Actual)Observational2006-10-31Completed
Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion® (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers [NCT01096498]Phase 124 participants (Actual)Interventional2009-02-28Completed
Feasibility Study of IUD Placement Without Sounding [NCT05700812]90 participants (Anticipated)Interventional2023-02-01Recruiting
Effectiveness of Early Versus Standard Insertion of Post Abortion Intrauterine Contraception After First Trimester Medical Management of Incomplete Abortion in Central Uganda: A Non-Inferiority Randomized Clinical Trial [NCT05343546]2,076 participants (Anticipated)Interventional2022-06-30Not yet recruiting
A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea [NCT00909857]Phase 3507 participants (Actual)Interventional2009-04-30Completed
Oral Contraceptive Efficacy and Body Weight: Does Obesity Affect the Risk of Contraceptive Failure? [NCT00662454]Phase 4120 participants (Actual)Interventional2006-01-31Completed
A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety of LNG IUS (Mirena®) as Compared to Medroxyprogesterone Acetate During 6 Cycles of Treatment in Patients With Idiopathic Menorrhagia [NCT00360490]Phase 3165 participants (Actual)Interventional2006-07-31Completed
Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study [NCT05316493]Phase 2/Phase 3172 participants (Anticipated)Interventional2022-06-13Recruiting
A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Normal Menstruating Women [NCT05695352]Phase 221 participants (Anticipated)Interventional2022-06-28Recruiting
MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study. [NCT01961375]600 participants (Actual)Observational2015-10-30Completed
A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Cont [NCT00933179]Phase 230 participants (Actual)Interventional2009-06-30Completed
Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial [NCT03992937]132 participants (Actual)Interventional2019-06-20Completed
Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas in Women With Diameters Smaller Than 4 Centimeters Thereof, at University Hospital Fundación Santa Fe de Bogota, Between the Years 2015-2017 [NCT02599077]Phase 2/Phase 350 participants (Anticipated)Interventional2015-11-30Suspended
Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison t [NCT03074045]Phase 3145 participants (Actual)Interventional2017-03-13Completed
MiCo - Mirena or Conventional Medical Treatment for Menorrhagia [NCT00864136]647 participants (Actual)Observational2008-11-30Completed
Multi-center, Open Label, Single Arm Study to Assess Efficacy, Safety, Bleeding Pattern and Pharmacokinetics of the Ultra Low Dose Levonorgestrel Intrauterine Contraceptive System (LCS) for a Maximum of 3 Years in Women 18 to 40 Years of Age [NCT00884260]Phase 3918 participants (Actual)Interventional2009-04-30Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04230070]Phase 130 participants (Actual)Interventional2020-10-24Completed
A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women Using One of Three Different Doses of DR-1031 Oral Contraceptive Compared to Seasonale Oral Contraceptive Regimen [NCT00394771]Phase 2567 participants (Actual)Interventional2006-10-31Completed
Insertion of an IUD After Medical Abortion [NCT00621543]120 participants (Actual)Interventional2006-03-31Completed
A Phase 1, Open-label Study to Assess the Effect of CTP-543 on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Subjects [NCT04309643]Phase 121 participants (Actual)Interventional2020-06-09Completed
A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years [NCT02903888]886 participants (Actual)Observational2016-09-08Completed
The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women [NCT01388582]Phase 440 participants (Actual)Interventional2011-04-30Completed
Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector [NCT01392157]Phase 4300 participants (Actual)Interventional2011-06-30Completed
Levonorgestrel Releasing Intrauterine System (MIRENA) in Idiopathic Menorrhagia [NCT00874653]78 participants (Actual)Observational2008-04-30Completed
A PHASE 1, RANDOMIZED, OPEN LABEL, 2 WAY CROSSOVER STUDY TO DEMONSTRATE A LACK OF AN EFFECT OF MULTIPLE DOSE PF 06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS [NCT04018274]Phase 129 participants (Actual)Interventional2019-08-09Completed
A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers [NCT00685906]Phase 124 participants (Anticipated)Interventional2008-04-30Completed
Cervical Device Contraception [NCT00689494]Phase 1/Phase 210 participants (Anticipated)Interventional2008-06-30Not yet recruiting
A Multicentre, Open Label, Uncontrolled Study of the Tolerance, Acceptability and Contraceptive Efficacy of Mirena 52 mg®, an Intra-uterine Levonorgestrel Device, During the First Year After Insertion Post-partum [NCT00696202]Phase 4199 participants (Actual)Interventional2003-09-30Completed
A Pilot Study of Copper T380A IUDs Versus Oral Levonorgestrel for Emergency Contraception [NCT00669396]57 participants (Actual)Interventional2008-04-30Completed
Acceptability of Long-term Progestin-only Contraception in Europe [NCT00931827]436 participants (Actual)Observational2008-01-31Completed
Contraceptive Hormone and Reward Measurement (CHARM Study) [NCT05058872]Phase 4144 participants (Anticipated)Interventional2021-10-01Recruiting
A Multiple Center, Randomised, Parallel Group, Single-blind Clinical Trial, to Assess the Therapeutic Equivalence in Terms of Efficacy and Safety of Test Product (Levosert) and Reference Product (Mirena®) in Patients With Menorrhagia - Phase III (Therapeu [NCT01695902]Phase 3280 participants (Actual)Interventional2007-12-31Completed
A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Ana [NCT02545452]Phase 152 participants (Actual)Interventional2015-09-15Completed
Preventing Future Pregnancy After Choosing the Copper IUD vs. Oral Levonorgestrel for Emergency Contraception [NCT00966771]548 participants (Actual)Observational2009-10-31Completed
Scandinavian Mirena Insertion Nulliparous Trial of an Observational Study. [NCT00798980]224 participants (Actual)Observational2007-02-28Completed
Mirena Observational Program [NCT00883662]2,725 participants (Actual)Observational2009-05-31Completed
A Pilot Randomized Control Trial of Advanced Supply of Levonorgestrel Emergency Contraception vs. Routine Postpartum Contraceptive Care in the Teenage Population [NCT00433004]Phase 450 participants (Actual)Interventional2007-02-28Completed
Multi-center, Open, Randomized, Dose Finding Phase II Study to Investigate Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) Releasing Different Amounts of Levonorgestrel Compared to MIRENA in Nulliparous and Parous Women in Need of C [NCT00185380]Phase 2742 participants (Actual)Interventional2005-04-30Completed
A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia [NCT01074892]Phase 4170 participants (Actual)Interventional2005-05-31Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug-Drug Interactions Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel-Ethinyl Estradiol-Containing Oral Contraceptives, and Carbamazepine in Healthy Adult Participants [NCT06071442]Phase 160 participants (Anticipated)Interventional2023-10-09Recruiting
A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate the Effects on Hemostasis, Lipids and Carbohydrate Metabolism, and on Adrenal and Thyroid Function of a Monophasic COC Containing 2.5 mg NOMAC and 1.5 mg E2 Compared to a Monophasic CO [NCT00511355]Phase 3121 participants (Actual)Interventional2006-10-31Completed
Hormonal Cycles in Women: Effects on TMD Pain & Symptoms [NCT00237042]252 participants (Actual)Interventional2005-10-31Completed
Postpartum Glucose Tolerance in Women With Recent Gestational Diabetes Using the Levonorgestrel IUD and Non-Hormonal Contraception: A Prospective Cohort Study [NCT01022645]42 participants (Actual)Observational2009-11-30Completed
Open-label, Randomized, Crossover Study to Prove the Bioequivalence Between Opxion® (Levonorgestrel 1.5 mg Coated Tablet From Bayer de Mexico) and Postinor 2® (Levonorgestrel 1.5 mg Tablet From Biofarma Natural CMD) in Healthy Volunteers [NCT01073904]Phase 132 participants (Actual)Interventional2009-09-30Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing a 2.2mg 17 Beta-Estradiol/0.69mg Levonorgestrel Combination Transdermal Patch, and a 1mg 17 Beta-Estradiol Transdermal Patch With a Placebo Patch in Postmenopausal Women to Determ [NCT00206622]Phase 4425 participants (Actual)Interventional2004-12-31Completed
Pre-treatment With Mifepristone in Patients With Mirena for Optimizing Bleeding Pattern in Pre-menopausal Women [NCT01931657]Phase 260 participants (Anticipated)Interventional2013-08-31Completed
Generating Evidence to Improve Same-day Etonogestrel (ENG) Implant Insertion for Emergency Contraception [NCT06162611]Phase 4790 participants (Anticipated)Interventional2023-11-06Recruiting
Impact of Gastric Bypass Surgery on the Pharmacokinetics of Oral Contraceptive Hormones [NCT01941134]Phase 40 participants (Actual)Interventional2013-04-30Withdrawn(stopped due to Recruitment trouble)
A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS) [NCT01943058]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn(stopped due to Lack of funding)
Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives [NCT05044962]700 participants (Anticipated)Interventional2021-11-26Recruiting
A Non-interventional Study to Observe the Bleeding Pattern of LNG-IUS Inserted Immediately After Surgical Abortion Compared With Copper IUD [NCT01958684]512 participants (Actual)Observational2013-10-31Completed
A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception [NCT01963962]188 participants (Actual)Observational2013-07-31Completed
RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia. A Pilot Study [NCT01965587]100 participants (Anticipated)Interventional2013-12-31Not yet recruiting
Prevention of Endometrial Tumors (POET) [NCT00566644]Phase 3600 participants (Anticipated)Interventional2007-07-31Terminated(stopped due to Withdrawn due to poor accrual)
Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses [NCT02002260]59 participants (Anticipated)Interventional2013-02-28Active, not recruiting
A Multicenter, Randomized, Open-labe, Controlled Study to Evaluate the Efficacy and Safety of the Combined Levonorgestrel(LNG) 100mcg and Ethinyl Estradiol(EE) 20mcg for Oral Contraception [NCT02021097]Phase 31,008 participants (Anticipated)Interventional2012-02-29Recruiting
Hormonal Contraception and the Risk of HIV Acquisition [NCT00006324]6,360 participants Interventional1999-12-31Completed
Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills [NCT00570440]Phase 4362 participants (Anticipated)Interventional2007-08-31Completed
The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters [NCT00584610]50 participants (Anticipated)Interventional2007-12-31Recruiting
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle [NCT00196326]Phase 32,235 participants (Actual)Interventional2005-06-30Completed
A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents [NCT00196313]Phase 295 participants (Actual)Interventional2005-05-31Completed
Evaluation of the Effectiveness, Safety and Tolerability of LevoCept (Levonorgestrel-Releasing Intrauterine System) for Long-Acting Reversible Contraception [NCT02882191]Phase 2279 participants (Actual)Interventional2016-11-30Completed
An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers [NCT04972396]Phase 140 participants (Actual)Interventional2021-10-05Completed
Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P [NCT02556411]50 participants (Anticipated)Interventional2021-06-01Not yet recruiting
The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women [NCT02697851]Phase 113 participants (Actual)Interventional2016-07-31Terminated(stopped due to "Insufficient enrolment and business reasons")
A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis [NCT01165307]Phase 477 participants (Actual)Interventional2009-08-31Completed
Immediate Post-placental Insertion of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean Delivery vs. 4-8 Week Post-delivery Interval Insertion: A Randomized Controlled Trial [NCT00635362]42 participants (Actual)Interventional2007-05-31Terminated(stopped due to Low recruitment)
A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings [NCT02855346]Phase 124 participants (Actual)Interventional2017-05-03Completed
Drug Use Investigation of Mirena [NCT01414140]567 participants (Actual)Observational2007-05-31Completed
A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women [NCT00096694]41 participants InterventionalCompleted
A Study of Continuous Oral Contraceptives and Doxycycline [NCT00480532]131 participants (Actual)Interventional2007-05-31Completed
A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers [NCT02846142]Phase 194 participants (Actual)Interventional2016-06-30Completed
"Assessing Use Of Mifepristone After Progestin Priming For Use As Missed Period Pills" [NCT04676776]Phase 2139 participants (Anticipated)Interventional2021-01-25Recruiting
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches. [NCT00781456]Phase 2109 participants (Actual)Interventional2009-01-31Completed
Immediate Versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial [NCT00475228]Phase 493 participants (Actual)Interventional2007-03-31Completed
A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Microgra [NCT00213096]Phase 250 participants Interventional2003-03-31Completed
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer [NCT02397083]Phase 2270 participants (Anticipated)Interventional2015-09-23Recruiting
An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study to Compare Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg in 2 Dosage Forms With Different Dissolution Characteristics in Healthy, Cycling Women [NCT00447863]Phase 10 participants (Actual)Interventional2007-08-31Withdrawn
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation [NCT02477202]7 participants (Actual)Interventional2015-06-30Completed
Phase I, 90-Day Safety, Pharmacokinetic, And Pharmacodynamic Study Of Intravaginal Rings Releasing Tenofovir And Levonorgestrel [NCT03279120]Phase 166 participants (Actual)Interventional2017-09-28Completed
Impact of Intrauterine Contraception on the Immune Environment of the Female Genital Tract [NCT01240811]42 participants (Actual)Interventional2010-11-30Completed
Multicenter, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 12 µg LNG/Day Initial in Vitro Release Rate (LCS12) in Comparison to [NCT01254292]Phase 3567 participants (Actual)Interventional2011-01-06Completed
A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women. [NCT01252186]Phase 2265 participants (Actual)Interventional2010-11-30Completed
A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN HEALTHY POST-MENOPAUSAL F [NCT05093205]Phase 135 participants (Actual)Interventional2021-10-25Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Spermatogenesis Suppression After Oral Administration of Dimethandrolone Undecanote (DMAU) Alone or With Levonorgestrel (LNG) for 12 Weeks Versus Placebo Alone in Normal Men [NCT03455075]Phase 2100 participants (Anticipated)Interventional2018-04-16Recruiting
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women [NCT01789879]Phase 260 participants (Actual)Interventional2014-03-04Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 0.1 mg/0.02 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04194905]Phase 110 participants (Actual)Interventional2020-11-21Completed
Pericoital Oral Contraception With Levonorgestrel: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Acceptability [NCT00922233]Phase 372 participants (Actual)Interventional2010-01-31Completed
The Effect of Exenatide on Single and Multiple Doses Oral Contraceptive Pharmacokinetics in Healthy Female Subjects [NCT00254800]Phase 138 participants (Actual)Interventional2005-11-30Completed
A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis [NCT00455845]Phase 354 participants (Anticipated)Interventional2007-04-30Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea an [NCT00117260]Phase 30 participants (Actual)Interventional2005-07-31Withdrawn(stopped due to Sponsor decision)
A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills [NCT00117273]Phase 336 participants (Anticipated)Interventional2005-06-30Completed
Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits [NCT00490087]Phase 321 participants (Actual)Interventional1999-01-31Completed
A Multicenter, Open Labelled, Uncontrolled, Phase IV Clinical Study to Evaluate the Health-related Quality of Life and Sexual Well-being in Young (18-35) Healthy Mirena Users Switching From OC, Over the First Year Post-insertion. [NCT00498784]Phase 4141 participants (Actual)Interventional2005-11-30Completed
A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35 [NCT00161226]44 participants (Anticipated)Observational2004-02-29Terminated(stopped due to Principal investigator left institution)
Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding [NCT05594186]158 participants (Actual)Interventional2019-03-01Completed
A Pilot Study of Early Postpartum Intrauterine Contraception [NCT00997932]Phase 440 participants (Actual)Interventional2009-06-30Completed
Improving Contraceptive Effectiveness in Obese Women [NCT01170390]Phase 432 participants (Actual)Interventional2009-09-30Completed
Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery [NCT01272960]53 participants (Actual)Interventional2010-10-31Completed
An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers [NCT01328184]Phase 118 participants (Actual)Interventional2011-04-30Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Levonorgestrel 90 Mcg and Ethinyl Estradiol 20 Mcg in a Continuous Daily Regimen on Menstrual Cycle-Related Symptoms [NCT00161681]Phase 3200 participants Interventional2005-07-31Completed
A Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval Compared to Conventional Oral Contraceptive Therapy for Cyclic Pelvic Pain [NCT00196365]Phase 397 participants (Actual)Interventional2005-01-31Completed
A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-free Interval. [NCT00196352]Phase 3320 participants (Actual)Interventional2003-05-31Completed
The Therapeutic Effect of Medroxyprogesterone Acetate vs. LNG-IUS in Early-stage Endometrioid Carcinoma [NCT05565573]Phase 2/Phase 3148 participants (Anticipated)Interventional2022-11-01Recruiting
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women [NCT00996580]Phase 33,597 participants (Actual)Interventional2009-10-31Completed
A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestr [NCT02957630]Phase 1/Phase 2101 participants (Actual)Interventional2016-09-30Completed
A Pilot Study of the Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Plan B, and Efavirenz [NCT00482963]Phase 124 participants (Actual)Interventional2007-05-31Completed
Randomized Controlled Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia [NCT00520455]177 participants (Actual)Interventional2004-01-31Completed
Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial [NCT01539720]273 participants (Actual)Interventional2012-12-31Completed
Multicenter Study to Investigate the Bleeding Profile and the Insertion Easiness in Women Inserted With a Second Consecutive MIRENA for Contraception or Menorrhagia [NCT00393198]Phase 4204 participants (Actual)Interventional2006-10-31Completed
Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality [NCT01805817]Phase 40 participants (Actual)Interventional2012-12-31Withdrawn
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder [NCT00128934]Phase 3744 participants (Anticipated)Interventional2005-08-31Completed
Human Ovarian Follicular Dynamics and Emergency Contraception [NCT00204451]Phase 440 participants Interventional2005-07-31Completed
Prospective Multicentre Non-interventional Comparative Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction [NCT01590537]2,348 participants (Actual)Observational2011-09-30Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder [NCT00195559]Phase 3526 participants (Anticipated)Interventional2005-09-30Completed
A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg [NCT04058873]1,980 participants (Actual)Observational2019-10-01Completed
Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes [NCT02121067]Phase 450 participants (Actual)Interventional2014-09-30Completed
Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery [NCT00476021]168 participants (Actual)Interventional2007-05-31Completed
A Phase I Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile of Intramuscular or Subcutaneous Injections of Levonorgestrel Butanoate (LB) for Female Contraception [NCT04143659]Phase 1136 participants (Anticipated)Interventional2020-03-03Recruiting
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate CYP3A4-Mediated, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adult Subjects [NCT04142762]Phase 180 participants (Actual)Interventional2019-10-18Completed
Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion [NCT01833793]35 participants (Actual)Observational2013-02-28Completed
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception [NCT00245921]Phase 32,000 participants Interventional2003-02-28Completed
A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive [NCT00248963]Phase 3600 participants InterventionalCompleted
A Single Center, Open-Label Study to Evaluate the Effects on Ovulation of Levonorgestrel 90mg and Ethinyl Estradiol 20mg in a Daily, Continuous, Oral Regimen. [NCT00254189]Phase 260 participants Interventional2002-12-31Completed
A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception [NCT00271583]Phase 2/Phase 31,672 participants (Actual)Interventional1999-09-30Completed
[NCT01501448]Phase 4118 participants (Actual)Interventional2012-01-31Completed
A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide [NCT01508858]Phase 121 participants (Actual)Interventional2006-11-30Completed
Functional Study of the Hypothalamus in High-resolution Magnetic Resonance Imaging (MRI) in Women With Polycystic Ovary Syndrome (PCOS): a Comparative Study [NCT03043924]52 participants (Anticipated)Interventional2017-09-26Active, not recruiting
RAPID EC - Randomized Controlled Trial Assessing Pregnancy With Intrauterine Devices for Emergency Contraception [NCT02175030]Phase 4711 participants (Actual)Interventional2016-08-31Completed
DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users. [NCT01731132]207 participants (Actual)Observational2012-07-31Completed
Immediate vs. 4-8 Week Postpartum Levonorgestrel-releasing Intrauterine System Placement: A Randomized Clinical Trial (Short Title: PPIUD1) [NCT01555931]Phase 461 participants (Actual)Interventional2012-03-31Completed
Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration [NCT01250210]Phase 2123 participants (Actual)Interventional2007-09-30Completed
Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women [NCT01546454]5 participants (Actual)Interventional2012-02-29Completed
Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Levonorgestrel IUD to Assess Breast Feeding Outcomes (BLIS - Breastfeeding Levonorgestrel IUD Study) [NCT01990703]Phase 4285 participants (Actual)Interventional2014-01-31Completed
Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users [NCT02362373]Phase 420 participants (Actual)Interventional2011-08-31Completed
Multi-center, Single-arm Study to Assess the Safety, Efficacy, Discontinuation Rate and Pharmacokinetics of the Low-dose Levonorgestrel Intrauterine Contraceptive System (LCS12) in Post-menarcheal Female Adolescents Under 18 Years of Age for 1 Year, and a [NCT01434160]Phase 3304 participants (Actual)Interventional2011-09-30Completed
Contraceptives and Dolutegravir-based ART [NCT04910711]Phase 4140 participants (Anticipated)Interventional2021-10-21Active, not recruiting
A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception [NCT00995150]Phase 31,910 participants (Actual)Interventional2009-11-30Completed
Immediate Postplacental Intrauterine Device Insertion in High-risk Patient Populations [NCT02169869]33 participants (Actual)Interventional2014-09-30Terminated(stopped due to Change in local healthcare policies and practices)
Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa [NCT00310791]Phase 2/Phase 380 participants (Actual)Interventional2004-04-30Completed
A Randomized, Open-Label, Parallel Group Study To Evaluate Pharmacokinetic Profile, Wearability And Safety of Two Progestin-Only Patches Containing Different Doses Of Levonorgestrel (LNG) [NCT01623466]Phase 1/Phase 236 participants (Actual)Interventional2012-07-31Completed
An Observational, Prospective, Multicenter Study to Assess the Continuation Rates and User Acceptability of Bleeding Profile in First-time Users of Low-dose LNG-IUS [NCT04785950]316 participants (Actual)Observational2021-02-21Completed
Improving the Effectiveness of Orally Dosed Emergency Contraceptives in Obese Women - Pharmacodynamics of 3.0mg LNG [NCT02863445]Phase 470 participants (Actual)Interventional2017-07-06Completed
Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel (Ethinyl Estradiol + Levonorgestrel + Folic Acid - Coated Tablet - 0.02 mg + 0.10 mg + 0.4 mg; Biolab Sanus Farmaceutica Ltda) in Female Volunt [NCT03359057]Phase 336 participants (Actual)Interventional2013-02-26Completed
Early Versus Standard Interval Postpartum Intrauterine Device (IUD) Placement at 3 Weeks or 6 Weeks Following Delivery: A Prospective Randomized Trial [NCT01594476]Phase 4201 participants (Actual)Interventional2012-03-31Terminated(stopped due to Incomplete study enrollment prior to depletion of funding)
Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri [NCT03037944]Early Phase 132 participants (Anticipated)Interventional2016-03-01Recruiting
Treatment With Medroxyprogesterone Acetate(MPA) Plus Levonorgestrel-releasing Intrauterine System(LNG-IUS) in Young Women With Early Stage Endometrial Cancer: Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2009) [NCT01594879]Phase 239 participants (Anticipated)Interventional2012-01-31Recruiting
A Multi-center, Single-blinded, Randomized, Controlled, Parallel-group Study to Evaluate the Wearing Comfort of Two Different Placebo Intrauterine Systems FR01 and FR20 Compared to a Placebo T-frame Intrauterine System for 3 Cycles in Healthy Women Aged 1 [NCT01595022]Phase 190 participants (Actual)Interventional2010-01-31Completed
An Open-label, Single-dose, Randomized, 2-period, Crossover, Bioequivalence Study to Compare Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women [NCT00319163]Phase 126 participants Interventional2006-05-31Completed
Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism [NCT01297348]598,682 participants (Actual)Observational2007-07-31Completed
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy [NCT03819114]Phase 2122 participants (Actual)Interventional2019-05-06Completed
Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women: a Cluster-randomized Trial [NCT04005391]208 participants (Actual)Interventional2018-10-23Completed
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa [NCT02475265]Phase 211 participants (Actual)Interventional2015-07-31Completed
Effects of Protease Inhibitor Use on Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics in HIV-positive Women [NCT02531321]Phase 417 participants (Actual)Interventional2015-08-31Terminated(stopped due to Difficulty recruiting)
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start [NCT05444582]Phase 41,404 participants (Anticipated)Interventional2022-11-07Recruiting
Determining the Impact of Combined Hormonal Contraceptives on Ulipristal Acetate [NCT02577601]Phase 436 participants (Actual)Interventional2015-09-08Completed
Immediate Postpartum Insertion of Kyleena vs Mirena Contraceptive Intrauterine Devices [NCT03657602]Early Phase 128 participants (Actual)Interventional2019-12-15Completed
Study on the Association of Uterine Perforation and Intrauterine Device (IUD) Expulsion With Breastfeeding Status at the Time of IUD Insertion and Postpartum Timing of IUD Insertion in Electronic Medical Record Databases - A Postmarketing Requirement for [NCT03754556]326,658 participants (Actual)Observational2018-12-03Completed
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer [NCT00445887]Phase 260 participants (Actual)Interventional2008-03-10Completed
Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement: A Randomized, Controlled Trial [NCT01598662]32 participants (Actual)Interventional2009-07-31Terminated(stopped due to Unable to secure funding)
Quantification of Immune Cells in Women Using Contraception [NCT01873170]326 participants (Actual)Observational2013-08-31Completed
Multi-center, Open-label, Single-arm Study to Assess the Safety and Contraceptive Efficacy of a Levonorgestrel-containing Intravaginal Ring During a Treatment Period of One Year in Healthy Women 18 to 35 Years of Age [NCT02403401]Phase 31,471 participants (Actual)Interventional2015-05-15Completed
A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore [NCT05492487]Phase 260 participants (Anticipated)Interventional2020-01-03Recruiting
An Observational, Prospective, Multicentre Study to Assess the Sensitivity to Change of the SAMANTA Questionnaire in Women With Heavy Menstrual Bleeding (HMB) [NCT03751800]422 participants (Actual)Observational2018-12-12Completed
A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leu [NCT02203331]Phase 2319 participants (Actual)Interventional2014-10-16Completed
A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on [NCT04255277]Phase 197 participants (Actual)Interventional2020-01-31Completed
Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? [NCT03104309]100 participants (Actual)Interventional2015-06-30Completed
Phase3, Placebo Controlled, Randomized, Double-blinded, Long-Term, NSAID-Add-on, Clinical Trial of NPC-16 for Treatment of Dysmenorrhea [NCT02362711]Phase 3248 participants (Actual)Interventional2015-02-28Completed
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study [NCT05916469]300 participants (Anticipated)Observational [Patient Registry]2024-07-31Not yet recruiting
Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial [NCT02341027]205 participants (Actual)Interventional2015-01-31Completed
An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Voluntee [NCT01570244]Phase 116 participants (Actual)Interventional2012-04-30Completed
Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa [NCT01721798]205 participants (Actual)Interventional2013-11-10Completed
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial [NCT03614494]Phase 2/Phase 3860 participants (Actual)Interventional2018-08-20Completed
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study [NCT02067663]123 participants (Actual)Observational2014-04-30Completed
A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium [NCT01686126]Phase 2165 participants (Actual)Interventional2012-12-31Active, not recruiting
The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS) [NCT00302848]59,510 participants (Actual)Observational2000-11-30Completed
A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Ugandan Women [NCT02722421]Phase 228 participants (Actual)Interventional2017-04-06Completed
A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding [NCT03642210]Phase 3105 participants (Actual)Interventional2019-01-17Completed
Open-label Randomized Controlled Trial for the Effects of Continuous Ethinylestradiol/Levonorgestrel (30/150 μg/Day) Compared With Vitamin E (400 IU/Day) in the Treatment of Menstrually-related Migraine and Migraine During Perimenopause [NCT04007874]Phase 3360 participants (Anticipated)Interventional2019-09-10Recruiting
Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects [NCT03506399]Phase 10 participants (Actual)Interventional2018-06-30Withdrawn(stopped due to Stopped for futility. Phase 3 studies not likely to meet primary endpoints.)
A Prospective Cohort Study Evaluating the Impact of Three Progestin-based Hormonal Contraceptive (HC) Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically [NCT03660046]225 participants (Anticipated)Observational2018-12-07Recruiting
Multi-center, Randomized, Comparator-controlled, Single-blind, Parallel-group Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of an Intrauterine System Releasing BAY 1007626, as Compared With Mirena and Jaydess, in a Combined Proof- [NCT02490774]Phase 2174 participants (Actual)Interventional2015-06-22Terminated
A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-based Antiretroviral Therapy [NCT03589027]Phase 260 participants (Anticipated)Interventional2018-08-07Recruiting
Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis [NCT03027648]1,100 participants (Actual)Interventional2006-12-31Completed
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk [NCT02357368]Phase 459 participants (Actual)Interventional2015-02-28Completed
An Open-label Drug-drug Interaction Study in Healthy Female Adult Subjects to Investigate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel [NCT03249402]Phase 124 participants (Actual)Interventional2017-08-14Completed
Effect of Initiation of Intrauterine Contraception on Hair Cortisol Concentration [NCT03499379]39 participants (Actual)Observational2018-04-16Completed
Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids [NCT03317795]Phase 418 participants (Actual)Interventional2017-11-14Completed
Ambispective Comparative Cohort Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin on ICSI and Vitrified-Warmed Embryo Transfer Outcomes in Women With Adenomyosis [NCT05152667]354 participants (Anticipated)Observational2021-11-27Recruiting
Control of Bleeding on Nexplanon in Latinx Patients [NCT05116371]144 participants (Anticipated)Observational2021-12-01Not yet recruiting
Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combina [NCT03353857]Phase 168 participants (Actual)Interventional2017-11-29Completed
The UMPALA Study: A Clinical Study to Assess the Impact of Contraceptives on the Cervico-Vaginal Mucosa [NCT04814927]Phase 4112 participants (Actual)Interventional2021-03-01Completed
A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users. [NCT02957292]Phase 4108 participants (Actual)Interventional2016-06-01Completed
Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis [NCT02480647]Phase 4100 participants (Actual)Interventional2016-05-31Completed
A Phase 1 Study to Evaluate the Pharmacokinetic Interaction Potential Between BIIB074 and an Oral Contraceptive Regimen in Healthy Female Subjects [NCT03324685]Phase 136 participants (Actual)Interventional2017-11-11Completed
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy [NCT03301207]Phase 125 participants (Actual)Interventional2017-10-20Completed
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer [NCT03241914]Phase 2/Phase 364 participants (Actual)Interventional2017-07-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00131885 (6) [back to overview]Number of Participants With Progesterone Levels Above 3.0 ng/ml at Time 1 (Baseline) and Time 2 (After Intervention With St John's Wort or Placebo).
NCT00131885 (6) [back to overview]Mean Levels of Luteinizing Hormone, Drawn at Weekly Intervals Until Next Menses
NCT00131885 (6) [back to overview]Mean Levels of Follicle-stimulating Hormone Drawn at Weekly Intervals Until Next Menses
NCT00131885 (6) [back to overview]Mean Levels of Estradiol-17b (E2) Drawn at Weekly Intervals Until Next Menses
NCT00131885 (6) [back to overview]Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time 2 (During Treatment With St. John's Wort or Placebo)
NCT00131885 (6) [back to overview]Clearance (L/hr) of Levonorgestrel Over 24 Hours for Each Dosage Group and Each Study Session.
NCT00185380 (7) [back to overview]Number of Subjects With Total or Partial Expulsions
NCT00185380 (7) [back to overview]Bleeding Pattern by 90-day Reference Periods - Reference Period 1
NCT00185380 (7) [back to overview]Pearl Index
NCT00185380 (7) [back to overview]Bleeding Pattern by 90-day Reference Periods - Reference Period 12
NCT00185380 (7) [back to overview]Bleeding Pattern by 90-day Reference Periods - Reference Period 2
NCT00185380 (7) [back to overview]Bleeding Pattern by 90-day Reference Periods - Reference Period 3
NCT00185380 (7) [back to overview]Bleeding Pattern by 90-day Reference Periods - Reference Period 4
NCT00196313 (5) [back to overview]Change From Baseline in Maximum Severity of Abdominal/Pelvic Pain
NCT00196313 (5) [back to overview]Analgesic Use
NCT00196313 (5) [back to overview]Number of Days Missed From School/Work or Other Activities
NCT00196313 (5) [back to overview]Mean Change in Average Severity for Abdominal/Pelvic Pain
NCT00196313 (5) [back to overview]Incidence of Menstrual Bleeding and /or Spotting
NCT00196326 (3) [back to overview]"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining On Drug Pregnancy"
NCT00196326 (3) [back to overview]Participants With Treatment-Emergent Adverse Events
NCT00196326 (3) [back to overview]"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining On Drug Pregnancy"
NCT00237042 (4) [back to overview]Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)
NCT00237042 (4) [back to overview]Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)
NCT00237042 (4) [back to overview]Number of Participants With Pain-Related Activity Interference
NCT00237042 (4) [back to overview]Number of Participants With Pain-Related Activity Interference
NCT00302848 (1) [back to overview]Number of Participants With Venous Thromboembolism (VTE)
NCT00310791 (1) [back to overview]Areal Bone Density by DXA
NCT00360490 (15) [back to overview]Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)
NCT00360490 (15) [back to overview]The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)
NCT00360490 (15) [back to overview]Percentage of Patients With Successful Treatment
NCT00360490 (15) [back to overview]Total Number of Spotting Days
NCT00360490 (15) [back to overview]Total Number of Spotting and Bleeding Days
NCT00360490 (15) [back to overview]Total Number of Bleeding Episodes
NCT00360490 (15) [back to overview]Total Number of Bleeding Days
NCT00360490 (15) [back to overview]Percent Change From Baseline MBL to End of Study MBL (Cycle 6)
NCT00360490 (15) [back to overview]Percentage of Patients With Improvement in the Investigator Global Assessment Scale
NCT00360490 (15) [back to overview]Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)
NCT00360490 (15) [back to overview]Percent Change in Hematocrit
NCT00360490 (15) [back to overview]Percent Change in Hemoglobin
NCT00360490 (15) [back to overview]Percent Change in Serum Ferritin
NCT00360490 (15) [back to overview]Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group
NCT00360490 (15) [back to overview]Percentage of Patients With Improvement in the Patients Overall Assessment Scale
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Days With Bleeding During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]Days With Bleeding During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)
NCT00433004 (3) [back to overview]PREGNANCY RATES
NCT00433004 (3) [back to overview]PLAN B USE
NCT00433004 (3) [back to overview]ABILITY TO FOLLOW POSTPARTUM TEENS FOR 1 YEAR.
NCT00445887 (5) [back to overview]Patients With High Expression of Transforming Growth Factor-beta 1
NCT00445887 (5) [back to overview]Number of Participants With Adverse Events According to Grade as Determined by NCI CTCAE v.3.0
NCT00445887 (5) [back to overview]Proportion of Proliferation as Measured by Ki-67
NCT00445887 (5) [back to overview]Median Proportion Cells That Are Apoptotic in Fallopian Tube Tissue
NCT00445887 (5) [back to overview]Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue
NCT00461253 (1) [back to overview]Breast Cancer Risk
NCT00475228 (3) [back to overview]To Compare Expulsion Rates Between Immediate Insertion and Delayed Insertion
NCT00475228 (3) [back to overview]To Examine the Number of Women Receiving the LNG-IUD in Each Group
NCT00475228 (3) [back to overview]The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment.
NCT00476021 (6) [back to overview]IUD Usage Rate at 6 Months
NCT00476021 (6) [back to overview]Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography
NCT00476021 (6) [back to overview]Follow-up Rates for Delayed Insertion of LNG-IUD
NCT00476021 (6) [back to overview]Proportion of Women Who Are Able to Have the LNG-IUD Placed Postplacentally and Are Not Excluded From Placement
NCT00476021 (6) [back to overview]Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion
NCT00476021 (6) [back to overview]Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates
NCT00480532 (3) [back to overview]Differences in Bleeding Patterns Between Study Groups.
NCT00480532 (3) [back to overview]Subject Compliance
NCT00480532 (3) [back to overview]Subject Satisfaction.
NCT00511355 (47) [back to overview]Area Under the Curve Over 3 Hours (AUC3) for Glucose (Oral Glucose Tolerance Test [OGTT])
NCT00511355 (47) [back to overview]AUC3 for Insulin (OGTT)
NCT00511355 (47) [back to overview]Serum Concentration of Free Thyroxine (T4)
NCT00511355 (47) [back to overview]Average Number of Withdrawal Bleeding/Spotting Days
NCT00511355 (47) [back to overview]Incremental AUC3 for Glucose (OGTT)
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIII
NCT00511355 (47) [back to overview]Serum Concentration of Corticosteroid Binding Globulin (CBG)
NCT00511355 (47) [back to overview]Serum Concentration of D-Dimer
NCT00511355 (47) [back to overview]Serum Concentration of Dehydroepiandrosterone Sulphate (DHEAS)
NCT00511355 (47) [back to overview]Serum Concentration of Dihydrotestosterone (DHT)
NCT00511355 (47) [back to overview]Serum Concentration of Free Testosterone
NCT00511355 (47) [back to overview]Serum Concentration of HDL2-cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of HDL3-cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Hemoglobin Type A1c (HbA1c)
NCT00511355 (47) [back to overview]Serum Concentration of High Density Lipoprotein (HDL)-Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Lipoprotein(a)
NCT00511355 (47) [back to overview]Serum Concentration of Low Density Lipoprotein (LDL)-Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Protein C
NCT00511355 (47) [back to overview]Serum Concentration of Protein S (Free)
NCT00511355 (47) [back to overview]Serum Concentration of Protein S (Total)
NCT00511355 (47) [back to overview]Serum Concentration of Prothrombin Fragments 1 + 2
NCT00511355 (47) [back to overview]Serum Concentration of Sex Hormone Binding Globulin (SHBG)
NCT00511355 (47) [back to overview]Serum Concentration of Thyroxin Binding Globulin (TBG)
NCT00511355 (47) [back to overview]Serum Concentration of Total Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Total Cortisol
NCT00511355 (47) [back to overview]Serum Concentration of Total Testosterone
NCT00511355 (47) [back to overview]Serum Concentration of Total Triglycerides
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIIa
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor II
NCT00511355 (47) [back to overview]Serum Concentration of C-Reactive Protein (CRP)
NCT00511355 (47) [back to overview]Serum Concentration of Apolipoprotein B
NCT00511355 (47) [back to overview]Serum Concentration of Apolipoprotein A-1
NCT00511355 (47) [back to overview]Serum Concentration of Antithrombin III
NCT00511355 (47) [back to overview]Serum Concentration of Androstenedione
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Early Withdrawal Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Continued Withdrawal Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Absence of Withdrawal Bleeding
NCT00511355 (47) [back to overview]Incremental AUC3 for Insulin (OGTT)
NCT00511355 (47) [back to overview]Serum Concentration of Thyroid Stimulating Hormone (TSH)
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIIc
NCT00511355 (47) [back to overview]Average Number of Breakthrough Bleeding/Spotting Days
NCT00511355 (47) [back to overview]Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)
NCT00511355 (47) [back to overview]Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)
NCT00511355 (47) [back to overview]APC Resistance Ratio (Activated Partial Thromboplastin Time [APTT]-Based)
NCT00551616 (3) [back to overview]Number of Participants With Pregnancy
NCT00551616 (3) [back to overview]Actual Pregnancy Rate Compared to Expected Pregnancy Rate
NCT00551616 (3) [back to overview]Menstrual Bleeding Patterns
NCT00621543 (2) [back to overview]Percentage of Women Continuing IUD Use at 3 Months
NCT00621543 (2) [back to overview]Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion.
NCT00635362 (5) [back to overview]Perforation Rates
NCT00635362 (5) [back to overview]Rates of Expulsion of the LNG-IUS
NCT00635362 (5) [back to overview]Satisfaction With LNG-IUS
NCT00635362 (5) [back to overview]Satisfaction With LNG-IUS
NCT00635362 (5) [back to overview]Use of the LNG-IUS for Contraception
NCT00653159 (5) [back to overview]Device Satisfaction Rates
NCT00653159 (5) [back to overview]Retention Rate
NCT00653159 (5) [back to overview]Pregnancy Rates
NCT00653159 (5) [back to overview]Expulsion Rates
NCT00653159 (5) [back to overview]Heavy Bleeding Rates
NCT00669396 (4) [back to overview]Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception
NCT00669396 (4) [back to overview]Pregnancy
NCT00669396 (4) [back to overview]IUD Expulsion, Removal, or Perforation
NCT00669396 (4) [back to overview]Infection
NCT00777556 (4) [back to overview]Participants With Treatment-Emergent Adverse Events (TEAE)
NCT00777556 (4) [back to overview]Participants Summarized by Repeat Use of Emergency Contraception (EC)
NCT00777556 (4) [back to overview]Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions
NCT00777556 (4) [back to overview]Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions
NCT00781456 (7) [back to overview]Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period
NCT00781456 (7) [back to overview]Mean Number of Days of Bleeding or Spotting
NCT00781456 (7) [back to overview]Percentage of Participants Who Required Rescue Medications During the Study Period
NCT00781456 (7) [back to overview]Change From Baseline in Migraine Disability Assessment
NCT00781456 (7) [back to overview]Number of Participants With Adverse Events (AEs)
NCT00781456 (7) [back to overview]Change From Baseline in Average Migraine Severity
NCT00781456 (7) [back to overview]Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months
NCT00788671 (3) [back to overview]Efficacy of the Levonorgestrel Intrauterine Device (IUD)
NCT00788671 (3) [back to overview]Quality of Life Score Using the Short Form-36 (SF-36) Survey
NCT00788671 (3) [back to overview]Response Rate at 12 Month
NCT00909857 (68) [back to overview]Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Percentage of Participants With Intracyclic Bleeding at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Intracyclic Bleeding at Cycle 3
NCT00909857 (68) [back to overview]Percentage of Participants With Withdrawal Bleeding at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Withdrawal Bleeding at Cycle 3
NCT00909857 (68) [back to overview]Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Participants With Improvement in Participants' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening
NCT00909857 (68) [back to overview]Percentage of Participants Satisfied With Study Treatment
NCT00909857 (68) [back to overview]Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)
NCT00909857 (68) [back to overview]Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination
NCT00909857 (68) [back to overview]Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain
NCT00909857 (68) [back to overview]Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode
NCT00909857 (68) [back to overview]Difference in Duration Between Longest and Shortest Spotting Only Episode
NCT00909857 (68) [back to overview]General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]Mean Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]Mean Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Number of Days With Bleeding or Spotting
NCT00909857 (68) [back to overview]Number of Days With Spotting-only
NCT00909857 (68) [back to overview]Number of Episodes With Bleeding or Spotting
NCT00909857 (68) [back to overview]Number of Episodes With Spotting-only
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Days at Cycle 1
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Days at Cycle 3
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00922233 (3) [back to overview]Participant Report of Adverse Events.
NCT00922233 (3) [back to overview]Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35)
NCT00922233 (3) [back to overview]Acceptability Based on Bleeding Patterns Reported
NCT00924560 (13) [back to overview]Change From Baseline in Serum Deoxypyridinoline
NCT00924560 (13) [back to overview]Number of Participants With Adverse Events (AEs)
NCT00924560 (13) [back to overview]Change From Baseline in Bone-specific Alkaline Phosphatase
NCT00924560 (13) [back to overview]Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Change From Baseline in Lumbar Spine Bone Mineral Density
NCT00924560 (13) [back to overview]Change From Baseline in Proximal Femur Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Change From Baseline in Proximal Femur Bone Mineral Density
NCT00924560 (13) [back to overview]Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)
NCT00924560 (13) [back to overview]Change From Baseline in Total Body Bone Mineral Density
NCT00924560 (13) [back to overview]Change From Baseline in Serum Osteocalcin
NCT00924560 (13) [back to overview]Change From Baseline in Serum Procollagen 1 N-terminal Propeptide
NCT00924560 (13) [back to overview]Change From Baseline in Total Body Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Change From Baseline in Serum Type I Collagen N-telopeptide
NCT00996580 (9) [back to overview]Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Summary of Participants With Treatment-emergent Adverse Events
NCT00996580 (9) [back to overview]All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00997932 (1) [back to overview]IUD Expulsion
NCT01044056 (4) [back to overview]Area Under the Curve (AUC) 0-21 Days (PK Parameter) Measured for the ASPE Group
NCT01044056 (4) [back to overview]AUC 0-infinity (PK Parameter) for the ASPE Group.
NCT01044056 (4) [back to overview]AUC 0-tlast (PK Parameter) for the ASPE Group.
NCT01044056 (4) [back to overview]Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group
NCT01165307 (12) [back to overview]Indirect Medical Costs
NCT01165307 (12) [back to overview]Direct Medical Costs
NCT01165307 (12) [back to overview]Bleeding Pattern at 12 Months
NCT01165307 (12) [back to overview]Quality of Life as Measured by the Menorrhagia Multi-Attribute Scale (MMAS )
NCT01165307 (12) [back to overview]Pain at 12 Months as Measured by the Pain Visual Analog Scale (VAS)
NCT01165307 (12) [back to overview]Hemoglobin at 12 Months
NCT01165307 (12) [back to overview]Ferritin at 12 Months
NCT01165307 (12) [back to overview]Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC).
NCT01165307 (12) [back to overview]Change in Ferritin From Baseline
NCT01165307 (12) [back to overview]Change in Hemoglobin
NCT01165307 (12) [back to overview]Subject Satisfaction at 12 Months
NCT01165307 (12) [back to overview]Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
NCT01170390 (5) [back to overview]EE Steady State After Randomization
NCT01170390 (5) [back to overview]EE Steady State Baseline
NCT01170390 (5) [back to overview]LNG AUC
NCT01170390 (5) [back to overview]LNG AUC
NCT01170390 (5) [back to overview]LNG Steady State at Baseline and Then Post-randomization
NCT01230242 (1) [back to overview]Number of Participants Who Expelled IUDs by12 Weeks Postpartum
NCT01240811 (3) [back to overview]Change in Vaginal Flora
NCT01240811 (3) [back to overview]Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis
NCT01240811 (3) [back to overview]%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium
NCT01250210 (2) [back to overview]Cycle Control
NCT01250210 (2) [back to overview]Ovulation Suppression in Three Treatment Groups Over 3 Cycles
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Antithrombin
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Plasminogen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Protein C Antigen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Sex Hormone Binding Globulin (SHBG)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Thyroid Stimulating Hormone (TSH)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Tissue Factor Pathway Inhibitor (TFPI)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Tissue Plasminogen Activator (t-PA)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Total Cortisol
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Total Protein S
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Corticosteroid Binding Globulin
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in D-dimer
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor VII
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Activated Partial Thromboplastin Time (APTT) Based Activated Protein-C Resistance (APC)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Protein C Activity
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Endogenous Thrombin Potential (EPT) Based Activated Protein-C Resistance (APC)
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor II
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Factor VIII
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Fibrinogen
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Free Protein S
NCT01252186 (21) [back to overview]Change From Baseline to End of Month 6 in Plasmin-Antiplasmin (PAP) Complex
NCT01254292 (31) [back to overview]User Satisfaction - Satisfaction With Menstrual Bleeding Pattern
NCT01254292 (31) [back to overview]User Satisfaction - Amount of Menstrual Bleeding
NCT01254292 (31) [back to overview]User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment
NCT01254292 (31) [back to overview]EVAPIL-R Scores at 12 Months - Bother Score
NCT01254292 (31) [back to overview]EVAPIL-R Scores at 12 Months - Composite Score
NCT01254292 (31) [back to overview]EVAPIL-R Scores at Screening - Bother Score
NCT01254292 (31) [back to overview]EVAPIL-R Scores at Screening - Composite Score
NCT01254292 (31) [back to overview]Overall Satisfaction Rate at 12 Months (LOCF)
NCT01254292 (31) [back to overview]Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)
NCT01254292 (31) [back to overview]Overall Satisfaction Rate at 6 Months (LOCF)
NCT01254292 (31) [back to overview]Compliance Rate for Yasmin Pill Intake
NCT01254292 (31) [back to overview]Cumulative Drop-out Rate
NCT01254292 (31) [back to overview]EVAPIL-R Scores at 18 Months/EOS
NCT01254292 (31) [back to overview]EVAPIL-R Scores at 6 Months
NCT01254292 (31) [back to overview]Investigator's Evaluation of IUS Removal Procedure
NCT01254292 (31) [back to overview]Investigator's Evaluation of Successful IUS Insertion Procedure
NCT01254292 (31) [back to overview]Overall Satisfaction Rating by the 5-point Likert Item at 12 Months
NCT01254292 (31) [back to overview]Overall Satisfaction Rating by the 5-point Likert Item at 18 Months
NCT01254292 (31) [back to overview]Overall Satisfaction Rating by the 5-point Likert Item at 6 Months
NCT01254292 (31) [back to overview]Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)
NCT01254292 (31) [back to overview]Participants' Evaluation of Pain During IUS Removal Procedure
NCT01254292 (31) [back to overview]Participants' Evaluation of Pain During Successful IUS Insertion Procedure
NCT01254292 (31) [back to overview]Pearl Index (PI)
NCT01254292 (31) [back to overview]User Satisfaction - Acceptability of the Administration of Study Treatment
NCT01254292 (31) [back to overview]User Satisfaction - Acceptability of the Administration of Study Treatment
NCT01254292 (31) [back to overview]User Satisfaction - Acceptability of the Administration of Study Treatment
NCT01254292 (31) [back to overview]User Satisfaction - Choices Upon Completion of the Study
NCT01254292 (31) [back to overview]Cumulative Number of Participants With Partial or Total Expulsion
NCT01254292 (31) [back to overview]User Satisfaction - Frequency of Experiencing Unexpected Bleeding
NCT01254292 (31) [back to overview]User Satisfaction - Rating of Usual Menstrual Pain Intensity
NCT01254292 (31) [back to overview]User Satisfaction - Satisfaction With Menstrual Bleeding Absence
NCT01272960 (4) [back to overview]Intrauterine Infection
NCT01272960 (4) [back to overview]Mirena Expulsion
NCT01272960 (4) [back to overview]Mirena in Place
NCT01272960 (4) [back to overview]Uterine Perforation
NCT01297348 (2) [back to overview]Incidence Rate of Idiopathic Venous Thromboembolism (VTE)
NCT01297348 (2) [back to overview]Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls
NCT01328184 (18) [back to overview]Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.
NCT01328184 (18) [back to overview]Assessment of Tolerability
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01546454 (1) [back to overview]Total to HDL Cholesterol Ratio
NCT01555931 (2) [back to overview]Breastfeeding
NCT01555931 (2) [back to overview]LNG-IUS Expulsion or Removal
NCT01570244 (8) [back to overview]Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.
NCT01570244 (8) [back to overview]Cmax,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]AUCt,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]AUCτ,ss of Levonorgestrel
NCT01570244 (8) [back to overview]C24,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]Cmax,ss of Levonorgestrel
NCT01570244 (8) [back to overview]Number of Participants With Drug Related Adverse Events
NCT01570244 (8) [back to overview]C24,ss of Levonorgestrel
NCT01594476 (5) [back to overview]Subjects With an IUD at 3 Months Postpartum
NCT01594476 (5) [back to overview]Uterine Thickness at the Fundus
NCT01594476 (5) [back to overview]Subjects With an IUD at 6 Months Postpartum
NCT01594476 (5) [back to overview]Pain With IUD Placement
NCT01594476 (5) [back to overview]Satisfaction With the Timing of IUD Placement.
NCT01598662 (1) [back to overview]IUD Expulsion Rate
NCT01623466 (5) [back to overview]Cycle Control
NCT01623466 (5) [back to overview]Evaluation of Irritation at Patch Application Site
NCT01623466 (5) [back to overview]Evaluation of Itching at Patch Application Site
NCT01623466 (5) [back to overview]Evaluation of Patch Adhesion
NCT01623466 (5) [back to overview]Levonorgestrel Pharmacokinetic Profile
NCT01990703 (2) [back to overview]Breastfeeding Continuation Rates at 8 Weeks Postpartum
NCT01990703 (2) [back to overview]Time to Lactogenesis Stage 2
NCT02067663 (8) [back to overview]Complications
NCT02067663 (8) [back to overview]Intrauterine Device Expulsion by 12 Weeks Postpartum
NCT02067663 (8) [back to overview]Satisfaction
NCT02067663 (8) [back to overview]Pregnancy
NCT02067663 (8) [back to overview]Pregnancy
NCT02067663 (8) [back to overview]IUD Expulsion Rate
NCT02067663 (8) [back to overview]Intrauterine Device Expulsion (Day 1)
NCT02067663 (8) [back to overview]Intrauterine Device Expulsion (6 Weeks)
NCT02121067 (3) [back to overview]Number of Participants With Expulsion (Complete or Partial) of LNG-IUS at Six-months.
NCT02121067 (3) [back to overview]Number of Participants Who Enrolled and Were Able to Have a Successful LNG-IUS Insertion in the 2 Week (Day 14-20) Postpartum Period.
NCT02121067 (3) [back to overview]Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum.
NCT02169869 (1) [back to overview]Proportion of Subjects With an IUD at 3 Months Postpartum
NCT02175030 (2) [back to overview]Percentage of Participants Reporting a Pregnancy
NCT02175030 (2) [back to overview]Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year.
NCT02203331 (7) [back to overview]Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD
NCT02203331 (7) [back to overview]Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD
NCT02203331 (7) [back to overview]Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD
NCT02203331 (7) [back to overview]Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD
NCT02203331 (7) [back to overview]Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD
NCT02203331 (7) [back to overview]Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD
NCT02203331 (7) [back to overview]Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD
NCT02357368 (4) [back to overview]Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood
NCT02362373 (5) [back to overview]Number of Participants Continuing With IUD
NCT02362373 (5) [back to overview]Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level
NCT02362373 (5) [back to overview]Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level
NCT02362373 (5) [back to overview]Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level
NCT02362373 (5) [back to overview]Change in Seizure Frequency
NCT02475265 (1) [back to overview]Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA)
NCT02477202 (1) [back to overview]Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+
NCT02531321 (2) [back to overview]Ethinyl Estradiol Area Under the Curve
NCT02531321 (2) [back to overview]Levonorgestrel Area Under the Curve
NCT02577601 (1) [back to overview]Number of Participants With Follicle Rupture
NCT02616146 (5) [back to overview]Number of Participants With Absence of Withdrawal Bleeding (AWB), by Cycle
NCT02616146 (5) [back to overview]Number of Participants Who Experienced an Adverse Event (AE)
NCT02616146 (5) [back to overview]Number of Participants Who Discontinued Treatment Due to an AE
NCT02616146 (5) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle
NCT02616146 (5) [back to overview]Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)
NCT02689804 (10) [back to overview]Maximum Concentration of Serum UPA
NCT02689804 (10) [back to overview]Maximum Concentration of Serum LNG
NCT02689804 (10) [back to overview]Elimination Half-life of Serum LNG
NCT02689804 (10) [back to overview]Clearance of Serum UPA
NCT02689804 (10) [back to overview]Clearance of Serum LNG
NCT02689804 (10) [back to overview]Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration
NCT02689804 (10) [back to overview]Time to Maximum Concentration of Serum UPA
NCT02689804 (10) [back to overview]Time to Maximum Concentration of Serum LNG
NCT02689804 (10) [back to overview]Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration
NCT02689804 (10) [back to overview]Elimination Half-life of Serum UPA
NCT02863445 (2) [back to overview]The Number of Participants in Two Treatment Groups (1.5mg Levonorgestrel and 3mg Levonorgestrel) With no Follicle Rupture at 5 Days Within One Menstrual (Treatment) Cycle.
NCT02863445 (2) [back to overview]Number of Participants With Follicle Rupture Before 5 Days
NCT02985541 (6) [back to overview]Menstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8
NCT02985541 (6) [back to overview]Number of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use
NCT02985541 (6) [back to overview]Total LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model
NCT02985541 (6) [back to overview]Participant's Satisfaction With Mirena by Visit
NCT02985541 (6) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02985541 (6) [back to overview]Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use
NCT03305081 (2) [back to overview]Number of Women With Placement of LARC
NCT03305081 (2) [back to overview]Patient Satisfaction With Method of LARC Using LARC Survey
NCT03317795 (7) [back to overview]Change in Quality of Life
NCT03317795 (7) [back to overview]Change in Fibroid Size
NCT03317795 (7) [back to overview]Change in Pain Score
NCT03317795 (7) [back to overview]Change in Quality of Life, as Measured by the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL)
NCT03317795 (7) [back to overview]Change in Self-Reported Menorrhagia Scores
NCT03317795 (7) [back to overview]Change in Symptoms, as Measured by the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL)
NCT03317795 (7) [back to overview]Number of Participants to Complete Study
NCT03754556 (39) [back to overview]Cumulative Incidence of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Breastfeeding Status and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Effect Modification of Breastfeeding Status on Postpartum Timing for Uterine Perforation
NCT03754556 (39) [back to overview]Effect Modification of IUD Type on Breastfeeding Status for IUD Expulsion
NCT03754556 (39) [back to overview]Effect Modification of IUD Type on Breastfeeding Status for Uterine Perforation
NCT03754556 (39) [back to overview]Effect Modification of IUD Type on Postpartum Timing for IUD Expulsion
NCT03754556 (39) [back to overview]Effect Modification of IUD Type on Postpartum Timing for Uterine Perforation
NCT03754556 (39) [back to overview]Number of Indicators of a Potentially Difficult Insertion, Overall, by Breastfeeding Status, and by Postpartum Timing of IUD Insertion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Number of Indicators of a Potentially Difficult Insertion, Overall, by IUD Type and by Menorrhagia Status-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Incidence Rate Ratio (IRR) for IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Incidence Rate Difference (IRD) for Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Incidence Rate Difference (IRD) for IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Incidence Rate Ratio (IRR) for Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Menorrhagia Status and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Breastfeeding Status and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for IUD Type and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for IUD Type and Uterine Perforation-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Adjusted Hazard Ratio (HR) for Menorrhagia Status and IUD Expulsion-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Cumulative Incidence of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions
NCT03754556 (39) [back to overview]Crude Incidence Rate of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
NCT03819114 (11) [back to overview]Volume of Distribution (Vd) of LNG
NCT03819114 (11) [back to overview]Time of Minimum Concentration (Tmin) of LNG
NCT03819114 (11) [back to overview]Oral Clearance (CL/F) of LNG
NCT03819114 (11) [back to overview]LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
NCT03819114 (11) [back to overview]LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
NCT03819114 (11) [back to overview]Half-life (T1/2) of LNG
NCT03819114 (11) [back to overview]Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration.
NCT03819114 (11) [back to overview]Minimum Concentration (Cmin) of LNG
NCT03819114 (11) [back to overview]Maximum Concentration (Cmax) of LNG
NCT03819114 (11) [back to overview]LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
NCT03819114 (11) [back to overview]LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants
NCT04005391 (5) [back to overview]Number of Participants With Implant Use at Three Months
NCT04005391 (5) [back to overview]Number of Participants With Contraceptive Continuation at Twelve Months
NCT04005391 (5) [back to overview]Number of Participants With Any Contraceptive Use at Three Months
NCT04005391 (5) [back to overview]Number of Participants With Repeat Pregnancy at Twelve Months
NCT04005391 (5) [back to overview]Contraceptive Satisfaction at Twelve Months

Number of Participants With Progesterone Levels Above 3.0 ng/ml at Time 1 (Baseline) and Time 2 (After Intervention With St John's Wort or Placebo).

"Serum progesterone levels were drawn at the time of dosing with levonorgestrel and then at weekly intervals until menses occurred. This was done at Time 1 (baseline), and again at Time 2 (after 5 weeks of dosing with St. John's Wort or placebo).~Possible ovulation was defined as a serum progesterone >3ng/ml within 2 weeks of Days 9-12 of the menstrual cycle." (NCT00131885)
Timeframe: Progesterone levels drawn at weekly intervals after dosing with levonorgestrel between Days 9 and 12 of the menstrual cycle, at each time point until menses

,,,
InterventionParticipants (Number)
Ovulation (Progesterone Levels > 3.0 ng/ml) Time 1Ovulation (Progesterone Levels >3.0 ng/ml) Time 2
LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg33
LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG32
LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose12
LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg12

[back to top] [back to top] [back to top] [back to top]

Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time 2 (During Treatment With St. John's Wort or Placebo)

"Pharmacokinetic studies were done between Days 9-12 of the menstrual cycle at Time 1 (baseline, before any treatment with herb or placebo), and at Time 2 (intervention, after treatment with herb or placebo). Serum samples drawn at 0, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 16, and 24 hours, following oral administration of a dose of levonorgestrel.~Treatment between the two time periods was with St. John's Wort or placebo herb, beginning after the Time 1 (baseline) and continued for 5 weeks until Time 2.~Estimates of levonorgestrel clearance were made using a two stage non-compartmental approach to determine individual and group parameters." (NCT00131885)
Timeframe: Area Under the Concentration versus Time curve for 0 to 24 hours after drug administration, between Days 9 and 12 of the menstrual cycle, done at Time 1 and at Time 2

,,,
Interventionng*hr/mL (Mean)
AUC 0-24 hours after drug administration Time 1AUC 0-24 hours after drug administration Time 2
LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg586.3478.2
LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG253.3210.1
LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose339.4439.4
LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg379.4317.4

[back to top]

Clearance (L/hr) of Levonorgestrel Over 24 Hours for Each Dosage Group and Each Study Session.

Average and standard deviation for Clearance (L/hr) of Levonorgestrel study for each dosage group and each study session. (NCT00131885)
Timeframe: Time Frame: Time 1 (pre-intervention baseline) and Time 2 (following a 6 week intervention)

,,,
InterventionL/hr (Mean)
Clearance (L/hr) Time 1Clearance L/hr Time 2
LNG 1.5 mg Dose, Then Placebo Herb, LNG 1.5 mg4.064.64
LNG 1.5 mg Dose, Then SJW 1500 ng Day, 1.5 mg LNG6.858.92
LNG 1.5 mg Dose, Then SJW 900 mg Daily, 2.25 mg LNG Dose6.397.68
LNG 1.5 mg Dose, Then SJW 900 mg Day, LNG 1.5 mg4.935.63

[back to top]

Number of Subjects With Total or Partial Expulsions

The numbers of subjects with partial or total IUS expulsions (device displaced from its correct position within the uterus) were to be given by treatment. (NCT00185380)
Timeframe: Up to 3 years

,,
Interventionparticipants (Number)
total expulsionpartial expulsion
IUS20 (Mirena)04
LCS1201
LCS1632

[back to top]

Bleeding Pattern by 90-day Reference Periods - Reference Period 1

Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning. (NCT00185380)
Timeframe: day 1 to day 90

,,
Interventiondays (Mean)
Number of bleeding days (light, normal or heavy)Number of bleeding/spotting daysNumber of spotting only days
IUS20 (Mirena)14.336.622.2
LCS1215.139.924.8
LCS1615.439.223.8

[back to top]

Pearl Index

The Pearl Index (PI) is defined as the number of pregnancies per 100 woman years. The 3-year PI was obtained by dividing the number of pregnancies that occurred during the first three years of treatment by the time (in 100 women years) that the women were under risk of getting pregnant. (NCT00185380)
Timeframe: Up to 3 years

InterventionNumber per 100 women years (Median)
LCS120.17
LCS160.82
IUS20 (Mirena)0.00

[back to top]

Bleeding Pattern by 90-day Reference Periods - Reference Period 12

Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning. (NCT00185380)
Timeframe: day 991 to day 1080

,,
Interventiondays (Mean)
Number of bleeding days (light, normal or heavy)Number of bleeding/spotting daysNumber of spotting only days
IUS20 (Mirena)1.98.86.9
LCS123.612.89.2
LCS163.010.67.7

[back to top]

Bleeding Pattern by 90-day Reference Periods - Reference Period 2

Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning. (NCT00185380)
Timeframe: day 91 to day 180

,,
Interventiondays (Mean)
Number of bleeding days (light, normal or heavy)Number of bleeding/spotting daysNumber of spotting only days
IUS20 (Mirena)7.621.814.2
LCS128.222.614.4
LCS167.721.814.1

[back to top]

Bleeding Pattern by 90-day Reference Periods - Reference Period 3

Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning. (NCT00185380)
Timeframe: day 181 to day 270

,,
Interventiondays (Mean)
Number of bleeding days (light, normal or heavy)Number of bleeding/spotting daysNumber of spotting only days
IUS20 (Mirena)5.316.811.5
LCS126.418.312.0
LCS165.416.711.3

[back to top]

Bleeding Pattern by 90-day Reference Periods - Reference Period 4

Subjects kept a bleeding diary and recorded any bleeding every day by category: none, spotting, light, normal or heavy. Any missing data were obtained by direct questioning. (NCT00185380)
Timeframe: day 271 to day 360

,,
Interventiondays (Mean)
Number of bleeding days (light, normal or heavy)Number of bleeding/spotting daysNumber of spotting only days
IUS20 (Mirena)4.215.211.0
LCS125.516.711.2
LCS164.715.010.2

[back to top]

Change From Baseline in Maximum Severity of Abdominal/Pelvic Pain

"Maximum pain severity score was calculated by identifying each subject's maximum recorded pain severity from baseline to end of Week 13.~The severity of the pain was assessed using a 4-points scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe)" (NCT00196313)
Timeframe: Baseline to end of Week 13

Interventionunits on a scale (Least Squares Mean)
Seasonique-0.62
Placebo-0.17

[back to top]

Analgesic Use

number of days analgesic (pain) medication was used over the 13 week treatment period (NCT00196313)
Timeframe: 13-week treatment period

InterventionDays Analgesic was used over 13 weeks (Mean)
Seasonique2.92
Placebo4.03

[back to top]

Number of Days Missed From School/Work or Other Activities

(NCT00196313)
Timeframe: 13-week treatment period

InterventionDays (Mean)
Seasonique0.83
Placebo2.75

[back to top]

Mean Change in Average Severity for Abdominal/Pelvic Pain

"Defined as the sum of pain scores divided by the total number of days in which the subject experienced abdominal/pelvic pain, from baseline to Week 13 The severity of the pain was assessed using a 4-points scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe)" (NCT00196313)
Timeframe: Baseline to end of 13-week treatment period

Interventionunits on a scale (Least Squares Mean)
Seasonique-0.45
Placebo-0.19

[back to top]

Incidence of Menstrual Bleeding and /or Spotting

(NCT00196313)
Timeframe: Baseline to end of Week 13

InterventionDays of bleeding/spotting over 13 weeks (Mean)
Seasonique28.389
Placebo18.000

[back to top]

"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining On Drug Pregnancy"

"Pearl Index= ((100)*(number of pregnancies)*(4 cycles/year))/number of 91-day cycles completed.~The pregnancy rate included on-drug pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication.~Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication.~Three denominators are reported;~excluding cycles where other birth control methods (BCMs) was used~all complete cycles~compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)" (NCT00196326)
Timeframe: up to one year

Interventionpregnancies per 100 woman years exposure (Number)
Excluding other BCMs (n=1732)All complete cycles (n=1735)Compliant-Use (n=1685)
DR-10112.152.121.77

[back to top]

Participants With Treatment-Emergent Adverse Events

Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values. (NCT00196326)
Timeframe: Day 1 up to one year

Interventionparticipants (Number)
DR-10111742

[back to top]

"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining On Drug Pregnancy"

"Pearl Index= ((100)*(number of pregnancies)*(4 cycles/year))/number of 91-day cycles completed.~The pregnancy rate included on-drug pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication.~Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication.~Three denominators are reported;~excluding cycles where other birth control methods (BCMs) was used~all complete cycles~compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)" (NCT00196326)
Timeframe: up to one year

Interventionpregnancies per 100 woman years exposure (Number)
Excluding other BCMs (n=1732)All complete cycles (n=1735)Compliant-Use (n=1685)
DR-10112.442.421.77

[back to top]

Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)

Average of 0-10 ratings of current facial pain, average facial pain in the last month and worst facial pain in the last month, where 0 is no pain and 10 is pain as bad as could be. For the combined outcome, the minimum score is 0 and maximum is 10, with 0 being better (no pain) and 10 being the worst outcome. (NCT00237042)
Timeframe: 12 months

InterventionUnits on a scale (Mean)
Self Management2.8
Targeted Self Management2.8
Continuous Oral Contraceptives3.9

[back to top]

Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)

Average of 0-10 ratings of current facial pain, average facial pain in the last month and worst facial pain in the last month, where 0 is no pain and 10 is pain as bad as could be. For the combined outcome, the minimum score is 0 and maximum is 10, with 0 being better (no pain) and 10 being the worst outcome. (NCT00237042)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Self Management3.1
Targeted Self Management2.9
Continuous Oral Contraceptives3.6

[back to top] [back to top] [back to top]

Number of Participants With Venous Thromboembolism (VTE)

(NCT00302848)
Timeframe: 1.5 to 5 years

InterventionParticipants (Number)
Users of DRSP26
Users of LNG25

[back to top]

Areal Bone Density by DXA

(NCT00310791)
Timeframe: 18-Months

Interventiong/cm2 (Mean)
Placebo0.88
Active0.89

[back to top]

Absolute Change From Baseline MBL to Mid-study MBL (Cycle 3)

The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Mid-study MBL was measured during Cycle 3 of the Treatment Phase. (NCT00360490)
Timeframe: Baseline and up to 3 months

Interventionmilliliter (mL) (Median)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours-115.13
Medroxyprogesterone Acetate (MPA)-3.15

[back to top]

The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)

The MBL for each cycle included intermenstrual bleeding in addition to withdrawal bleeding. Baseline MBL was the composite MBL measured during each of the cycles during the Screening Phase. End-of-study MBL was measured during Cycle 6 of the Treatment Phase. (NCT00360490)
Timeframe: Baseline and up to 6 months

Interventionmilliliter (mL) (Median)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours-128.78
Medroxyprogesterone Acetate (MPA)-17.7

[back to top]

Percentage of Patients With Successful Treatment

End-of-study MBL < 80 mL and a decrease to a value no greater than 50% of the Baseline MBL was considered to be treatment success. (NCT00360490)
Timeframe: At 6 months

InterventionPercentage of participants (Number)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours84.8
Medroxyprogesterone Acetate (MPA)22.2

[back to top]

Total Number of Spotting Days

In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts. (NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventiondays (Mean)
BaselineCycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours1.239.479.587.275.656.485.38
Medroxyprogesterone Acetate (MPA)1.841.482.312.271.842.002.23

[back to top]

Total Number of Spotting and Bleeding Days

In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts. (NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventiondays (Mean)
BaselineCycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours6.3019.7017.4611.8910.4210.258.58
Medroxyprogesterone Acetate (MPA)6.806.657.466.926.666.896.90

[back to top]

Total Number of Bleeding Episodes

A bleeding episode is defined as a light, normal or heavy bleeding, during a minimum of one day. In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts. (NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventionnumber of bleeding episodes (Mean)
BaselineCycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours1.011.750.880.990.760.770.70
Medroxyprogesterone Acetate (MPA)1.030.981.010.970.991.011.04

[back to top]

Total Number of Bleeding Days

In the LNG IUS group, each cycle has 30 days. In the MPA group, each menstrual cycle starts on the 1st bleeding day (withdrawal bleeding) and lasts until the last non-bleeding day before next withdrawal bleeding starts. (NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventiondays (Mean)
BaselineCycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours5.6410.237.885.924.773.774.16
Medroxyprogesterone Acetate (MPA)5.645.175.155.254.824.895.29

[back to top]

Percent Change From Baseline MBL to End of Study MBL (Cycle 6)

The percent change = {(End of Study MBL - Baseline MBL)/Baseline MBL} x 100. (NCT00360490)
Timeframe: Baseline and up to 6 months

InterventionPercent change (Mean)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours-70.75
Medroxyprogesterone Acetate (MPA)-21.54

[back to top]

Percentage of Patients With Improvement in the Investigator Global Assessment Scale

"Improved is classified as 'very much improved', 'much improved', or 'improved' and not improved is classified as 'no change', 'worse', 'much worse', or 'very much worse'" (NCT00360490)
Timeframe: Up to 6 months

,
Interventionpercentage (Number)
Cycle 3Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours94.793.6
Medroxyprogesterone Acetate (MPA)71.261.0

[back to top]

Percent Change From Baseline MBL to Mid-study MBL (Cycle 3)

The percent change = {(Mid-study MBL - Baseline MBL)/Baseline MBL} x 100. (NCT00360490)
Timeframe: Baseline and up to 3 months

InterventionPercent change (Mean)
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours-61.71
Medroxyprogesterone Acetate (MPA)-11.11

[back to top]

Percent Change in Hematocrit

(NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventionpercent change (Median)
Baseline to cycle 3Cycle 3 to cycle 6Baseline to cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours4.92.45.4
Medroxyprogesterone Acetate (MPA)0.00.00.0

[back to top]

Percent Change in Hemoglobin

(NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventionpercent change (Median)
Baseline to cycle 3Cycle 3 to cycle 6Baseline to cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours3.823.287.50
Medroxyprogesterone Acetate (MPA)1.650.831.87

[back to top]

Percent Change in Serum Ferritin

(NCT00360490)
Timeframe: Baseline and up to 6 months

,
Interventionpercent change (Median)
Baseline to cycle 3Cycle 3 to cycle 6Baseline to cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours13.848.368.8
Medroxyprogesterone Acetate (MPA)0.016.714.3

[back to top]

Percentage of Subjects Who Completed the Study in Levonorgestrel Intrauterine System (LNG IUS) Group

(NCT00360490)
Timeframe: Baseline and up to 6 months

Interventionpercentage of participants (Number)
0 days30 days60 days90 days120 days150 days180 days
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours97.5395.0693.8392.5991.3690.1290.12

[back to top]

Percentage of Patients With Improvement in the Patients Overall Assessment Scale

"Improved is classified as 'very much improved', 'much improved', or 'improved' and not improved is classified as 'no change', 'worse', 'much worse', or 'very much worse'." (NCT00360490)
Timeframe: Up to 6 months

,
Interventionpercentage (Number)
Cycle 3Cycle 6
Levonorgestrel Intrauterine System (LNG IUS) 20µg Per 24 Hours93.393.6
Medroxyprogesterone Acetate (MPA)74.067.1

[back to top] [back to top]

Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1. (NCT00394771)
Timeframe: Day 85-91

,,,
Interventionparticipants (Number)
0 day1-3 days4-7 days
High Dose DR-1031252754
Low Dose DR-1031143659
Midrange Dose DR-1031281763
Seasonale271875

[back to top]

Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2. (NCT00394771)
Timeframe: Day 177-183

,,,
Interventionparticipants (Number)
0 day1-3 days4-7 days
High Dose DR-1031232645
Low Dose DR-1031153250
Midrange Dose DR-1031203244
Seasonale212460

[back to top] [back to top] [back to top]

Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10310
Midrange Dose DR-10310
High Dose DR-10310
Seasonale0

[back to top]

Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-10310
Midrange Dose DR-10310
High Dose DR-10310
Seasonale0

[back to top]

Days With Bleeding During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10311
Midrange Dose DR-10312
High Dose DR-10311
Seasonale2

[back to top] [back to top]

Days With Bleeding During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-10313.5
Midrange Dose DR-10312.5
High Dose DR-10314
Seasonale2

[back to top]

Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-103113
Midrange Dose DR-103113.5
High Dose DR-103115
Seasonale15

[back to top]

Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10316
Midrange Dose DR-10317
High Dose DR-10315
Seasonale6

[back to top]

PREGNANCY RATES

(NCT00433004)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
No Advance EC8
Advance EC Given3

[back to top]

PLAN B USE

(NCT00433004)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
No Advance EC8
Advance EC Given12

[back to top]

ABILITY TO FOLLOW POSTPARTUM TEENS FOR 1 YEAR.

(NCT00433004)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
No Advance EC22
Advance EC Given16

[back to top]

Patients With High Expression of Transforming Growth Factor-beta 1

(NCT00445887)
Timeframe: Baseline to time of surgery (4 to 6 weeks)

InterventionParticipants (Count of Participants)
Arm I (Levenorgestrel)6
Arm II (Placebo)3

[back to top]

Number of Participants With Adverse Events According to Grade as Determined by NCI CTCAE v.3.0

Participants were graded using CTCAE v.30 criteria. Grade 1 is the least severe grade. Each adverse event lists criteria for grading, grade 1 being mild, up to grade 5. Grade 4 is generally life threatening. Grade 5 is death. (NCT00445887)
Timeframe: Up to 20 weeks

,,,,,,,,,
InterventionParticipants (Count of Participants)
Allergy/ImmunologyConstitutional SymptomsCardiacDermatology/SkinEndocrineGastrointestinalRenal/GenitourinaryHemorrhage/BleedingBlood/Bone MarrowInfectionMetabolic/LaboratoryNeurologyPulmonary/Upper RespiratoryPainSexual/Reproductive Function
Grade 1 CTCAE 3.0 Arm II (Placebo)000120013021021
Grade 1 CTCAE v 3.0 Arm I (Levonorgestrel)111211235020133
Grade 2 CTCAE 3.0 Arm II (Placebo)110011001100020
Grade 2 CTCAE v 3.0 Arm 1 (Levonorgestrel)000000002000010
Grade 3 CTCAE 3.0 Arm II (Placebo)000000000000000
Grade 3 CTCAE v 3.0 Arm 1 (Levonorgestrel)000000000100000
Grade 4 CTCAE 3.0 Arm II (Placebo)000000000000000
Grade 4 CTCAE v3.0 Arm 1 Levonorgestrel)000000000000000
Grade 5 CTCAE 3.0 Arm II (Placebo)000000000000000
Grade 5 CTCAE v3.0 Arm I (Levonorgestrel)000000000000000

[back to top]

Proportion of Proliferation as Measured by Ki-67

(NCT00445887)
Timeframe: Time of surgery (4 to 6 weeks after entry)

InterventionProportion of cells exhibiting Ki-67 (Median)
Arm I (Levenorgestrel).003
Arm II (Placebo).008

[back to top]

Median Proportion Cells That Are Apoptotic in Fallopian Tube Tissue

The median proportion of cells that are considered to be apoptotic are counted in the fallopian tube tissue sample, among the total number of cells available in the sample slide (NCT00445887)
Timeframe: Surgical specimen (4-6 weeks after entry)

Interventionproportion of total cells (Median)
Arm I (Levenorgestrel).205
Arm II (Placebo).079

[back to top]

Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue

The median proportion of cells that are considered to be apoptotic are counted in the ovarian tissue sample, among the total number of cells available in the sample slide. (NCT00445887)
Timeframe: Surgical specimen (4 - 6 weeks after entry)

Interventionproportion of total cells (Median)
Arm I (Levenorgestrel).093
Arm II (Placebo).115

[back to top]

Breast Cancer Risk

Breast cancer (invasive carcinoma or carcinoma in situ) in women aged <50 years at diagnosis. Cases were excluded if they had died before study start or had a history of malignancy. (NCT00461253)
Timeframe: retrospective, January 2000 to December 2007

Interventionparticipants (Number)
LNG IUD1076
Cu-IUD1068

[back to top]

To Compare Expulsion Rates Between Immediate Insertion and Delayed Insertion

Compared the expulsion rate of the LNG-IUD in the participants who received the LNG-IUD in the immediate and delayed insertion group (NCT00475228)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Arm I: Immediate LNG-IUD Insertion Group6.8
Arm 2: Delayed LNG-IUD Insertion Group5.0

[back to top]

To Examine the Number of Women Receiving the LNG-IUD in Each Group

The difference between the overall number of women who had the LNG-IUD inserted immediately post D&E successfully (Arm 1) was compared to the overall number of women who had the LNG-IUD inserted 3 -6 weeks post D&E (standard or routine) (Arm 2). (NCT00475228)
Timeframe: 2 Months

InterventionCompleted LNG-IUD Insertions (Number)
Arm 2: Delayed (3-6 Weeks) LNG-IUD Insertion Group20
Arm I: Immediate LNG-IUD Insertion Group44

[back to top]

The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment.

"To assess the six-month usage rate of the LNG-IUD when placed immediately after D&E compared to 3-6 weeks later, as measured by the proportion of women with a LNG-IUD in place at six months after the D&E.~We hypothesize that more women receiving immediate insertion will be using the LNG-IUD 6 months after the D&E procedure than women receiving delayed insertion." (NCT00475228)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Arm I: Immediate LNG-IUD Insertion Group85.2
Arm 2: Delayed (3-6 Weeks) LNG-IUD Insertion Group62.9

[back to top]

IUD Usage Rate at 6 Months

Usage rate of the LNG-IUD at 6 months after delivery (NCT00476021)
Timeframe: 6 months after delivery

Interventionparticipants (Number)
Postplacental IUD Insertion43
Delayed IUD Insertion39

[back to top]

Expulsion Rates of Post-placental and Delayed Insertion of the LNG-IUD Using Clinical Exam and Ultrasonography

(NCT00476021)
Timeframe: 6 months

Interventionparticipants (Number)
Postplacental IUD Insertion12
Delayed IUD Insertion2

[back to top]

Follow-up Rates for Delayed Insertion of LNG-IUD

(NCT00476021)
Timeframe: 6 months

Interventionparticipants (Number)
Delayed IUD Insertion46

[back to top]

Proportion of Women Who Are Able to Have the LNG-IUD Placed Postplacentally and Are Not Excluded From Placement

(NCT00476021)
Timeframe: 6 months

Interventionparticipants (Number)
Received Postplacental IUD50

[back to top]

Rates of Follow-up and Unintended Pregnancy Rates for Subjects Who Are Excluded From Postpartum Insertion

(NCT00476021)
Timeframe: 6 months

Interventionparticipants (Number)
Pregnancy Within 6 Months for Ineligible Participants2
Follow-up for IUD Insertion for Ineligible Participants11

[back to top]

Safety of Postplacental Insertion of the LNG-IUD as Measured by Infection Rates

(NCT00476021)
Timeframe: 6 months

Interventionparticipants (Number)
Postplacental IUD Insertion1
Delayed IUD Insertion1

[back to top]

Differences in Bleeding Patterns Between Study Groups.

number of days of bleeding and spotting, self reported on calendar (NCT00480532)
Timeframe: The outcome was also assessed for day 1 to 84

Interventiondays (Mean)
Placebo (Treatment)26.72
Doxy (7 Day Treatment Arm)31.86
Placebo (Prevention)25.69
Subantibmicrobial Dose Doxy18.84

[back to top]

Subject Compliance

measured by self report of pill intake on daily diary (yes/no), and reported as percentage with no missed pills over entire study (NCT00480532)
Timeframe: Assessed on day 112 of the study (the end of the study period). The outcome reflects the number of subjects who did not miss pills during the entire 112 day study. It does not represent a change from baseline.

Interventionnumber of participants with no missed pi (Number)
Placebo (Treatment)25
Doxy (7 Day Treatment Arm)21
Placebo (Prevention)19
Subantibmicrobial Dose Doxy20

[back to top]

Subject Satisfaction.

"measured using 100 mm visual analog scale. anchors of not at all satisfied (0mm) extremely satisfied (100mm)" (NCT00480532)
Timeframe: Assessed on day 112 of the study (the end of the study period). This outcome does not represent a change from baseline. It was assessed at the end of the study period.

Interventionmm (Mean)
Placebo (Treatment)63.9
Doxy (7 Day Treatment Arm)64.2
Placebo (Prevention)72.0
Subantibmicrobial Dose Doxy67.0

[back to top]

Area Under the Curve Over 3 Hours (AUC3) for Glucose (Oral Glucose Tolerance Test [OGTT])

Blood glucose levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*mmol/L (Mean)
Baseline (n=59 NOMAC-E2; n=55 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE14.4416.69
NOMAC-E215.8216.09

[back to top]

AUC3 for Insulin (OGTT)

Blood insulin levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*pmol/L (Mean)
Baseline (n=51 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=46 NOMAC-E2; n=47 LNG-EE)
LNG-EE558721
NOMAC-E2650658

[back to top]

Serum Concentration of Free Thyroxine (T4)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionpmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE14.115.7
NOMAC-E214.015.9

[back to top]

Average Number of Withdrawal Bleeding/Spotting Days

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Withdrawal bleeding/spotting was defined as any episode that occurred during the expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionDays (Mean)
Cycle 1 (n=50 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=47 NOMAC-E2; n=50 LNG-EE)Cycle 3 (n=49 NOMAC-E2); n=52 LNG-EE)Cycle 4 (n=46 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=47 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=42 NOMAC-E2; n=49 LNG-EE)
LNG-EE5.84.94.95.04.94.2
NOMAC-E24.84.73.94.03.83.5

[back to top]

Incremental AUC3 for Glucose (OGTT)

Blood glucose levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Incremental area under the curve was defined as incremental AUC3 = AUC3 - 3*fasting concentration. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*mmol/L (Mean)
Baseline (n=59 NOMAC-E2; n=55 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1.063.19
NOMAC-E21.581.76

[back to top]

Serum Concentration of Clotting Factor VIII

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9598
NOMAC-E29389

[back to top]

Serum Concentration of Corticosteroid Binding Globulin (CBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline to Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9321980
NOMAC-E29101116

[back to top]

Serum Concentration of D-Dimer

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L Fibrinogen Equivalent Units (FEU) (Mean)
Baseline (n=60; NOMAC-E2; n=58)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.190.26
NOMAC-E20.210.18

[back to top]

Serum Concentration of Dehydroepiandrosterone Sulphate (DHEAS)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionumol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE5.194.00
NOMAC-E24.944.32

[back to top]

Serum Concentration of Dihydrotestosterone (DHT)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE0.620.36
NOMAC-E20.590.53

[back to top]

Serum Concentration of Free Testosterone

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionpmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE26.39.9
NOMAC-E224.512.8

[back to top]

Serum Concentration of HDL2-cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=58 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.690.40
NOMAC-E20.630.55

[back to top]

Serum Concentration of HDL3-cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=58 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.141.10
NOMAC-E21.101.16

[back to top]

Serum Concentration of Hemoglobin Type A1c (HbA1c)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). HbA1c was determined before glucose loading. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of glycosylated hemoglobin (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE5.35.4
NOMAC-E25.35.3

[back to top]

Serum Concentration of High Density Lipoprotein (HDL)-Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.681.41
NOMAC-E21.631.65

[back to top]

Serum Concentration of Lipoprotein(a)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=57 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.150.12
NOMAC-E20.150.17

[back to top]

Serum Concentration of Low Density Lipoprotein (LDL)-Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE2.472.61
NOMAC-E22.412.40

[back to top]

Serum Concentration of Protein C

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE103113
NOMAC-E2107108

[back to top]

Serum Concentration of Protein S (Free)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE8699
NOMAC-E28599

[back to top]

Serum Concentration of Protein S (Total)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE7976
NOMAC-E27883

[back to top]

Serum Concentration of Prothrombin Fragments 1 + 2

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.190.42
NOMAC-E20.180.31

[back to top]

Serum Concentration of Sex Hormone Binding Globulin (SHBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE77100
NOMAC-E274108

[back to top]

Serum Concentration of Thyroxin Binding Globulin (TBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE20.328.4
NOMAC-E220.324.2

[back to top]

Serum Concentration of Total Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE4.534.48
NOMAC-E24.484.51

[back to top]

Serum Concentration of Total Cortisol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE502944
NOMAC-E2482608

[back to top]

Serum Concentration of Total Testosterone

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE1.900.91
NOMAC-E21.681.23

[back to top]

Serum Concentration of Total Triglycerides

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.821.02
NOMAC-E20.941.00

[back to top]

Serum Concentration of Clotting Factor VIIa

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionU/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE8598
NOMAC-E284118

[back to top]

Serum Concentration of Clotting Factor II

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9497
NOMAC-E29495

[back to top]

Serum Concentration of C-Reactive Protein (CRP)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.984.43
NOMAC-E20.821.32

[back to top]

Serum Concentration of Apolipoprotein B

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.640.80
NOMAC-E20.640.68

[back to top]

Serum Concentration of Apolipoprotein A-1

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.601.67
NOMAC-E21.581.78

[back to top]

Serum Concentration of Antithrombin III

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9996
NOMAC-E2100102

[back to top]

Serum Concentration of Androstenedione

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE10.276.96
NOMAC-E29.608.23

[back to top]

Number of Participants With an Occurrence of Early Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Early withdrawal bleeding was defined as any withdrawal bleeding that started before the current expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE411002
NOMAC-E2543212

[back to top]

Number of Participants With an Occurrence of Continued Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Continued withdrawal bleeding was defined as any withdrawal bleeding that continued into the expected non-bleeding period of the next cycle. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 5 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=54 NOMAC-E2; n=50 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=53 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE2528262729
NOMAC-E21511131113

[back to top]

Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough spotting was defined as any spotting episode that occurred during the expected non-bleeding period that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1695243
NOMAC-E217104744

[back to top]

Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1695243
NOMAC-E218115866

[back to top]

Number of Participants With an Occurrence of Breakthrough Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding was defined as any bleeding episode that occurred during the expected non-bleeding period that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE100000
NOMAC-E2311123

[back to top]

Number of Participants With an Occurrence of Absence of Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Absence of withdrawal bleeding was defined as no bleeding/spotting episode that began during or continued into the expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE010001
NOMAC-E26858510

[back to top]

Incremental AUC3 for Insulin (OGTT)

Blood insulin levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Incremental area under the curve was defined as incremental AUC3 = AUC3 - 3*fasting concentration. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*pmol/L (Mean)
Baseline (n=51 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=46 NOMAC-E2; n=47 LNG-EE)
LNG-EE451603
NOMAC-E2517534

[back to top]

Serum Concentration of Thyroid Stimulating Hormone (TSH)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionmU/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE2.202.75
NOMAC-E22.692.96

[back to top]

Serum Concentration of Clotting Factor VIIc

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE10596
NOMAC-E2105109

[back to top]

Average Number of Breakthrough Bleeding/Spotting Days

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionDays (Mean)
Cycle 1 (n=18 NOMAC-E2; n=16 LNG-EE)Cycle 2 (n=11 NOMAC-E2; n=9 LNG-EE)Cycle 3 (n=5 NOMAC-E2; n=5 LNG-EE)Cycle 4 (n=8 NOMAC-E2; n=2 LNG-EE)Cycle 5 (n=6 NOMAC-E2; n=4 LNG-EE)Cycle 6 (n=6 NOMAC-E2; n=3 LNG-EE)
LNG-EE4.63.33.24.02.03.0
NOMAC-E23.54.34.63.83.34.7

[back to top]

Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)

In-treatment pregnancies were pregnancies with an estimated date of conception from the day of first intake of trial medication up to and including the day of last (active or placebo) intake of trial medication extended with a maximum of 2 days. Each 13 cycles (28 days per cycle) constitutes a woman year. The Pearl Index was obtained by dividing the number of in-treatment pregnancies that occurred by the time (in 100 women years) that the women were under risk of becoming pregnant. (NCT00511355)
Timeframe: 6 cycles

InterventionPregnancies per 100 woman years (Number)
NOMAC-E20
LNG-EE0

[back to top]

Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). APC resistance ratio (ETP-based) measures the anticoagulation response of plasma to APC after activation of the extrinsic coagulation pathway. An increase in the ratio indicates a reduced responsiveness to APC. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionRatio (Mean)
Baseline (n=59 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.831.99
NOMAC-E20.801.14

[back to top]

APC Resistance Ratio (Activated Partial Thromboplastin Time [APTT]-Based)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). APC resistance ratio (APTT-based) measures the anticoagulation response of plasma to APC after activation of the intrinsic coagulation pathway. An increase in the ratio indicates a increased responsiveness to APC. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionRatio (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE1.001.03
NOMAC-E21.011.05

[back to top]

Number of Participants With Pregnancy

The rate of pregnancy in women who received emergency contraception within 72 h of unprotected sexual intercourse. (NCT00551616)
Timeframe: Within 72 hours of unprotected Intercourse

InterventionParticipants (Count of Participants)
CDB-291420
Levonorgestrel30

[back to top]

Actual Pregnancy Rate Compared to Expected Pregnancy Rate

Conditional probabilities of pregnancy from the time of unprotected sex intercourse to treatment were estimated for up to 120 hours using Spline Cubic Estimation (Stone & Koo, 1985) Pregnancy rate expected in the absence of emergency contraception is based on Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 1998;57(6):363-9. (NCT00551616)
Timeframe: Within 120 hours of unprotected Intercourse

,
InterventionParticipants (Count of Participants)
Number of pregnancies observedNumber of expected pregnancies
CDB-29141547
Levonorgestrel2246

[back to top]

Menstrual Bleeding Patterns

Onset of next menses after emergency contraception compared to usual date. (NCT00551616)
Timeframe: within the menstrual cycle of the unprotected Intercourse

InterventionDAYS (Mean)
CDB-29142.1
Levonorgestrel-1.2

[back to top]

Percentage of Women Continuing IUD Use at 3 Months

(NCT00621543)
Timeframe: 3 months

Interventionpercentage of participants (Mean)
Single Arm Study80.

[back to top]

Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion.

(NCT00621543)
Timeframe: Three months

Interventionpercentage of participants (Mean)
Single Arm Study4

[back to top]

Perforation Rates

(NCT00635362)
Timeframe: 12 months after cesarean delivery

Interventionparticipants (Number)
Delayed Insertion Group0
Postplacental Insertion After Cesarean0

[back to top]

Rates of Expulsion of the LNG-IUS

(NCT00635362)
Timeframe: 12 months after cesarean delivery

Interventionparticipants (Number)
Delayed Insertion Group0
Postplacental Insertion After Cesarean4

[back to top]

Satisfaction With LNG-IUS

"We measured satisfaction with the IUS at each visit using a single question with a 5 point Likert scale, with 1 being very unsatisfied, 2 unsatisfied, 3 neutral, 4 satisfied, and 5 very satisfied. For statistical purposes, subjects were determined to be SATISFIED with the IUS if they chose either 4 or 5 for this question." (NCT00635362)
Timeframe: 12 months after cesarean delivery

Interventionparticipants (Number)
Delayed Insertion Group9
Postplacental Insertion After Cesarean11

[back to top]

Satisfaction With LNG-IUS

"We measured satisfaction with the IUS at each visit using a single question with a 5 point Likert scale, with 1 being very unsatisfied, 2 unsatisfied, 3 neutral, 4 satisfied, and 5 very satisfied. For statistical purposes, subjects were determined to be SATISFIED with the IUS if they chose either 4 or 5 for this question." (NCT00635362)
Timeframe: 6 months after cesarean delivery

Interventionparticipants (Number)
Delayed Insertion Group7
Postplacental Insertion After Cesarean10

[back to top]

Use of the LNG-IUS for Contraception

(NCT00635362)
Timeframe: 12 months after cesarean delivery

,
Interventionparticipants (Number)
Confirmed use of LNG-IUDLost to follow up at 12 monthsDid not have IUD placedExpelled prior to 12 months, not replacedRemoved per patient request
Delayed Insertion Group98401
Postplacental Insertion After Cesarean126020

[back to top]

Device Satisfaction Rates

"Satisfaction rate is the proportion of subjects who report being happy or very happy with their assigned intrauterine contraceptive method on the date of their 6 month study visit." (NCT00653159)
Timeframe: 6 months

Interventionpercentage of subjects completing study (Number)
Paragard IUD [CuT380A]80
Mirena IUD [LNG-IUS]70

[back to top]

Retention Rate

Percentage of participants who completed the final visit (i.e., not subject to early termination or loss to follow-up) (NCT00653159)
Timeframe: 6 months

Interventionpercentage of randomized subjects (Number)
Paragard IUD [CuT380A]55
Mirena IUD [LNG-IUS]75

[back to top]

Pregnancy Rates

Proportion of subjects who became pregnant within 6 months of IUD insertion (NCT00653159)
Timeframe: 6 months

Interventionpercentage of randomized subjects (Number)
Paragard IUD [CuT380A]9
Mirena IUD [LNG-IUS]0

[back to top]

Expulsion Rates

Rates of partial or complete expulsion for teens randomized to the LNG-IUS or Copper T 380A. Patients experiencing partial expulsion had IUDs visible on speculum exam. Complete expulsion is characterized by complete evacuation of the IUD. (NCT00653159)
Timeframe: 6 months

Interventionpercentage of randomized subjects (Number)
Paragard IUD [CuT380A]18
Mirena IUD [LNG-IUS]0

[back to top]

Heavy Bleeding Rates

Rates of participants experiencing heavy bleeding among teens randomized to the LNG-IUS or Copper T 380A. (NCT00653159)
Timeframe: 6 months

Interventionpercentage of randomized subjects (Number)
Paragard IUD [CuT380A]55
Mirena IUD [LNG-IUS]33

[back to top]

Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception

Use of a method of contraception with a typical efficacy rate >= to 92%. This includes combined hormonal contraception (combined oral contraceptive pills, the contraceptive patch and ring), sterilization, IUDs, Depo-provera, and contraceptive implants. (NCT00669396)
Timeframe: 6 months

Interventionparticipants (Number)
Copper T380 IUD9
Levonorgestrel13

[back to top]

Pregnancy

positive urine pregnancy test at anytime within 6 months of presenting for emergency contraception. (NCT00669396)
Timeframe: 6 months

Interventionparticipants (Number)
Copper T380 IUD0
Levonorgestrel2

[back to top]

IUD Expulsion, Removal, or Perforation

patient reports IUD expulsion, removal, or perforation OR one of these events was documented at the clinic where patient received care. (NCT00669396)
Timeframe: 6 months

Interventionparticipants (Number)
Copper T380 IUD5
Levonorgestrel0

[back to top]

Infection

diagnosis and treatment for pelvic inflammatory disease (NCT00669396)
Timeframe: 6 months

Interventionparticipants (Number)
Copper T380 IUD0
Levonorgestrel0

[back to top]

Participants With Treatment-Emergent Adverse Events (TEAE)

Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug. (NCT00777556)
Timeframe: Day 1 to week 8

Interventionparticipants (Number)
At least one TEAEWithdrawn from study due to an AEAt least one SAE
DR-1044301

[back to top]

Participants Summarized by Repeat Use of Emergency Contraception (EC)

As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses. (NCT00777556)
Timeframe: up to week 8

Interventionparticipants (Number)
Repeat uses: 0Repeat uses: 1Repeat uses: 2Repeat uses: 3
DR-10425138162

[back to top]

Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions

The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions. (NCT00777556)
Timeframe: Week 1

Interventionpercentage of treated participants (Number)
DR-10488.6

[back to top]

Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions

The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them. (NCT00777556)
Timeframe: Day 1

Interventionpercentage of participants (Number)
DR-10490.1

[back to top]

Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period

The number of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) through the end of the 91-day treatment period compared with Baseline (the 25- to 35-day baseline qualification period). Participants recorded the incidence, timing and intensity of migraines in a migraine diary during the prequalification period and throughout the 91-day treatment period. (NCT00781456)
Timeframe: Baseline (25-35 days before Day 1) and Days 1-91

Interventionpercentage of participants (Number)
91-day Levonorgestrel Oral Contraceptive48.1
Placebo48.9

[back to top]

Mean Number of Days of Bleeding or Spotting

Bleeding and spotting were recorded by participants in the migraine diary during the 91-day treatment period. (NCT00781456)
Timeframe: 91-day treatment period

Interventiondays (Mean)
91-day Levonorgestrel Oral Contraceptive21.2
Placebo15.5

[back to top]

Percentage of Participants Who Required Rescue Medications During the Study Period

Participants recorded use of rescue medications for migraines in the migraine diary during the course of study treatment. (NCT00781456)
Timeframe: Baseline, Month 1, Month 2 and Month 3

,
Interventionpercentage of participants (Number)
Baseline (N=54, 45)First Month (N=54, 45)Second Month (N=51, 44)Third Month (N=40, 37)During the 91-day treatment period (N=54, 45)
91-day Levonorgestrel Oral Contraceptive85.263.045.135.072.2
Placebo75.655.654.562.275.6

[back to top]

Change From Baseline in Migraine Disability Assessment

"The migraine disability assessment (MIDAS) test is used to determine how severely migraines affect a patient's life. Participants were asked five questions about how often their headaches limited their ability to go to work or school, to do household work or to do family or leisure activities in the past 3 months.~The MIDAS score equals the sum of the days answered for each question and ranges from 0 (no disability) to approximately 270 (severe disability; the upper bound is dependent on the number of days a participant would plan to work or participate in other activities).~The MIDAS score is classified into four grades of severity:~0 to 5: MIDAS Grade I, Little or no disability~6 to 10: MIDAS Grade II, Mild disability~11 to 20: MIDAS Grade III, Moderate disability~21+: MIDAS Grade IV, Severe disability" (NCT00781456)
Timeframe: Baseline and Week 15

Interventionunits on a scale (Mean)
91-day Levonorgestrel Oral Contraceptive-7.8
Placebo-8.5

[back to top]

Number of Participants With Adverse Events (AEs)

"An AE is any untoward medical occurrence in a clinical investigation participant and which does not necessarily have to have a causal relationship with this treatment or clinical study.~The following definitions were used to assess AE severity: Mild: Awareness of signs or symptoms, but they are easily tolerated; Moderate: Enough discomfort to cause interference with usual activity; Severe: Incapacitating, with inability to perform usual activity.~Relationship to study drug was assessed as either: None: Causal relationship can be ruled out; Possibly: Causal relationship at least reasonably possible, i.e. relationship cannot be ruled out; Definitely: Causal relationship is certain.~A serious adverse event (SAE) is one that met any one of the following criteria:~Fatal or life threatening~Requires or prolongs in patient hospitalization~Results in persistent or significant disability/incapacity~Congenital anomaly / birth defect~Important medical event." (NCT00781456)
Timeframe: Up to 15 weeks

,
Interventionparticipants (Number)
Any adverse eventMild adverse eventModerate adverse eventSevere adverse eventAdverse event not related to study drugAdverse event possibly related to study drugAdverse event related to study drugDeathsOther serious adverse eventWithdrawn due to adverse event
91-day Levonorgestrel Oral Contraceptive321117411201003
Placebo1721056110003

[back to top]

Change From Baseline in Average Migraine Severity

"Migraine severity was recorded by participants in the Baseline qualification diary and study migraine diary during the treatment period. Participants could report a severity of none (score = 0), mild (1), moderate (2), or severe (3). In general, if a headache was mild, daily activities could be resumed and little to no medication was taken. Moderate headaches required medication and effected daily activities. Severe headaches were debilitating and required medication.~Average migraine severity is defined as the sum of the severity ratings divided by the total number of migraine episodes reported during the observation period (for example, Baseline, First Month, Second Month, Third Month, and 91-Day Treatment Period). A negative change from Baseline score indicates improvement in severity." (NCT00781456)
Timeframe: Baseline and Month 1, Month 2 and Month 3

,
Interventionunits on a scale (Least Squares Mean)
91-Day Treatment Period (N=54, 45)First Month (N=54, 45)Second Month (N= 51, 44)Third Month (N=40, 37)
91-day Levonorgestrel Oral Contraceptive-0.37-0.55-0.98-1.06
Placebo-0.18-0.52-0.72-0.66

[back to top]

Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months

The percentage of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) compared to Baseline at each month of the treatment period. (NCT00781456)
Timeframe: Baseline, Month1, Month 2 and Month 3

,
Interventionpercentage of participants (Number)
First Month (N=54, 45)Second Month (N=51, 44)Third Month (N=40, 37)
91-day Levonorgestrel Oral Contraceptive42.662.760.0
Placebo37.852.364.9

[back to top]

Efficacy of the Levonorgestrel Intrauterine Device (IUD)

To determine the efficacy of the Levonorgestrel Intrauterine Device (IUD) to treat complex atypical hyperplasia (CAH) and grade 1 endometrioid endometrial carcinoma (G1 EEC), defined as complete regression disease. The primary efficacy endpoint was pathologic response rate (RR) at 12 months defined as complete response (CR) or partial response (PR). CR was defined as no evidence of cancer or hyperplasia with atypia in patients with (CAH) or EEC. PR was defined as CAH in patients with EEC. Progressive disease (PD) was defined as grade 2 endometrioid endometrial cancer or above in patients with EEC or the presence of any cancer in patients with CAH. (NCT00788671)
Timeframe: At 1 year

InterventionParticipants (Count of Participants)
Complete RespondersPartial RespondersStable DiseaseProgressive Disease
Treatment37235

[back to top]

Quality of Life Score Using the Short Form-36 (SF-36) Survey

"SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from 0=much worse now to 4=much better now. Higher subscale and summary score reflect better health status." (NCT00788671)
Timeframe: At baseline, 3 month, 6 month, 9 month and 12 month

Interventionscore on a scale (Mean)
Physical Functioning BaselinePhysical Functioning 3 monthPhysical Functioning 6 monthPhysical Functioning 9 monthPhysical Functioning 12 monthRole-Physical BaselineRole-Physical 3 monthRole-Physical 6 monthRole-Physical 9 monthRole-Physical 12 monthRole-Emotional BaselineRole-Emotional 3 monthRole-Emotional 6 monthRole-Emotional 9 monthRole-Emotional 12 monthVitality BaselineVitality 3 monthVitality 6 monthVitality 9 monthVitality 12 monthMental health BaselineMental health 3 monthMental health 6 monthMental health 9 monthMental health 12 monthSocial functioning BaselineSocial functioning 3 monthSocial functioning 6 monthSocial functioning 9 monthSocial functioning 12 monthPain BaselinePain 3 monthPain 6 monthPain 9 monthPain 12 monthGeneral health BaselineGeneral health 3 monthGeneral health 6 monthGeneral health 9 monthGeneral health 12 month
Treatment61.165.069.068.366.355.161.969.074.474.365.361.672.471.772.150.050.157.556.951.967.767.773.373.170.568.567.377.778.872.067.770.572.073.570.755.656.860.862.060.1

[back to top]

Response Rate at 12 Month

Will be defined as complete response or partial response based on the endometrial biopsy. (NCT00788671)
Timeframe: At 1 year

Interventionpercentage of participants (Number)
Treatment83

[back to top]

Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Percentage of Participants With Intracyclic Bleeding at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)19.0
Ethinyl Estradiol, Levonorgestrel (Miranova)16.7

[back to top]

Percentage of Participants With Intracyclic Bleeding at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)10.8
Ethinyl Estradiol, Levonorgestrel (Miranova)11.6

[back to top]

Percentage of Participants With Withdrawal Bleeding at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)91.2
Ethinyl Estradiol, Levonorgestrel (Miranova)93.2

[back to top]

Percentage of Participants With Withdrawal Bleeding at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)68.1
Ethinyl Estradiol, Levonorgestrel (Miranova)79.3

[back to top]

Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)90.2
Ethinyl Estradiol, Levonorgestrel (Miranova)89.6

[back to top]

Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: at final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)93.7
Ethinyl Estradiol, Levonorgestrel (Miranova)92.5

[back to top]

Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)81.91
Ethinyl Estradiol, Levonorgestrel (Miranova)79.18

[back to top]

Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)88.64
Ethinyl Estradiol, Levonorgestrel (Miranova)83.87

[back to top]

Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.8
Ethinyl Estradiol, Levonorgestrel (Miranova)79.4

[back to top]

Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)89.6
Ethinyl Estradiol, Levonorgestrel (Miranova)87.9

[back to top]

Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)78.85
Ethinyl Estradiol, Levonorgestrel (Miranova)77.35

[back to top]

Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)85.95
Ethinyl Estradiol, Levonorgestrel (Miranova)84.79

[back to top]

Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)62.6
Ethinyl Estradiol, Levonorgestrel (Miranova)62.2

[back to top]

Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)68.2
Ethinyl Estradiol, Levonorgestrel (Miranova)67.2

[back to top]

Participants With Improvement in Participants' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionParticipants (Number)
MissingNot assessedVery much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worse
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)116091471850
Ethinyl Estradiol, Levonorgestrel (Miranova)014675572443

[back to top]

Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionParticipants (Number)
MissingNot assessedVery much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worse
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)016387491760
Ethinyl Estradiol, Levonorgestrel (Miranova)014284542336

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At Baseline (28 days per cycle)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.047.913.220.917.9
Ethinyl Estradiol, Levonorgestrel (Miranova)0.051.711.723.912.2

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.078.68.56.42.1
Ethinyl Estradiol, Levonorgestrel (Miranova)0.072.66.58.74.3

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At screening (28 days)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.438.016.226.518.8
Ethinyl Estradiol, Levonorgestrel (Miranova)0.040.416.129.613.9

[back to top]

Percentage of Participants Satisfied With Study Treatment

Participants were asked to express the degree of their satisfaction with study treatment. (NCT00909857)
Timeframe: From cycle 1 to cycle 3 (28 days per cycle)

,
InterventionPercentage of participants (Number)
MissingVery satisfiedSaatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery dissatisfied
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.953.432.17.32.10.4
Ethinyl Estradiol, Levonorgestrel (Miranova)1.350.430.08.33.50.4

[back to top]

Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

,
InterventionPercentage of Participants (Number)
Baseline period-daily activities impairedBaseline period- leisure activities impairedTreatment period-daily activities impairedTreatment period- leisure activities impaired
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)93.292.354.752.6
Ethinyl Estradiol, Levonorgestrel (Miranova)92.290.060.061.3

[back to top]

Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

,
InterventionPercentage of participants (Number)
Baseline period-daily activities impairedBaseline period- leisure activities impairedTreatment period-daily activities impairedTreatment period- leisure activities impaired
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)92.390.651.747.9
Ethinyl Estradiol, Levonorgestrel (Miranova)91.389.656.556.5

[back to top]

Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

,
InterventionPercentage of participants (Number)
SpottingLightNormalHeavy
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)53.530.29.37.0
Ethinyl Estradiol, Levonorgestrel (Miranova)62.210.813.513.5

[back to top]

Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

,
InterventionPercentage of participants (Number)
SpottingLightNormalHeavy
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)45.527.313.613.6
Ethinyl Estradiol, Levonorgestrel (Miranova)30.421.730.417.4

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At final examination (28 days)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.485.95.63.01.7
Ethinyl Estradiol, Levonorgestrel (Miranova)0.085.22.64.81.7

[back to top]

Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)50.7
Ethinyl Estradiol, Levonorgestrel (Miranova)51.8

[back to top]

Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.0
Ethinyl Estradiol, Levonorgestrel (Miranova)74.0

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding

Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.3
Ethinyl Estradiol, Levonorgestrel (Miranova)0.1

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding

Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.0
Ethinyl Estradiol, Levonorgestrel (Miranova)-3.7

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionTablets (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.5
Ethinyl Estradiol, Levonorgestrel (Miranova)-5.6

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionTablets (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-6.2
Ethinyl Estradiol, Levonorgestrel (Miranova)-6.6

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain

Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.6
Ethinyl Estradiol, Levonorgestrel (Miranova)-4.2

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain

Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst) (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-10.6
Ethinyl Estradiol, Levonorgestrel (Miranova)-10.0

[back to top]

Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.6
Ethinyl Estradiol, Levonorgestrel (Miranova)4.6

[back to top]

Difference in Duration Between Longest and Shortest Spotting Only Episode

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)1.2
Ethinyl Estradiol, Levonorgestrel (Miranova)0.7

[back to top]

General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)75.8
Ethinyl Estradiol, Levonorgestrel (Miranova)72.7

[back to top]

General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.2
Ethinyl Estradiol, Levonorgestrel (Miranova)76.5

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.2
Ethinyl Estradiol, Levonorgestrel (Miranova)5.4

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)4.5
Ethinyl Estradiol, Levonorgestrel (Miranova)5.2

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.7
Ethinyl Estradiol, Levonorgestrel (Miranova)4.0

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.7
Ethinyl Estradiol, Levonorgestrel (Miranova)4.1

[back to top]

Maximum Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)7.1
Ethinyl Estradiol, Levonorgestrel (Miranova)8.4

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)6.0
Ethinyl Estradiol, Levonorgestrel (Miranova)6.2

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.5
Ethinyl Estradiol, Levonorgestrel (Miranova)4.9

[back to top]

Maximum Length of Spotting Only Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.9
Ethinyl Estradiol, Levonorgestrel (Miranova)3.6

[back to top]

Mean Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.17
Ethinyl Estradiol, Levonorgestrel (Miranova)5.83

[back to top]

Mean Length of Spotting Only Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.29
Ethinyl Estradiol, Levonorgestrel (Miranova)3.26

[back to top]

Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)73.6
Ethinyl Estradiol, Levonorgestrel (Miranova)72.6

[back to top]

Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.3
Ethinyl Estradiol, Levonorgestrel (Miranova)76.4

[back to top]

Number of Days With Bleeding or Spotting

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)20.0
Ethinyl Estradiol, Levonorgestrel (Miranova)23.6

[back to top]

Number of Days With Spotting-only

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)7.3
Ethinyl Estradiol, Levonorgestrel (Miranova)7.6

[back to top]

Number of Episodes With Bleeding or Spotting

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.9
Ethinyl Estradiol, Levonorgestrel (Miranova)4.1

[back to top]

Number of Episodes With Spotting-only

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.5
Ethinyl Estradiol, Levonorgestrel (Miranova)0.4

[back to top]

Number of Intracyclic Bleeding Days at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)1.2
Ethinyl Estradiol, Levonorgestrel (Miranova)1.0

[back to top]

Number of Intracyclic Bleeding Days at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.6
Ethinyl Estradiol, Levonorgestrel (Miranova)0.6

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.2
Ethinyl Estradiol, Levonorgestrel (Miranova)0.2

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.1
Ethinyl Estradiol, Levonorgestrel (Miranova)0.1

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)4.8
Ethinyl Estradiol, Levonorgestrel (Miranova)4.9

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.1
Ethinyl Estradiol, Levonorgestrel (Miranova)4.3

[back to top]

Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.46
Ethinyl Estradiol, Levonorgestrel (Miranova)5.04

[back to top]

Participant Report of Adverse Events.

Safety data includes data from each subject up to two weeks after her last use of the study tablets as well as all events deemed related to study product, regardless of date last tablet was taken (NCT00922233)
Timeframe: 6.5 months

Interventionadverse events (Number)
Levonorgestrel Arm45

[back to top]

Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35)

Participants were followed for 6.5 months.Pearl Index in the 18-35 year population was collected excluding months in which barrier methods, condoms, or emergency contraception were used unless the subject conceived (NCT00922233)
Timeframe: 6.5 months

Interventionpregnancies per 100 woman years (Number)
Levonorgestrel22.4

[back to top]

Acceptability Based on Bleeding Patterns Reported

Number of participants who reported bleeding patterns were acceptable and would therefore use Levonorgestrel (NCT00922233)
Timeframe: 6.5 months

Interventionparticipants (Number)
Levonorgestrel Arm43

[back to top]

Change From Baseline in Serum Deoxypyridinoline

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionnmol/L (Mean)
Change from Baseline to Month 6 (n=234, 224, 349)Change from Baseline to Month 12 (n=233, 226, 348)
28-day Levonorgestrel OC-0.10.1
91-day Levonorgestrel OC-0.1-0.1
Untreated Control0.1-0.1

[back to top]

Number of Participants With Adverse Events (AEs)

"An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below.~A severe AE is defined as incapacitating, with inability to perform usual activities.~A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions:~fatal or life-threatening;~required or prolonged inpatient hospitalization;~resulted in persistent or significant disability/incapacity;~congenital anomaly or birth defect;~important medical event." (NCT00924560)
Timeframe: 12 months

,,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreat-related adverse eventDeathsOther serious adverse eventsWithdrawn from study due to adverse events
28-day Levonorgestrel OC258209501233
91-day Levonorgestrel OC252141000934
Untreated Control274107001

[back to top]

Change From Baseline in Bone-specific Alkaline Phosphatase

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionµg/L (Mean)
Change from Baseline to Month 6 (n=236, 224, 353)Change from Baseline to Month 12 (n=235, 225, 347)
28-day Levonorgestrel OC-5.9-6.6
91-day Levonorgestrel OC-6.8-6.9
Untreated Control-6.2-10.3

[back to top]

Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6Change from Baseline to Month 12
28-day Levonorgestrel OC0.691.20
91-day Levonorgestrel OC1.291.86
Untreated Control1.121.94

[back to top]

Change From Baseline in Lumbar Spine Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6Change from Baseline to Month 12
28-day Levonorgestrel OC0.010.01
91-day Levonorgestrel OC0.020.02
Untreated Control0.010.03

[back to top]

Change From Baseline in Proximal Femur Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6 (n=238, 227, 358)Change from Baseline to Month 12 (n=238, 224, 359)
28-day Levonorgestrel OC0.090.28
91-day Levonorgestrel OC0.260.59
Untreated Control0.130.43

[back to top]

Change From Baseline in Proximal Femur Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6 (n=238, 227, 358)Change from Baseline to Month 12 (n=238, 224, 359)
28-day Levonorgestrel OC0.000.01
91-day Levonorgestrel OC0.010.02
Untreated Control0.010.01

[back to top]

Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)

"Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.~Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline * 100%." (NCT00924560)
Timeframe: Baseline and Month 12

Interventionpercent change (Least Squares Mean)
91-day Levonorgestrel OC2.26
28-day Levonorgestrel OC1.45
Untreated Control2.50

[back to top]

Change From Baseline in Total Body Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6 (n=130, 126, 149)Change from Baseline to Month 12 (n=130, 126, 150)
28-day Levonorgestrel OC0.010.01
91-day Levonorgestrel OC0.010.01
Untreated Control0.010.02

[back to top]

Change From Baseline in Serum Osteocalcin

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionnmol/L (Mean)
Change from Baseline to Month 6 (n=236, 224, 354)Change from Baseline to Month 12 (n=235, 225, 348)
28-day Levonorgestrel OC-3.9-3.7
91-day Levonorgestrel OC-4.8-4.5
Untreated Control-5.1-7.1

[back to top]

Change From Baseline in Serum Procollagen 1 N-terminal Propeptide

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionµg/L (Mean)
Change from Baseline to Month 6 (n=237, 225, 355)Change from Baseline to Month 12 (n=235, 226, 349)
28-day Levonorgestrel OC-38.7-39.8
91-day Levonorgestrel OC-49.9-50.4
Untreated Control-57.8-86.0

[back to top]

Change From Baseline in Total Body Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6 (n=130, 126, 149)Change from Baseline to Month 12 (n=130, 126, 150)
28-day Levonorgestrel OC38.7063.78
91-day Levonorgestrel OC40.7772.86
Untreated Control46.2684.95

[back to top]

Change From Baseline in Serum Type I Collagen N-telopeptide

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
InterventionnM bone collagen equivalents (BCE) (Mean)
Change from Baseline to Month 6 (n=235, 224, 356)Change from Baseline to Month 12 (n=236, 225, 350)
28-day Levonorgestrel OC-3.9-4.3
91-day Levonorgestrel OC-4.8-4.5
Untreated Control-0.7-3.1

[back to top]

Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight

A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles. (NCT00996580)
Timeframe: Day 1 up to year 1

,,
Interventionpregnancies / cumulative exposure (Number)
Cycle 1Cycle 2Cycle 3Cycle 4
DR-103: <90 kg Subpopulation0.00620.01160.02030.0256
DR-103: >=90kg Subpopulation0.01640.02150.03920.0457
DR-103: Total0.00800.01340.02360.0291

[back to top]

All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight

A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles. (NCT00996580)
Timeframe: Day 1 up to year 1

,,
Interventionpregnancies / cumulative exposure (Number)
Cycle 1Cycle 2Cycle 3Cycle 4
DR-103: <90 kg Subpopulation0.00600.01140.01850.0239
DR-103: >=90kg Subpopulation0.01390.02310.03390.0429
DR-103: Total0.00740.01340.02120.0272

[back to top]

Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.25
DR-103: <90 kg Subpopulation2.83
DR-103: >=90kg Subpopulation5.32

[back to top]

Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.92
DR-103: <90 kg Subpopulation2.55
DR-103: >=90kg Subpopulation4.72

[back to top]

Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.71
DR-103: <90 kg Subpopulation3.23
DR-103: >=90kg Subpopulation6.04

[back to top]

Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.07
DR-103: <90 kg Subpopulation2.68
DR-103: >=90kg Subpopulation4.94

[back to top]

All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.82
DR-103: <90 kg Subpopulation2.46
DR-103: >=90kg Subpopulation4.54

[back to top]

Summary of Participants With Treatment-emergent Adverse Events

"The on-treatment time frame spanned the time during which study drug was administered until 3 weeks beyond the last study drug date.~Relationship to study drug was assessed by the investigator.~Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention." (NCT00996580)
Timeframe: Day 1 up to 13 months

Interventionparticipants (Number)
Treatment-emergent AEs (TEAEs)Treatment-related AEsSerious AEsTEAEs leading to discontinuation
DR-1032605108658463

[back to top]

All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.74
DR-103: <90 kg Subpopulation2.40
DR-103: >=90kg Subpopulation4.42

[back to top]

IUD Expulsion

Expulsion of the LNG-IUS (NCT00997932)
Timeframe: From time of insertion to final study date which is 6 months after IUD insertion.

InterventionParticipants (Count of Participants)
Immediate Insertion11

[back to top]

Area Under the Curve (AUC) 0-21 Days (PK Parameter) Measured for the ASPE Group

AUC 0-21 days was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment (NCT01044056)
Timeframe: 21 days

Interventionnh.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill21.9
Norelgestrominum and Ethinylestradiol Contraceptive Patch35.8
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring10.6

[back to top]

AUC 0-infinity (PK Parameter) for the ASPE Group.

AUC 0-infinity was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter. AUC 0-infinity was calculated as AUC 0-tlast extrapolated to infinity using the regression line from which t 1/2 was calculated. (NCT01044056)
Timeframe: 21 days of active treatment and the washout period thereafter

Interventionng.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill22.7
Norelgestrominum and Ethinylestradiol Contraceptive Patch37.7
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring11.2

[back to top]

AUC 0-tlast (PK Parameter) for the ASPE Group.

AUC 0-tlast was measured using ethinylestradiol serum concentrations using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter. (NCT01044056)
Timeframe: 21 days of active treatment and washout period thereafter

Interventionng.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill22.5
Norelgestrominum and Ethinylestradiol Contraceptive Patch37.5
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring11.1

[back to top]

Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group

Cmax was measured using ethinylstradiol serum concentration at several time points during the 21 days of active treatment and the washout thereafter. (NCT01044056)
Timeframe: 21 days of active treatment and washout period thereafter

Interventionpg/ml (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill168
Norelgestrominum and Ethinylestradiol Contraceptive Patch105
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring37.1

[back to top]

Indirect Medical Costs

Indirect cost A refers to cost of sanitary products and lack of activity, indirect cost B refers to cost of sanitary products and reduced work days, and indirect cost C refers to cost of sanitary products, lack of activity, and reduced work days. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

,
Interventiondollars (Mean)
Indirect costs AIndirect costs BIndirect costs C
Medical Therapy741264968
Radiofrequency Endometrial Ablation12427138

[back to top]

Direct Medical Costs

Direct Medical Costs consisted of two categories: primarily hospital billed services, and primarily physician billed services. Primary hospital billed services were as defined by Medicare billing practice. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

,
Interventiondollars (Mean)
Primarily hospital billed servicesPrimarily physician billed services
Medical Therapy13001601
Radiofrequency Endometrial Ablation34941837

[back to top]

Bleeding Pattern at 12 Months

"The menstruation pattern of the subjects was evaluated. A bleeding episode was defined as any set of one or more bleeding days bounded at each end by two or more bleeding-free days. The bleeding pattern was analyzed using a 90 day reference period and divided into groups, (based on World Health Organization (WHO) classification of clinically important bleeding patterns). The groups are Amenorrhea (no bleeding during the reference period); Infrequent bleeding (fewer than 3 bleeding episodes); Irregular bleeding (between 3 and 5 episodes with less than 3 bleeding-free intervals of length 14 days or more); Prolonged bleeding (1 or more bleeding episodes lasting 14 days or more); Eumenorrhea normal pattern (none of the above patterns)." (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

,
Interventionparticipants (Number)
AmenorrheaIrregular/Infrequent bleedingProlonged bleedingEumenorrhea
Medical Therapy5428
Radiofrequency Endometrial Ablation16609

[back to top]

Quality of Life as Measured by the Menorrhagia Multi-Attribute Scale (MMAS )

The MMAS questionnaire captures the subjective consequences of menorrhagia on six domains: practical difficulties; social life; psychological wellbeing; physical health; work routine; and family life. Each of the six domains has four statements that represent four levels of response. Respondents indicate the statement that best matches their feelings for each domain. The statement scores derive from a weighting of the domains and a weighting of the statements in level of severity by women in the original study. Scores range from 0 (worst possible state in all domains) to 100 (best possible state in all domains). (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventionunits on a scale (Median)
Medical Therapy100
Radiofrequency Endometrial Ablation100

[back to top]

Pain at 12 Months as Measured by the Pain Visual Analog Scale (VAS)

The pain VAS is a continuous scale comprised of a horizontal (HVAS) line, 100 mm in length. Possible scores range from 0 (no pain) to 100 (worst possible pain). The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventionmm (Median)
Medical Therapy0.4
Radiofrequency Endometrial Ablation0.0

[back to top]

Hemoglobin at 12 Months

(NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventiong/dL (Median)
Medical Therapy13.2
Radiofrequency Endometrial Ablation13.4

[back to top]

Ferritin at 12 Months

(NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventionug/L (Median)
Medical Therapy25.0
Radiofrequency Endometrial Ablation26.5

[back to top]

Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC).

The PBLAC is a simple, pictorial tool used in women with menorrhagia to assess menstrual blood loss. The total score is calculated by adding up the sum of all scores for the tampons or sanitary napkin used in the menstrual cycle. For tampons: 1 for lightly stained, 5 for moderately soiled and 10 for completely saturated tampons. For sanitary napkins: 1 for lightly stained, 5 for moderately soiled, and 20 for completely saturated pads. Clots were given a score of 1 for small and 5 for large clots. Abnormal PBLAC bleeding score greater than or equal to 100, which correlates with menorrhagia, defined as greater than 80 mL of menstrual blood loss. Normal bleeding is defined as a score of 75 or less. A score of 0 indicates amenorrhea, or absence of menstruation. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventionunits on a scale (Median)
Medical Therapy15
Radiofrequency Endometrial Ablation0

[back to top]

Change in Ferritin From Baseline

(NCT01165307)
Timeframe: Measured at 12 months following initial treatment

Interventionug/L (Median)
Medical Therapy4.0
Radiofrequency Endometrial Ablation10.0

[back to top]

Change in Hemoglobin

(NCT01165307)
Timeframe: baseline, 12 months

Interventiong/dL (Median)
Medical Therapy0.0
Radiofrequency Endometrial Ablation0.5

[back to top]

Subject Satisfaction at 12 Months

Subject satisfaction was ascertained by asking study participants to choose from one of four categories relating to their general satisfaction with treatment: totally satisfied, generally satisfied, acceptable improvement in symptoms, or unacceptable treatment. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

,
Interventionparticipants (Number)
Totally satisfiedGenerally satisfiedAcceptable improvementUnacceptable
Medical Therapy12421
Radiofrequency Endometrial Ablation30100

[back to top]

Quality of Life Score Using the Short Form-12 (SF-12) Health Survey

Quality of life (QoL) was measured by the SF-12 questionnaire. The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. Physical and Mental Health Composite Scores are computed (combined, scored, and weighted) using the scores of the 12 questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Improvement was defined as a change of ≥ 6 points. (NCT01165307)
Timeframe: Measured at 12 months following initial treatment

,
Interventionunits on a scale (Mean)
SF-12 Physical ScaleSF-12 Mental Scale
Medical Therapy54.249.8
Radiofrequency Endometrial Ablation54.553.8

[back to top]

EE Steady State After Randomization

Steady state levels of ethinyl estradiol (EE) post- randomization (NCT01170390)
Timeframe: Post-randomiziation 4 months

Interventionng/mL (Mean)
Aviane & Aviane0.08
Aviane and Portia0.11

[back to top]

EE Steady State Baseline

Steady state levels of ethinyl estradiol (EE) at baseline (2 months) (NCT01170390)
Timeframe: Baseline (2 months)

Interventionng/mL (Mean)
Aviane & Aviane0.12
Aviane and Portia0.1

[back to top]

LNG AUC

Area under the curve post-randomization for levonorgestrel. AUC was calculated and extrapolated using post randomization in single daily samples drawn during Cycle 4 days 20-26. Serial repeat sampling to obtain a detailed PK curve was not performed to obtain this AUC. Subjects could provide samples during these days at times convenient to them and PK software accounted for the time between when the drug was dosed versus when the sample was drawn. (NCT01170390)
Timeframe: post-randomization (4 months)

Interventionhr*ng/mL (Mean)
Aviane & Aviane412
Aviane and Portia283

[back to top]

LNG AUC

Baseline measurements of levonorgestrel AUC (on Aviane). Area under the curve at baseline for levonorgestrel. AUC was calculated from time zero to 168 hours and extrapolated to infinity from serial repeat sampling (0,0.5,1.1.5,2,3,4,6,8,12 hours and then single samples daily for 4 days between Cycles 1 and 2. (NCT01170390)
Timeframe: baseline (2 months)

Interventionhr*ng/mL (Mean)
Aviane and Aviane267
Aviane and Portia199

[back to top]

LNG Steady State at Baseline and Then Post-randomization

The main goal is to test whether key pharmacokinetic parameters of levonordestrel (LNG) differ between obese women taking traditionally dosed OCs versus the interventional arms (i.e. using each obese subject as their own control). (NCT01170390)
Timeframe: baseline (2 months) and post-randomization (4 months)

,
Interventionng/mL (Mean)
LNG steady state levels at baselineAfter randomization (4 months)
Aviane & Aviane3.823.01
Aviane and Portia3.133.58

[back to top]

Number of Participants Who Expelled IUDs by12 Weeks Postpartum

Number of participants who expelled IUDs by12 weeks postpartum across all participants (NCT01230242)
Timeframe: up to 12 weeks postpartum

InterventionParticipants (Count of Participants)
Mirena IUD Placement Immediately Post-delivery1

[back to top]

Change in Vaginal Flora

Changes in vaginal flora as assessed by Nugent score The Nugent score is calculated by microscopically assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with bacterial vaginosis, 4-6 is consistent with intermediate vaginal flora, and 0-3 is normal vaginal flora. (NCT01240811)
Timeframe: 2 Months

Interventionunits on a scale (Median)
Control-No IUD0
Levonorgestrel IUS1
Copper T380A IUD0

[back to top]

Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis

Changes in vaginal flora as assessed by qPCR quantitation of H2O2 producing Lactobacilli species and Gardnerella vaginalis. Quantitative PCR (qPCR) results are reported as log concentration of gene copies/swab specimen. (NCT01240811)
Timeframe: 2 Months

,,
Interventionlog gene copies/swab (Median)
Change in log Lactobacilli quantityChange in log Garnerella vaginalis quantity
Control-No IUD-0.60
Copper T380A IUD0.10
Levonorgestrel IUS-0.10

[back to top]

%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium

Change in CCR5 expression on T-lymphocytes 2 months after insertion of IUD (either hormonal LNG-IUD or non-hormonal Cu-IUD) in cervix and endometrium as measured by flow cytomety (NCT01240811)
Timeframe: 2 months

Intervention% of T-cells expressing CCR5 (Mean)
Control-No IUD4.9
Levonorgestrel IUS11.7
Copper T380A IUD7.2

[back to top]

Cycle Control

The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days. (NCT01250210)
Timeframe: 3 months

Interventionnumber of episodes (Mean)
AG200LE0.29
AG2000.29
AG200-150.15

[back to top]

Ovulation Suppression in Three Treatment Groups Over 3 Cycles

"Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are:~Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points.~Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points.~Perfect compliance: If no patch has been off >1 day and no more than 1 day has elapsed between patch changes.~Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit." (NCT01250210)
Timeframe: 3 months

,,
Intervention%of cycles with possible ovulation (Number)
ITT, perfect complianceComplete progesterone, perfect complianceITT, verifiable complianceComplete progesterone, verifiable compliance
AG20020.720.714.914.9
AG200-1511.511.712.012.0
AG200LE36.536.932.532.5

[back to top]

Change From Baseline to End of Month 6 in Antithrombin

"Antithrombin is a protein in the blood that naturally blocks blood clots from forming.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 80% to 130%.for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive2.36
28-day Levonorgestrel Oral Contraceptive-0.05
28-day Desogestrel Oral Contraceptive-0.83

[back to top]

Change From Baseline to End of Month 6 in Plasminogen

Plasminogen is the precursor of plasmin, which lyses fibrin clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventiong/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.04
28-day Levonorgestrel Oral Contraceptive0.04
28-day Desogestrel Oral Contraceptive0.04

[back to top]

Change From Baseline to End of Month 6 in Protein C Antigen

"Protein C helps to regulate blood clot formation. Activated Protein C (APC) combines with Protein S (a cofactor) to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140% in adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive12.83
28-day Levonorgestrel Oral Contraceptive11.97
28-day Desogestrel Oral Contraceptive10.00

[back to top]

Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels

Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive169.53
28-day Levonorgestrel Oral Contraceptive157.99
28-day Desogestrel Oral Contraceptive592.29

[back to top]

Change From Baseline to End of Month 6 in Sex Hormone Binding Globulin (SHBG)

(NCT01252186)
Timeframe: Baseline to Month 6

InterventionmIU/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive34.87
28-day Levonorgestrel Oral Contraceptive30.85
28-day Desogestrel Oral Contraceptive165.01

[back to top]

Change From Baseline to End of Month 6 in Thyroid Stimulating Hormone (TSH)

(NCT01252186)
Timeframe: Baseline top Month 6

InterventionmIU/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.22
28-day Levonorgestrel Oral Contraceptive0.10
28-day Desogestrel Oral Contraceptive0.22

[back to top]

Change From Baseline to End of Month 6 in Tissue Factor Pathway Inhibitor (TFPI)

Tissue Factor Pathway Inhibitor (TFPI) is an anti-coagulation protein that binds to activated protein X. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive4.65
28-day Levonorgestrel Oral Contraceptive2.54
28-day Desogestrel Oral Contraceptive-1.34

[back to top]

Change From Baseline to End of Month 6 in Tissue Plasminogen Activator (t-PA)

Tissue plasminogen activator catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for the breakdown of blood clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionµg/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.91
28-day Levonorgestrel Oral Contraceptive-1.48
28-day Desogestrel Oral Contraceptive-9.3

[back to top]

Change From Baseline to End of Month 6 in Total Cortisol

(NCT01252186)
Timeframe: Baseline to Month 6

Interventionnmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive217.94
28-day Levonorgestrel Oral Contraceptive262.40
28-day Desogestrel Oral Contraceptive227.68

[back to top]

Change From Baseline to End of Month 6 in Total Protein S

"Protein S helps to regulate blood clot formation. Protein S exists in two forms: a free form and a complex form. Free protein S combines with activated protein C to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%; lower for women than for men." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-11.06
28-day Levonorgestrel Oral Contraceptive-11.48
28-day Desogestrel Oral Contraceptive-21.59

[back to top]

Change From Baseline to End of Month 6 in Corticosteroid Binding Globulin

(NCT01252186)
Timeframe: Baseline to Month 6

Interventionnmol/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive576.33
28-day Levonorgestrel Oral Contraceptive563.85
28-day Desogestrel Oral Contraceptive634.64

[back to top]

Change From Baseline to End of Month 6 in D-dimer

D-dimer is the degradation product of cross-linked fibrin and is a marker of thrombin and fibrin formation and turnover. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive86.74
28-day Levonorgestrel Oral Contraceptive72.43
28-day Desogestrel Oral Contraceptive158.05

[back to top]

Change From Baseline to End of Month 6 in Factor VII

"Clotting factor VII, also called proconvertin or autoprothrombin I, functions in blood coagulation.~Results are reported as percent of normal plasma concentrations. By definition, normal plasma contains 100% (1 unit/mL) of each factor. The reference range is approximately 60% to 140% for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive14.27
28-day Levonorgestrel Oral Contraceptive22.98
28-day Desogestrel Oral Contraceptive43.22

[back to top]

Change From Baseline to End of Month 6 in Activated Partial Thromboplastin Time (APTT) Based Activated Protein-C Resistance (APC)

"The APC resistance assay is a clotting test that measures the ratio of APTT clotting times in the presence and absence of a standard amount of exogenous APC. APC resistance is calculated as the ratio of the clotting time after APC addition over the clotting time with no APC addition.~APC resistance is defined as a poor anticoagulant response of plasma to APC (minimal prolongation of the APTT) and a correspondingly low ratio." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionratio (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-0.12
28-day Levonorgestrel Oral Contraceptive-0.15
28-day Desogestrel Oral Contraceptive-0.27

[back to top]

Change From Baseline to End of Month 6 in Protein C Activity

"Protein C helps to regulate blood clot formation. Activated Protein C (APC) combines with Protein S (a cofactor) to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140% for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-6.15
28-day Levonorgestrel Oral Contraceptive-4.39
28-day Desogestrel Oral Contraceptive-2.41

[back to top]

Change From Baseline to End of Month 6 in Endogenous Thrombin Potential (EPT) Based Activated Protein-C Resistance (APC)

"This assay is based on measurement of the effect of activated protein C on the endogenous thrombin potential, the time integral of thrombin generation initiated in plasma through the extrinsic coagulation pathway.~The APC resistance assay measures the ratio of endogenous thrombin potential in the presence and absence of a standard amount of exogenous APC.~APC resistance is calculated as the ratio of EPT after APC addition over the EPT with no APC addition.~APC resistance is defined as a poor anticoagulant response of plasma to APC (less inhibition of thrombin formation) and a correspondingly higher ratio." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionratio (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.38
28-day Levonorgestrel Oral Contraceptive0.37
28-day Desogestrel Oral Contraceptive0.57

[back to top]

Change From Baseline to End of Month 6 in Factor II

Clotting factor II, also called prothrombin, functions in blood coagulation. Results are reported as percent of normal plasma concentrations. By definition, normal plasma contains 100% (1 unit/mL) of each factor. The reference range is approximately 60% to 140% for adults. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive6.89
28-day Levonorgestrel Oral Contraceptive7.98
28-day Desogestrel Oral Contraceptive8.57

[back to top]

Change From Baseline to End of Month 6 in Factor VIII

"Clotting factor VIII, also known as anti-hemophilic factor (AHF), functions in blood coagulation by stabilizing fibrin clots.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%.for adults." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive-3.23
28-day Levonorgestrel Oral Contraceptive0.08
28-day Desogestrel Oral Contraceptive5.53

[back to top]

Change From Baseline to End of Month 6 in Fibrinogen

Fibrinogen (factor I) is a glycoprotein that helps in the formation of blood clots. (NCT01252186)
Timeframe: Baseline to Month 6

Interventiong/L (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive0.12
28-day Levonorgestrel Oral Contraceptive0.22
28-day Desogestrel Oral Contraceptive-0.04

[back to top]

Change From Baseline to End of Month 6 in Free Protein S

"Protein S helps to regulate blood clot formation. Protein S exists in two forms: a free form and a complex form. Free protein S combines with Protein C to degrade coagulation factors VIIIa and Va, slowing down the generation of new thrombin and inhibiting further clotting.~Results are reported as a percent of the amount expected in normal plasma. By definition, the mean value in normal plasma is 100%. The reference range is approximately 70% to 140%; lower for women than for men." (NCT01252186)
Timeframe: Baseline to Month 6

Interventionpercentage of normal (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive2.96
28-day Levonorgestrel Oral Contraceptive4.62
28-day Desogestrel Oral Contraceptive-18.2

[back to top]

Change From Baseline to End of Month 6 in Plasmin-Antiplasmin (PAP) Complex

The plasmin-antiplasmin (PAP) complex is a marker of thrombin and fibrin formation and turnover. (NCT01252186)
Timeframe: Baseline to Month 6

Interventionng/mL (Least Squares Mean)
91-day Levonorgestrel Oral Contraceptive10.72
28-day Levonorgestrel Oral Contraceptive-6.42
28-day Desogestrel Oral Contraceptive107.81

[back to top]

User Satisfaction - Satisfaction With Menstrual Bleeding Pattern

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
Very satisfiedSomewhat satisfiedNeither satisfied nor dissatisfiedDissatisfiedVery dissatisfiedNot applicable
EE30/DRSP (Yasmin, BAY86-5131)918468412
LCS12 (Skyla, BAY86-5028)1016548191020

[back to top]

User Satisfaction - Amount of Menstrual Bleeding

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
DecreasedNot ChangedIncreased
EE30/DRSP (Yasmin, BAY86-5131)352078
LCS12 (Skyla, BAY86-5028)8016317

[back to top]

User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
DecreasedNot changedIncreased
EE30/DRSP (Yasmin, BAY86-5131)6116917
LCS12 (Skyla, BAY86-5028)11810239

[back to top]

EVAPIL-R Scores at 12 Months - Bother Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. (NCT01254292)
Timeframe: At 12 months

InterventionScores on a scale (Mean)
LCS12 (Skyla, BAY86-5028)0.7789
EE30/DRSP (Yasmin, BAY86-5131)0.6015

[back to top]

EVAPIL-R Scores at 12 Months - Composite Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. (NCT01254292)
Timeframe: At 12 months

InterventionScores on a scale (Mean)
LCS12 (Skyla, BAY86-5028)1.4022
EE30/DRSP (Yasmin, BAY86-5131)1.0535

[back to top]

EVAPIL-R Scores at Screening - Bother Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, , with higher values indicating more severe symptoms/less tolerability. (NCT01254292)
Timeframe: At screening

InterventionScores on a scale (Mean)
LCS12 (Skyla, BAY86-5028)0.5569
EE30/DRSP (Yasmin, BAY86-5131)0.5188

[back to top]

EVAPIL-R Scores at Screening - Composite Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. (NCT01254292)
Timeframe: At screening

InterventionScores on a scale (Mean)
LCS12 (Skyla, BAY86-5028)0.9386
EE30/DRSP (Yasmin, BAY86-5131)0.8846

[back to top]

Overall Satisfaction Rate at 12 Months (LOCF)

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 12 months

InterventionPercentage of participants (Number)
LCS12 (Skyla, BAY86-5028)84.3
EE30/DRSP (Yasmin, BAY86-5131)83.8

[back to top]

Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 18 months

InterventionPercentage of participants (Number)
LCS12 (Skyla, BAY86-5028)82.1
EE30/DRSP (Yasmin, BAY86-5131)81.9

[back to top]

Overall Satisfaction Rate at 6 Months (LOCF)

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 6 months

InterventionPercentage of participants (Number)
LCS12 (Skyla, BAY86-5028)87.9
EE30/DRSP (Yasmin, BAY86-5131)83.8

[back to top]

Compliance Rate for Yasmin Pill Intake

(NCT01254292)
Timeframe: Up to 18 months

InterventionPercentage of participants (Number)
MissingCompliance <=75%Compliance >75%
EE30/DRSP (Yasmin, BAY86-5131)2.82.195.0

[back to top]

Cumulative Drop-out Rate

The drop-out rate is the amount of participants that could not complete the study for various reasons. Discontinuation rates due to the following reasons and overall discontinuations were calculated: • LCS12 expulsions • Bleeding pattern alterations • Bleeding pattern alterations with increased bleeding (amount) • Bleeding pattern alterations with decreased bleeding (amount) • Adverse Events The analyses described above were also done by parity. Furthermore, overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates. (NCT01254292)
Timeframe: Up to 6, 12, 18, 24 and 36 months

,
InterventionPercentage of participants (Number)
Up to 6 monthsUp to 12 monthsUp to 18 monthsUp to 24 monthsUp to 36 months
EE30/DRSP (Yasmin, BAY86-5131)11.3921.7127.40NANA
LCS12 (Skyla, BAY86-5028)7.5313.2618.6430.8533.34

[back to top]

EVAPIL-R Scores at 18 Months/EOS

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionScores on a scale (Mean)
Composite scoreBother score
EE30/DRSP (Yasmin, BAY86-5131)1.02460.5908
LCS12 (Skyla, BAY86-5028)1.48040.8113

[back to top]

EVAPIL-R Scores at 6 Months

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. (NCT01254292)
Timeframe: At 6 months

,
InterventionScores on a scale (Mean)
Composite scoreBother score
EE30/DRSP (Yasmin, BAY86-5131)1.15370.6550
LCS12 (Skyla, BAY86-5028)1.31870.7364

[back to top]

Investigator's Evaluation of IUS Removal Procedure

(NCT01254292)
Timeframe: Up to 36 months

InterventionParticipants (Number)
EasySlightly difficultVery difficult
LCS12 (Skyla, BAY86-5028)252114

[back to top]

Investigator's Evaluation of Successful IUS Insertion Procedure

(NCT01254292)
Timeframe: Up to 18 months

InterventionParticipants (Number)
EasySlightly difficultVery difficult
LCS12 (Skyla, BAY86-5028)247311

[back to top]

Overall Satisfaction Rating by the 5-point Likert Item at 12 Months

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 12 months

,
InterventionPercentage of participants (Number)
Very SatisfiedSatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery Dissatisfied
EE30/DRSP (Yasmin, BAY86-5131)45.044.15.93.81.3
LCS12 (Skyla, BAY86-5028)66.822.95.94.30.0

[back to top]

Overall Satisfaction Rating by the 5-point Likert Item at 18 Months

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 18 months

,
InterventionPercentage of participants (Number)
Very SatisfiedSatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery Dissatisfied
EE30/DRSP (Yasmin, BAY86-5131)52.537.86.92.80.0
LCS12 (Skyla, BAY86-5028)64.325.16.43.01.3

[back to top]

Overall Satisfaction Rating by the 5-point Likert Item at 6 Months

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question." (NCT01254292)
Timeframe: At 6 months

,
InterventionPercentage of participants (Number)
Very SatisfiedSatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery Dissatisfied
EE30/DRSP (Yasmin, BAY86-5131)48.135.89.66.20.4
LCS12 (Skyla, BAY86-5028)60.427.57.31.82.9

[back to top]

Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)

"Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting 1. Very satisfied or 2. Satisfied for the above question.~The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase." (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionPercentage of participants (Number)
Very SatisfiedSatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery Dissatisfied
EE30/DRSP (Yasmin, BAY86-5131)46.635.19.67.61.2
LCS12 (Skyla, BAY86-5028)58.623.58.65.63.7

[back to top]

Participants' Evaluation of Pain During IUS Removal Procedure

(NCT01254292)
Timeframe: Up to 36 months

InterventionParticipants (Number)
NoneMildModerateSevere
LCS12 (Skyla, BAY86-5028)13696305

[back to top]

Participants' Evaluation of Pain During Successful IUS Insertion Procedure

(NCT01254292)
Timeframe: Up to 18 months

InterventionParticipants (Number)
NoneMildModerateSevere
LCS12 (Skyla, BAY86-5028)491258025

[back to top]

Pearl Index (PI)

The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution. (NCT01254292)
Timeframe: Up to 18, 24, 36 months

,
InterventionPregnancies per 100 women years (Mean)
Pearl index up to 18 monthsPearl index up to 24 monthsPearl index up to 36 months
EE30/DRSP (Yasmin, BAY86-5131)1.82NANA
LCS12 (Skyla, BAY86-5028)0.570.670.65

[back to top]

User Satisfaction - Acceptability of the Administration of Study Treatment

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
Acc. without inconvenience/discomfortAcc. with some inconv/discomfortNot acc. with moderate inconv./discomf.Not acc. with extreme inconv./discomf
EE30/DRSP (Yasmin, BAY86-5131)18646153
LCS12 (Skyla, BAY86-5028)153871112

[back to top]

User Satisfaction - Acceptability of the Administration of Study Treatment

The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D. (NCT01254292)
Timeframe: At 12 months

,
InterventionParticipants (Number)
Acc. without inconvenience/discomfortAcc. with some inconv/discomfortNot acc. with moderate inconv./discomf.Not acc. with extreme inconv./discomf.
EE30/DRSP (Yasmin, BAY86-5131)1853320
LCS12 (Skyla, BAY86-5028)1527491

[back to top]

User Satisfaction - Acceptability of the Administration of Study Treatment

The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D. (NCT01254292)
Timeframe: At 6 months

,
InterventionParticipants (Number)
Acc. without inconvenience/discomfortAcc. with some inconv/discomfortNot acc. with moderate inconv./discomf.Not acc. with extreme inconv./discomf.
EE30/DRSP (Yasmin, BAY86-5131)1924840
LCS12 (Skyla, BAY86-5028)1638742

[back to top]

User Satisfaction - Choices Upon Completion of the Study

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
Continue with study treatmentUse a different hormonal contraceptiveUse a different contraceptive methodDiscont. use of all types of contracept.No need for contraceptive at this timeUndecided
EE30/DRSP (Yasmin, BAY86-5131)1225127141222
LCS12 (Skyla, BAY86-5028)17434176527

[back to top]

Cumulative Number of Participants With Partial or Total Expulsion

Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal. (NCT01254292)
Timeframe: Up to 18, 24, 36 months

InterventionParticipants (Number)
Partial expulsion up to 18 monthsTotal expulsion up to 18 monthsPartial expulsion up to 24 monthsTotal expulsion up to 24 monthsPartial expulsion up to 36 monthsTotal expulsion up to 36 months
LCS12 (Skyla, BAY86-5028)001010

[back to top]

User Satisfaction - Frequency of Experiencing Unexpected Bleeding

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
NeverSeldomOftenVery Often
EE30/DRSP (Yasmin, BAY86-5131)2192551
LCS12 (Skyla, BAY86-5028)14592179

[back to top]

User Satisfaction - Rating of Usual Menstrual Pain Intensity

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
NoneMildModerateSevere
EE30/DRSP (Yasmin, BAY86-5131)8292678
LCS12 (Skyla, BAY86-5028)124784316

[back to top]

User Satisfaction - Satisfaction With Menstrual Bleeding Absence

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase. (NCT01254292)
Timeframe: At 18 months/EOS

,
InterventionParticipants (Number)
Very satisfiedSomewhat satisfiedNeither satisfied nor dissatisfiedDissatisfiedVery dissatisfied
EE30/DRSP (Yasmin, BAY86-5131)60800
LCS12 (Skyla, BAY86-5028)96181411

[back to top]

Intrauterine Infection

The proportion of patients in each arm who experience an intrauterine infection (endometritis, pelvic inflammatory disease) (NCT01272960)
Timeframe: 6 months

Interventionparticipants (Number)
Interval Insertion0
Post-Placental Mirena Insertion0

[back to top]

Mirena Expulsion

The percentage of patients with post-placental placement of Mirena who experience an expulsion (NCT01272960)
Timeframe: 6 weeks

Interventionparticipants (Number)
Interval Insertion0
Post-Placental Mirena Insertion0

[back to top]

Mirena in Place

Proportion of women in each arm with Mirena in place at 6 months (NCT01272960)
Timeframe: 6 months

Interventionparticipants (Number)
Post Placental Mirena Insertion10
Interval Insertion3

[back to top]

Uterine Perforation

The proportion of patients in each arm who experience a uterine perforation (NCT01272960)
Timeframe: 6 months

Interventionparticipants (Number)
Interval Insertion0
Post-Placental Mirena Insertion0

[back to top]

Incidence Rate of Idiopathic Venous Thromboembolism (VTE)

Idiopathic VTE=deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) occurring in absence of known risk factors. Incidence rate reported for current, past users. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control. (NCT01297348)
Timeframe: Index date (date of VTE diagnosis for case and corresponding date for matched control)

,,
Interventionincidence rate per 100000 person-years (Number)
Current usersPast users
Lybrel176.254.1
Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)87.518.0
Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)50.517.6

[back to top]

Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls

Idiopathic VTE cases=new DVT, PE or CVST occurring in absence of known risk factors. Matched Control was defined as participants with no diagnosis of VTE matched for age, calendar time, exposure status and database. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control. (NCT01297348)
Timeframe: Index date (date of VTE diagnosis for case and corresponding date for matched control)

,,
Interventionparticipants (Number)
Current user: CaseCurrent user: Matched ControlPast user: CasePast user: Matched Control
Lybrel174711
Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)27611441439
Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)53254410

[back to top]

Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg*h/mL (Geometric Mean)
Microgynon907
Microgynon Plus Empa932

[back to top]

Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg/mL (Geometric Mean)
Microgynon97.6
Microgynon Plus Empa96.8

[back to top]

Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of ethinylestradiol in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon18.6
Microgynon Plus Empa19.5

[back to top]

Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon15.3
Microgynon Plus Empa16.3

[back to top]

Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0454
Microgynon Plus Empa0.0425

[back to top]

Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.26
Microgynon Plus Empa1.50

[back to top]

Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of levonorgestrel in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon26.6
Microgynon Plus Empa26.1

[back to top]

Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon84.6
Microgynon Plus Empa85.0

[back to top]

Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng*h/mL (Geometric Mean)
Microgynon94.0
Microgynon Plus Empa95.9

[back to top]

Levonorgestrel: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng/mL (Geometric Mean)
Microgynon7.98
Microgynon Plus Empa8.44

[back to top]

Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of levonorgestrel in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon48.8
Microgynon Plus Empa49.6

[back to top]

Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon36.7
Microgynon Plus Empa37.6

[back to top]

Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0189
Microgynon Plus Empa0.0184

[back to top]

Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.00
Microgynon Plus Empa1.00

[back to top]

Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.

Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events. (NCT01328184)
Timeframe: Day 1 to day 17

Interventionparticipants (Number)
Microgynon0
Microgynon Plus Empa0

[back to top]

Assessment of Tolerability

Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable. (NCT01328184)
Timeframe: Within Day 24 to Day 31

,
Interventionpercentage of participants (Number)
GoodSatisfactoryNot satisfactoryBadNot assessable
Microgynon94.45.60.00.00.0
Microgynon Plus Empa94.45.60.00.00.0

[back to top]

Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon552
Microgynon Plus Empa536

[back to top]

Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon729
Microgynon Plus Empa757

[back to top]

Total to HDL Cholesterol Ratio

(NCT01546454)
Timeframe: Entire Study

InterventionTotal to HDL Cholesterol Ratio (Mean)
Non-steroidal Effects0.146
Contraceptive Effects0.148
Steroid Effects-0.89

[back to top]

Breastfeeding

Reported any breastfeeding at the final 6 month visit (NCT01555931)
Timeframe: 6 months

Interventionparticipants (Number)
Immediate10
Control9

[back to top]

LNG-IUS Expulsion or Removal

Expulsion or indicated removal of the originally placed LNG-IUS at any point during the study (NCT01555931)
Timeframe: up to 6 months

Interventionparticipants (Number)
Immediate8
Control0

[back to top]

Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.

Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. (NCT01570244)
Timeframe: from drug administration up to 14 days

Interventionparticipants (Number)
Microgynon0
Microgynon + Faldaprevir0

[back to top]

Cmax,ss of Ethinylestradiol

maximum measured concentration over the uniform dosing interval under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionpg/mL (Geometric Mean)
Microgynon108
Microgynon + Faldaprevir127

[back to top]

AUCt,ss of Ethinylestradiol

Area under the curve over the dosing interval t under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 hours (h) after drug administration

Interventionpg*h/mL (Geometric Mean)
Microgynon1010
Microgynon + Faldaprevir1450

[back to top]

AUCτ,ss of Levonorgestrel

Area under the curve over the dosing interval τ under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng*h/mL (Geometric Mean)
Microgynon83.3
Microgynon + Faldaprevir120

[back to top]

C24,ss of Ethinylestradiol

measured concentration of the analyte at the end of dosing interval under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionpg/mL (Geometric Mean)
Microgynon19.1
Microgynon + Faldaprevir33.2

[back to top]

Cmax,ss of Levonorgestrel

maximum measured concentration over the uniform dosing interval under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng/mL (Geometric Mean)
Microgynon7.57
Microgynon + Faldaprevir8.95

[back to top] [back to top]

C24,ss of Levonorgestrel

measured concentration of the analyte at the end of dosing interval under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng/mL (Geometric Mean)
Microgynon2.43
Microgynon + Faldaprevir3.85

[back to top]

Subjects With an IUD at 3 Months Postpartum

Subjects will be contacted by phone or email at 3 months after delivery. We will compare the proportion of subjects who report having an IUD in place at 3 months after delivery of those who are randomized to each group (placement at either 3 weeks or 6 weeks) . (NCT01594476)
Timeframe: Three months after delivery

InterventionParticipants (Count of Participants)
IUD Insertion at 3 Weeks66
IUD Insertion at 6 Weeks73

[back to top]

Uterine Thickness at the Fundus

Transvaginal ultrasound will be performed immediately following IUD placement. The thickness of the uterine myometrium at the fundus from the endometrium to the outer edge of the serosa will be measured in centimeters using an ultrasound caliper in the sagittal view. (NCT01594476)
Timeframe: At IUD placement

Interventioncm (Mean)
IUD Insertion at 3 Weeks2.3
IUD Insertion at 6 Weeks1.7

[back to top]

Subjects With an IUD at 6 Months Postpartum

Subjects will return to clinic for an ultrasound and exam at six months after delivery. We will compare the proportion of subjects with an IUD at this time of those randomized to each placement timing. (NCT01594476)
Timeframe: Six months after delivery

InterventionParticipants (Count of Participants)
IUD Insertion at 3 Weeks53
IUD Insertion at 6 Weeks53

[back to top]

Pain With IUD Placement

"Subjects were asked to record their current pain immediate at the time of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating no pain and worst pain in my life. The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher pain. The distance from the left side of the 10 cm line to the mark will be measured in millimeters and compared between randomization groups if they received an IUD at the allocated timing of 18-24 or 39-45 days." (NCT01594476)
Timeframe: At the time of IUD placement.

Interventionmm (Mean)
18-24 Days After Vaginal Delivery15.7
39-45 Days After Vaginal Delivery23.0
18-24 Days After Cesarean Delivery30.9
39-45 Days After Cesarean Delivery32.1

[back to top]

Satisfaction With the Timing of IUD Placement.

"Subjects were asked to record their overall satisfaction with the timing of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating very dissatisfied and very satisfied. The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher satisfaction." (NCT01594476)
Timeframe: Immediately following IUD placement.

Interventionmm on VAS (Mean)
IUD Insertion at 3 Weeks90.6
IUD Insertion at 6 Weeks93.5

[back to top]

IUD Expulsion Rate

The investigators wanted to compare the expulsion rate of IUDs between the two treatment arms: immediate placement after placental delivery and interval placement 6 weeks after delivery. IUD expulsion is confirmed by the inability of the physician to visualize the string attached to the IUD coming from the cervix. (NCT01598662)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
IUD Insertion 6 Weeks After Delivery0
Immediate Post-placental Insertion2

[back to top]

Cycle Control

Measurement of unscheduled bleeding/spotting days. (NCT01623466)
Timeframe: 8 weeks

Interventiondays (Mean)
AG890-6.58.4
AG890-12.58.3

[back to top]

Evaluation of Irritation at Patch Application Site

"Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale:~0: None~Mild~Moderate~Severe" (NCT01623466)
Timeframe: 8 weeks

InterventionScore on a scale (Mean)
AG890-6.50.11
AG890-12.50.06

[back to top]

Evaluation of Itching at Patch Application Site

"Self-reported worst skin itching at patch application site by subject using a 4-point scale:~0. None~Mild~Moderate~Severe" (NCT01623466)
Timeframe: 8 weeks

InterventionScore (Mean)
AG890-6.50.33
AG890-12.50.39

[back to top]

Evaluation of Patch Adhesion

"Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale:~0: ≥90% adhered (no lift)~≥75% adhered but <90% (some edges showing lift)~≥50% adhered but <75% (half of system lifts off)~<50% (< half of system lifts off, but undetached)~patch completely detached" (NCT01623466)
Timeframe: 8 weeks

InterventionScore on a scale (Mean)
AG890-6.50.41
AG890-12.50.78

[back to top]

Levonorgestrel Pharmacokinetic Profile

The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study. (NCT01623466)
Timeframe: 8 weeks

Intervention% of subjects below 175 pg/mL (Number)
AG890-6.5100
AG890-12.583.3

[back to top]

Breastfeeding Continuation Rates at 8 Weeks Postpartum

To determine breastfeeding continuation rates at 8 weeks in women randomized to immediate post-placental vs. delayed (4-8 weeks) postpartum levonorgestrel IUD insertion. (NCT01990703)
Timeframe: 8 weeks postpartum

InterventionParticipants (Count of Participants)
Early IUD Insertion Group88
Standard Postpartum Insertion Group86

[back to top]

Time to Lactogenesis Stage 2

To evaluate potential delay in lactogenesis caused by immediate postpartum insertion of the LNG IUD. (NCT01990703)
Timeframe: First 5 days after birth

InterventionHours (Mean)
Early IUD Insertion Group65.3
Standard Postpartum Insertion Group63.6

[back to top]

Complications

A questionnaire will be administered to determine if the participant has had any complications since placement. Number of women reporting complications are reported. (NCT02067663)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Mirena Group0
Paragard Group0

[back to top]

Intrauterine Device Expulsion by 12 Weeks Postpartum

Position of the IUD within the uterus will be documented by ultrasound. (NCT02067663)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Mirena Group21
Paragard Group8

[back to top]

Satisfaction

A questionnaire will be administered to determine the participant's satisfaction level with the IUD. Satisfaction levels of >= 8 are reported by percent of participants. (NCT02067663)
Timeframe: 3 months

Interventionpercent of participants (Number)
Mirena Group91.4
Paragard Group94.2

[back to top]

Pregnancy

A urine pregnancy test will be performed at the 6 week follow up visit if clinically indicated. (NCT02067663)
Timeframe: 6 weeks

InterventionParticipants (Count of Participants)
Mirena Group0
Paragard Group0

[back to top]

Pregnancy

A urine pregnancy test will be performed at the 3 month follow up visit if clinically indicated. (NCT02067663)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Mirena Group0
Paragard Group0

[back to top]

IUD Expulsion Rate

The primary outcome of the study is the total number of expulsions in the full 3 month study period. The provider will perform a speculum exam and transvaginal ultrasound. If expulsion has occurred, the participant will have an abdominal x-ray to confirm. (NCT02067663)
Timeframe: 3 months postpartum

InterventionParticipants (Count of Participants)
Mirena Group20
Paragard Group7

[back to top]

Intrauterine Device Expulsion (Day 1)

Number of expulsions at Day 1. Position of the IUD within the uterus will be documented by ultrasound. (NCT02067663)
Timeframe: Day 1

Interventionparticipants (Number)
Mirena Group0
Paragard Group0

[back to top]

Intrauterine Device Expulsion (6 Weeks)

Number of expulsions. Position of the IUD within the uterus will be documented by ultrasound. (NCT02067663)
Timeframe: 6 weeks

Interventionparticipants (Number)
Mirena Group18
Paragard Group6

[back to top]

Number of Participants With Expulsion (Complete or Partial) of LNG-IUS at Six-months.

Expulsion will be defined as any of the following (1) patient report that the LNG-IUS came out, (2) ultrasound evaluation that demonstrates the LNG-IUS is not intrauterine (3) ultrasound or clinical evaluation that demonstrates the majority of the LNG-IUS is located in the cervix. (NCT02121067)
Timeframe: 6 months postpartum

InterventionParticipants (Count of Participants)
LNG-IUS Placed at 2 Weeks Postpartum2

[back to top]

Number of Participants Who Enrolled and Were Able to Have a Successful LNG-IUS Insertion in the 2 Week (Day 14-20) Postpartum Period.

Was the LNG-IUS successfully placed in the study period, as determined by whether the participant had an LNG-IUS placed on the day of insertion? (NCT02121067)
Timeframe: Day 14-20 postpartum

InterventionParticipants (Count of Participants)
LNG-IUS Placed at 2 Weeks Postpartum50

[back to top]

Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum.

"A dichotomous, yes/no answer to the following question Would you recommend Mirena placement at two-weeks postpartum to a friend?" (NCT02121067)
Timeframe: 6 months postpartum

InterventionParticipants (Count of Participants)
LNG-IUS Placed at 2 Weeks Postpartum40

[back to top]

Proportion of Subjects With an IUD at 3 Months Postpartum

Subjects were contacted at 3 months after delivery. Comparison of the proportion of women randomized to placement of IUD within 60 minutes of placental delivery or at their 6-week routine postpartum visit who report having an IUD in place at 3 months after delivery. (NCT02169869)
Timeframe: 3 months postpartum (after delivery)

InterventionParticipants (Count of Participants)
Immediate Postplacental IUD Insertion12
6 Weeks Postpartum IUD Insertion5

[back to top]

Percentage of Participants Reporting a Pregnancy

Urine pregnancy tests within 30 days after IUD insertion will be performed either at home or in clinic. We will use the total number of pregnancies per ARM and the overall number of participants analyzed per ARM to calculate, for each ARM, the percentage of participants reporting a pregnancy in the first month of use of the IUD. (NCT02175030)
Timeframe: 1 month after enrollment

Intervention% of participants reporting pregnancy (Number)
Copper T380 IUD0
LNG20 IUD0.3

[back to top]

Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year.

Participants will be followed for pregnancies at regular intervals throughout the year and pregnancies will be recorded. (NCT02175030)
Timeframe: 1 year after enrollment

InterventionParticipants (Count of Participants)
Copper T380 IUD7
LNG20 IUD7

[back to top]

Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), end of treatment (Treatment 3) (last 28 days of the treatment period, Day 57-84)

Interventionunits on a scale (Mean)
LNG 40 mcg IVR + Placebo Injection-1.8974
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection-1.6061
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection-2.4014
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection-2.2653
Placebo IVR + Leuprorelin Injection-3.7679
Placebo IVR + Placebo Injection-2.293

[back to top]

Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56)

,,,,,
Interventionunits on a scale (Mean)
Change at Treatment 1Change at Treatment 2
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection-1.0000-1.9959
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection-0.6849-1.5126
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection-1.1463-2.1224
LNG 40 mcg IVR + Placebo Injection-0.7582-1.6447
Placebo IVR + Leuprorelin Injection-1.2071-2.8607
Placebo IVR + Placebo Injection-0.9048-1.8022

[back to top]

Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain within a 28-day window was calculated as the sum of ESD item 1 within that 28-day window divided by the number with non-missing days within that 28-day window. Here, number of subjects 'n' signifies evaluable subjects for the respective category. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56), and third cycle (Treatment 3) (last 28 days of the treatment period, Day 57-84)

,,,,,
Interventionunits on a scale (Mean)
BaselineChange at Treatment 1Change at Treatment 2Change at Treatment 3
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection5.7128-1.1257-1.9615-2.1268
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection5.7409-0.9009-1.5068-1.6411
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection6.3694-1.0931-1.7349-2.0112
LNG 40 mcg IVR + Placebo Injection6.0938-0.8472-1.5774-1.8001
Placebo IVR + Leuprorelin Injection6.3962-1.5315-2.6855-3.502
Placebo IVR + Placebo Injection5.6399-0.9777-1.8994-2.2228

[back to top]

Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain >=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was >=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

,,,,,
Interventionpercentage of days (Mean)
Change at Treatment 1Change at Treatment 2Change at Treatment 3
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection-15.1947-33.2423-35.1119
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection-15.4147-26.8462-27.4770
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection-15.1334-26.4468-32.2600
LNG 40 mcg IVR + Placebo Injection-12.8228-22.4950-23.5498
Placebo IVR + Leuprorelin Injection-21.4331-37.7330-53.4266
Placebo IVR + Placebo Injection-14.5323-30.9527-33.3421

[back to top]

Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain >=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was >=7. Here, number of subjects 'n' signifies evaluable subjects for the respective category. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

,,,,,
Interventionpercentage of days (Mean)
Change at Treatment 1Change at Treatment 2Change at Treatment 3
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection-13.3722-22.3713-22.9682
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection-12.5862-17.2826-20.8529
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection-15.0341-20.6791-25.3052
LNG 40 mcg IVR + Placebo Injection-13.6756-24.1404-26.4197
Placebo IVR + Leuprorelin Injection-19.8898-36.3540-39.9516
Placebo IVR + Placebo Injection-16.0105-26.9979-28.4273

[back to top]

Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain >=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was >=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

,,,,,
Interventionpercentage of days (Mean)
Treatment 1Treatment 2Treatment 3
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection70.650452.602850.7332
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection69.309257.877757.0171
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection73.895662.582256.7691
LNG 40 mcg IVR + Placebo Injection71.803761.819960.2902
Placebo IVR + Leuprorelin Injection70.206654.096538.6986
Placebo IVR + Placebo Injection65.907449.48747.0976

[back to top]

Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain >=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was >=7. (NCT02203331)
Timeframe: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

,,,,,
Interventionpercentage of days (Mean)
Treatment 1Treatment 2Treatment 3
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection23.932214.933114.3362
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection27.565922.869519.9332
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection40.081334.436429.8103
LNG 40 mcg IVR + Placebo Injection35.603425.625723.1293
Placebo IVR + Leuprorelin Injection28.201512.13208.5351
Placebo IVR + Placebo Injection25.174214.186912.7574

[back to top]

Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood

Following exposure to HIV, initial infection occurs at the genital mucosa and may involve complex interactions between a number of HIV target immune cells. HIV often uses C-C Chemokine Receptor Type 5 (CCR5) for entrance into target immune cells, causing infection of the cell. The amount of CCR5 expressing macrophages is associated with HIV infection. Cluster of differentiation 4 (CD4) T Cells are targeted and infected by HIV and CD4 percentages are used to assess immune status. CD4 counts vary by individuals and generally decrease with HIV infection. (NCT02357368)
Timeframe: Week 1, Week 17

,,,
Interventionpercentage of HIV target immune cells (Mean)
CCR5+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1CCR5+ CD4 T-cells CVL Week 17CCR5+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1CCR5+ CD4 T-cells PBMC Week 17CD4% CVL Week 1CD4% CVL Week 17CD4% PBMC Week 1CD4% PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)26.639.24.15.747.247.465.663.9
Etonogestrel Impant (Eng-Implant)22.832.23.94.248.747.067.467.5
Levonorgestrel Intrauterine Device (Lng-IUD)16.923.32.92.654.048.865.763.4
ParaGard® T 380A Intrauterine Copper Contraceptive22.415.38.37.563.447.573.371.1

[back to top]

Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood

The concentration levels of interleukin 1 (IL-1) family cytokines and interferon gamma-induced protein 10 (IP-10) chemokines were determined using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines. IL-1 and IP-10 have been found to influence recruitment of HIV target cells to the female reproductive tract and this study is examining changes in IL-1 and PI-10 to gain further understanding of these mechanisms. (NCT02357368)
Timeframe: Week 1, Week 17

,,
Interventionpg/mL (Mean)
IP-10 Cervicovaginal Lavage (CVL) Week 1IP-10 CVL Week 17IP-10 Peripheral Blood Mononuclear Cell (PBMC) Week 1IP-10 PBMC Week 17IL-1a CVL Week 1IL-1a CVL Week 17IL-1a PBMC Week 1IL-1a PBMC Week 17IL-1b CVL Week 1IL-1b CVL Week 17IL-1b PBMC Week 1IL-1b PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)689.8445.83298.53114.4752.2550.758.547.832.921.120.020.8
Etonogestrel Impant (Eng-Implant)2551.12417.64107.33954.31640.22120.6156.2144.1583.4485.851.446.5
Levonorgestrel Intrauterine Device (Lng-IUD)1100.21241.5204.4209.6256.4184.754.665.143.937.14.24.3

[back to top]

Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood

T cell activation correlates with HIV infection progression and this study seeks to gain better understanding of these underlying mechanisms by assessment of HIV target cells. Changes in cluster of differentiation 38 (CD38) expression are indicators of HIV disease progression with increases seen in CD38+ when a chronic HIV infection is progressing. Human leukocyte antigen-antigen D related (HLA-DR)+ expression appears to be involved in HIV proliferation. (NCT02357368)
Timeframe: Week 1, Week 17

,,,
Interventionpercentage of T cell activation markers (Mean)
CD38+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1CD38+ CD4 T-cells CVL Week 17CD38+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1CD38+ CD4 T-cells PBMC Week 17HLA-DR+ CD4 T-cells CVL Week 1HLA-DR+ CD4 T-cells CVL Week 17HLA-DR+ CD4 T-cells PBMC Week 1HLA-DR+ CD4 T-cells PBMC Week 17CD38+ Target (CCR5+ CD4+) T cells CVL Week 1CD38+ Target (CCR5+ CD4+) T cells CVL Week 17CD38+ Target (CCR5+ CD4+) T cells PBMC Week 1CD38+ Target (CCR5+ CD4+) T cells PBMC Week 17HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 1HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 17HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 1HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)36.735.917.117.725.021.24.84.462.552.522.724.130.730.024.423.2
Etonogestrel Impant (Eng-Implant)36.941.717.617.626.917.83.02.364.561.626.029.641.325.522.621.6
Levonorgestrel Intrauterine Device (Lng-IUD)32.644.017.017.215.411.43.33.666.270.828.231.728.217.628.325.5
ParaGard® T 380A Intrauterine Copper Contraceptive23.245.525.236.38.721.13.42.512.742.418.630.920.126.516.510.1

[back to top]

Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood

CD4/CD8 ratios above 1 indicate a strong immune system while lower ratios indicate a viral infection. (NCT02357368)
Timeframe: Week 1, Week 17

,,,
InterventionCD4/CD8 (Mean)
CD4/CD8 Ratio Cervicovaginal Lavage (CVL) Week 1CD4/CD8 Ratio CVL Week 17CD4/CD8 Ratio Peripheral Blood Mononuclear Cell (PBMC) Week 1CD4/CD8 Ratio PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)2.42.64.32.6
Etonogestrel Impant (Eng-Implant)2.62.33.13.3
Levonorgestrel Intrauterine Device (Lng-IUD)2.92.32.92.5
ParaGard® T 380A Intrauterine Copper Contraceptive3.94.94.75.4

[back to top]

Number of Participants Continuing With IUD

Women continuing the IUD for contraception at 6 months (NCT02362373)
Timeframe: 6 months

Interventionparticipants (Number)
Women With Epilepsy Receiving the LNG IUS20

[back to top]

Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level

The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of lamotrigine after IUD insertion. (NCT02362373)
Timeframe: from baseline to 6 months after LNG IUS insertion

Interventionpercentage of participants (Number)
Women With Epilepsy Receiving the LNG IUS0

[back to top]

Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level

The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of levetiracetam after IUD insertion. (NCT02362373)
Timeframe: from baseline to 6 months after LNG IUS insertion

Interventionpercentage of participants (Number)
Women With Epilepsy Receiving the LNG IUS0

[back to top]

Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level

The outcome measure is designed to examine whether participants will experience subtherapeutic or toxic serum trough level of oxcarbazepine after IUD insertion. (NCT02362373)
Timeframe: from baseline to 6 months after LNG IUS insertion

Interventionpercentage of participants (Number)
Women With Epilepsy Receiving the LNG IUS0

[back to top]

Change in Seizure Frequency

Number of participants with increased, unchanged or decreased mean monthly seizure frequency. (NCT02362373)
Timeframe: baseline to 6 months

Interventionparticipants (Number)
Seizure control unchangedSeizure control decreasedSeizure control improved
Women With Epilepsy Receiving the LNG IUS1334

[back to top]

Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA)

Percent change in lumbar spine bone mineral density after six-months. Lumbar spine bone mineral density measured by dual energy x-ray absorptiometry. (NCT02475265)
Timeframe: 6 months

Interventionpercent change (Mean)
Estradiol 0.045mg/Levonorgestrel 0.015mg2.0

[back to top]

Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+

Women will be deemed evaluable for this primary outcome if they successfully underwent placement of the Mirena® IUD, received a RRSO or RRS as planned, and had a P4 value ≤1 ng/ml. (NCT02477202)
Timeframe: 1 year

Interventionpercentage of positively stained cells (Median)
Mirena® IUD8.3

[back to top]

Ethinyl Estradiol Area Under the Curve

Ethinyl estradiol area under the curve from 0 to 72 hours (NCT02531321)
Timeframe: 24 days

Interventionng/mL*h (Mean)
Ritonavir3867
Control3270

[back to top]

Levonorgestrel Area Under the Curve

Levonorgestrel AUC from 0 to 72 hours (NCT02531321)
Timeframe: 24 days

Interventionng/mL*h (Mean)
Ritonavir321
Control243

[back to top]

Number of Participants With Follicle Rupture

Following dosing with UPA, subjects underwent daily visits with ultrasound monitoring until evidence of follicle rupture (complete disappearance or >50% reduction of the mean size of the leading follicle). (NCT02577601)
Timeframe: within 5 days of taking the study drug

InterventionParticipants (Count of Participants)
UPA Only1
UPA + COC9

[back to top]

Number of Participants With Absence of Withdrawal Bleeding (AWB), by Cycle

Participants were asked to keep a daily diary to record vaginal bleeding events. AWB was defined as no bleeding/spotting during the expected bleeding period. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

,
InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9
ENG-E2 125 μg/300 μg7634261733000
LNG-EE 150 μg/30 μg151010601210

[back to top]

Number of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
ENG-E2 125 μg/300 μg530
LNG-EE 150 μg/30 μg140

[back to top]

Number of Participants Who Discontinued Treatment Due to an AE

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
ENG-E2 125 μg/300 μg61
LNG-EE 150 μg/30 μg23

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle

BTB-S was considered any bleeding/spotting that occurred during expected non-bleeding interval that was neither early nor continued withdrawal bleeding. BTB-S was classified as follows: Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

,
InterventionParticipants (Count of Participants)
Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9
ENG-E2 125 μg/300 μg1661127942291381
LNG-EE 150 μg/30 μg543620138720

[back to top]

Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)

The Primary Efficacy Outcome Measure for this study was contraceptive efficacy, or the prevention of in-treatment pregnancy. The total incidence of in-treatment pregnancies was expressed as the Pearl Index, which is defined as the number of in-treatment pregnancies per 100 woman-years of exposure (one woman-year defined as a period of 365.25 days). NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year (13 28-day cycles)

InterventionPregnancies per 100 woman years (Number)
ENG-E2 125 μg/300 μg1.54
LNG-EE 150 μg/30 μg2.93

[back to top]

Maximum Concentration of Serum UPA

(Cmax) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionng/mL (Mean)
Normal-BMI89.3
Obese-MRI95.6

[back to top]

Maximum Concentration of Serum LNG

(Cmax) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionng/mL (Mean)
Normal-BMI18.2
Obese-MRI10.8

[back to top]

Elimination Half-life of Serum LNG

(t1/2) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionh (Mean)
Normal-BMI27.0
Obese-BMI50.4

[back to top]

Clearance of Serum UPA

(Cl) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

InterventionL/h (Mean)
Normal-BMI4.1
Obese-MRI3.0

[back to top]

Clearance of Serum LNG

(Cl) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

InterventionL/h (Mean)
Normal-BMI4.8
Obese-MRI9.8

[back to top]

Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration

UPA-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women. (NCT02689804)
Timeframe: Up to 24 hours

Interventionng*h/mL (Mean)
Normal-BMI293.5
Obese-BMI362.5

[back to top]

Time to Maximum Concentration of Serum UPA

(Tmax) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionh (Mean)
Normal-BMI1.6
Obese-MRI1.5

[back to top]

Time to Maximum Concentration of Serum LNG

(Tmax) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionh (Mean)
Normal-BMI2.0
Obese-MRI3.0

[back to top]

Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration

LNG-EC PK parameter (AUC 0-24 h) in women with normal and obese BMI women. (NCT02689804)
Timeframe: Up to 24 hours

Interventionng*h/mL (Mean)
Normal-BMI208.5
Obese-BMI100.8

[back to top]

Elimination Half-life of Serum UPA

(t1/2) calculated in women with normal and obese BMI (NCT02689804)
Timeframe: Up to 24 hours

Interventionh (Mean)
Normal-BMI34.9
Obese-MRI65.9

[back to top]

The Number of Participants in Two Treatment Groups (1.5mg Levonorgestrel and 3mg Levonorgestrel) With no Follicle Rupture at 5 Days Within One Menstrual (Treatment) Cycle.

No evidence of follicle rupture achieved by participant in one menstrual (treatment) cycle at 5 days post LNG dosing. Follicle rupture is defined as the disappearance of or >50% reduction in the size of the leading follicle. Dosing occurred after a dominant follicle measuring 15 mm or greater in at least one dimension was visualized on ultrasound. (NCT02863445)
Timeframe: 5 days post-LNG dosing

Interventionparticipants (Number)
LNG-ECx118
LNG-ECx224

[back to top]

Number of Participants With Follicle Rupture Before 5 Days

Among the participants with follicle rupture before 5 days, the time to rupture was measured and reported for each day up to day 5. If the date of follicle rupture was unclear by ultrasonographic imaging (eg, collapse was seen, but reduction of size was less than 50%), serum hormone levels were used to adjudicate day of ruptures. (NCT02863445)
Timeframe: 5 days

InterventionParticipants (Count of Participants)
LNG-ECx117
LNG-ECx211

[back to top]

Menstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8

Menstrual blood loss (MBL) during a 30-day period starting at the baseline visit and at the end of Year 6, Year 7, and Year 8, measured by the alkaline hematin method. The assessment of this variable was restricted to women who had Mirena inserted for heavy menstrual bleeding (HMB). (NCT02985541)
Timeframe: Baseline and end of Years 6, 7 and 8 of Mirena use

InterventionmL/30 days (Median)
Beginning of Year 6 (baseline)End of Year 6End of Year 7End of Year 8
Levonorgestrel IUS (Mirena, BAY86-5028)0.0000.0000.0000.000

[back to top]

Number of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use

Categorized menstrual blood loss (MBL) (≥ 80 mL per 30 days) at end of Year 6, Year 7, and Year 8. The assessment of this variable was restricted to women who had Mirena inserted for HMB. (NCT02985541)
Timeframe: At end of Year 6, 7 and 8 of Mirena use

InterventionParticipants (Number)
End of Year 6End of Year 7End of Year 8
Levonorgestrel IUS (Mirena, BAY86-5028)000

[back to top]

Total LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model

A population pharmacokinetic (popPK) analysis was performed including sparse data from the study. (NCT02985541)
Timeframe: At the beginning of Year 6 (baseline) and at the end of Years 6, 7, and 8 of Mirena use

Interventionng/L (Geometric Mean)
At the beginning of Year 6 (baseline)At the end of Year 6At the end of Year 7At the end of Year 8
Levonorgestrel IUS (Mirena, BAY86-5028)123114106100

[back to top]

Participant's Satisfaction With Mirena by Visit

Participants were asked to evaluate their satisfaction with Mirena on a 5-point scale as very satisfied, somewhat satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied. (NCT02985541)
Timeframe: Baseline, at end of Year 6, 7 and 8 of Mirena use

InterventionParticipants (Number)
Baseline (very satisfied)Baseline (somewhat satisfied)Baseline (neither satisfied nor dissatisfied)Baseline (dissatisfied)Baseline (very dissatisfied)Year 6 (very satisfied)Year 6 (somewhat satisfied)Year 6 (neither satisfied nor dissatisfied)Year 6 (dissatisfied)Year 6 (very dissatisfied)Year 7 (very satisfied)Year 7 (somewhat satisfied)Year 7 (neither satisfied nor dissatisfied)Year 7 (dissatisfied)Year 7 (very dissatisfied)Year 8 (very satisfied)Year 8 (somewhat satisfied)Year 8 (neither satisfied nor dissatisfied)Year 8 (dissatisfied)Year 8 (very dissatisfied)
Levonorgestrel IUS (Mirena, BAY86-5028)34220000279203002182013120713300

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence (ie any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalization or prolongation of existing hospitalization, 4) resulted in persistent or significant disability/incapacity, 5) was a congenital anomaly/birth defect, or 6) was another medically important serious event as judged by the investigator. Treatment-emergent adverse event (TEAE) was defined as an AE that occurred on Day 1 Year 6 of Mirena use or later. (NCT02985541)
Timeframe: Years 6 to 8 of Mirena use

InterventionParticipants (Number)
Any AEAny SAE
Levonorgestrel IUS (Mirena, BAY86-5028)24914

[back to top]

Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use

The Pearl Index (PI) is defined as the number of pregnancies per 100 women years. The 3-year PI (Years 6 to 8) was obtained by dividing the number of pregnancies the occurred during that time (starting at Day 1 Year 6 and up to Day 365 of Year 8) by the time (in 100 women years) that the women were at risk of getting pregnant during that time. (NCT02985541)
Timeframe: Years 6 to 8 of Mirena use

InterventionPregnancies per 100 women years (Number)
Levonorgestrel IUS (Mirena, BAY86-5028)0.28

[back to top]

Number of Women With Placement of LARC

The outcome will be measured by the number of participants with LARC placement. The total number of women who expressed a desire to have postpartum contraception placed and randomized to the appropriate arm will be assessed. (NCT03305081)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Immediate or Early Placement10
Interval Placement2

[back to top]

Patient Satisfaction With Method of LARC Using LARC Survey

"Number of patients satisfied with LARC obtained by LARC survey at 6-weeks, 12-weeks postpartum, and 6 months postpartum. Patients identify Yes/No response via telephone survey asking, Are you satisfied with this form of contraception?. Satisfaction determined if subject answers Yes. A single value was calculated at the end of the study by summation at all three time points." (NCT03305081)
Timeframe: 6 Weeks, 12 weeks postpartum, 6 months postpartum

InterventionParticipants (Count of Participants)
Immediate or Early Placement10
Interval Placement2

[back to top]

Change in Quality of Life

Measured by the RAND 36-Item Health Survey (Version 1.0). Physical function and mental well-being on scale range from 0-100. A high score defines a more favorable health state. (NCT03317795)
Timeframe: Baseline, 3 months

,
Interventionunits on a scale (Median)
Physical FunctionMental Well-being
Levonorgestrel IUS11.1-1.0
Tranexamic Acid1.73.3

[back to top]

Change in Fibroid Size

Fibroid size will be reported as millimeters (mm). (NCT03317795)
Timeframe: 9 months

Interventionmm (Median)
Levonorgestrel IUS3
Tranexamic Acid10.5

[back to top]

Change in Pain Score

Pain will be measured by a 10 cm visual analog scale (VAS) which uses a 100 point score, with 0 indicating no pain and 100 indicating worst pain ever. Change was determine by subtracting the 3 month score from baseline, a negative score indicates a decrease in pain. (NCT03317795)
Timeframe: Baseline, 3 months

Interventionunits on a scale (Median)
Levonorgestrel IUS-57.5
Tranexamic Acid0

[back to top] [back to top]

Change in Self-Reported Menorrhagia Scores

The Menorrhagia Multi-Attribute Scale (MMAS) questionnaire captures the subjective consequences of menorrhagia on six domains: practical difficulties; social life; psychological wellbeing; physical health; work routine; and family life. Each of the six domains has four statements that represent four levels of response. Respondents indicate the statement that best matches their feelings for each domain. The statement scores derive from a weighting of the domains and a weighting of the statements in level of severity by women in the original study. Scores range from 0 (worst possible state in all domains) to 100 (best possible state in all domains). (NCT03317795)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Median)
Levonorgestrel IUS59.1
Tranexamic Acid25.4

[back to top] [back to top]

Number of Participants to Complete Study

Total number of study participants to complete assigned treatment. (NCT03317795)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
Levonorgestrel IUS7
Tranexamic Acid2

[back to top]

Cumulative Incidence of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
Breastfeeding, 1 year of follow-upNot breastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD1.552.453.494.57

[back to top]

Cumulative Incidence of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
LNG-IUD, 1 year of follow upCopper IUD, 1 year of follow upLNG-IUD, 5 years of follow upCopper IUD, 5 years of follow up
Women With IUD2.302.304.524.82

[back to top]

Cumulative Incidence of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
Yes, 1 year of follow-upNo, 1 year of follow-upYes, 5 years of follow-upNo, 5 years of follow-up
Women With IUD6.891.7811.893.72

[back to top]

Cumulative Incidence of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
≤ 6 weeks postpartum (pp), 1 year of follow-up> 6 weeks and ≤ 14 weeks pp, 1 year of follow-up> 14 weeks and ≤ 52 weeks pp, 1 year of follow-up> 52 weeks pp or no delivery, 1 year of follow-up≤ 6 weeks pp, 5 years of follow-up> 6 weeks and ≤ 14 weeks pp, 5 years of follow-up> 14 weeks and ≤ 52 weeks pp, 5 years of follow-up> 52 weeks pp or no delivery, 5 years of follow-up
Women With IUD0.700.540.330.071.891.420.740.29

[back to top]

Adjusted Hazard Ratio (HR) for Breastfeeding Status and Uterine Perforation-first Observed IUD Insertions

Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women who were breastfeeding at the time of first observed IUD insertion differs from the risk of uterine perforation among women who were not breastfeeding at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionajusted hazard ratio (Number)
Women With IUD1.37

[back to top]

Cumulative Incidence of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
LNG-IUD, 1 year of follow upCopper IUD, 1 year of follow upLNG-IUD, 5 years of follow upCopper IUD, 5 years of follow up
Women With IUD0.220.160.630.55

[back to top]

Cumulative Incidence of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
Yes, 1 year of follow-upNo, 1 year of follow-upYes, 5 years of follow-upNo, 5 years of follow-up
Women With IUD0.100.220.410.63

[back to top]

Effect Modification of Breastfeeding Status on Postpartum Timing for Uterine Perforation

Propensity score-adjusted hazard ratios to evaluate the extent to which breastfeeding status (yes vs. no) modified the association of uterine perforation for women with IUD insertion at different time periods postpartum (i.e., IUD insertion ≤ 14 weeks versus IUD insertion > 14 weeks postpartum) among women with a recorded delivery within the past 52 weeks at the time of the first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
≤ 14 weeks, breastfeeding yes vs.no> 14 to ≤ 52 weeks, breastfeeding yes vs.noBreastfeeding yes, ≤ 14 vs. > 14 to ≤ 52 weeksBreastfeeding no, ≤ 14 vs. > 14 to ≤ 52 weeks
Women With IUD1.282.411.362.56

[back to top]

Effect Modification of IUD Type on Breastfeeding Status for IUD Expulsion

Propensity score-adjusted hazard ratios to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between IUD expulsion and breastfeeding among women who were and were not breastfeeding at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
LNG-IUD, breastfeeding yes vs.noCopper IUD, breastfeeding yes vs.no
Women With IUD0.720.66

[back to top]

Effect Modification of IUD Type on Breastfeeding Status for Uterine Perforation

Propensity score-adjusted hazard ratios to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between uterine perforation and breastfeeding among women who were and were not breastfeeding at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
LNG-IUD, breastfeeding yes vs.noCopper IUD, breastfeeding yes vs.no
Women With IUD1.331.66

[back to top]

Effect Modification of IUD Type on Postpartum Timing for IUD Expulsion

Adjusted for propensity score and breastfeeding status, to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between IUD expulsion and postpartum timing of IUD insertion for women with IUD insertion at different time periods postpartum (i.e., ≤ 6 weeks, > 6 and ≤ 14 weeks, > 14 and ≤ 52 weeks) versus IUD insertion more than 52 weeks postpartum, including no recorded delivery within the past 52 weeks, at the time of the first observed IUD insertion. Reference group: LNG-IUD or Copper IUD, > 52 weeks or no delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
LNG-IUD, ≤ 6 weeksLNG-IUD, > 6 to ≤ 14 weeksLNG-IUD, > 14 to ≤ 52 weeksCopper IUD, ≤ 6 weeksCopper IUD, > 6 to ≤ 14 weeksCopper IUD, > 14 to ≤ 52 weeks
Women With IUD1.591.011.401.230.961.35

[back to top]

Effect Modification of IUD Type on Postpartum Timing for Uterine Perforation

Adjusted for propensity score and breastfeeding status, to evaluate the extent to which type of IUD (LNG-IUD vs. copper IUD) modified the association between uterine perforation and postpartum timing of IUD insertion for women with IUD insertion at different time periods postpartum (i.e., ≤ 6 weeks, > 6 and ≤ 14 weeks, > 14 and ≤ 52 weeks) versus IUD insertion more than 52 weeks postpartum, including no recorded delivery within the past 52 weeks, at the time of the first observed IUD insertion. Reference group: LNG-IUD or Copper IUD, > 52 weeks or no delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
LNG-IUD, ≤ 6 weeksLNG-IUD, > 6 to ≤ 14 weeksLNG-IUD, > 14 to ≤ 52 weeksCopper IUD, ≤ 6 weeksCopper IUD, > 6 to ≤ 14 weeksCopper IUD, > 14 to ≤ 52 weeks
Women With IUD6.785.113.134.302.612.01

[back to top]

Number of Indicators of a Potentially Difficult Insertion, Overall, by Breastfeeding Status, and by Postpartum Timing of IUD Insertion-first Observed IUD Insertions

To describe the prevalence of indicators of a difficult IUD insertion (e.g., need for cervical dilation, ultrasound guidance, paracervical block, clinician not indicating difficulty, use of misoprostol among all users) (NCT03754556)
Timeframe: Up to 11 years

Interventionindicators (Number)
OverallBreastfeedingNot breastfeeding≤ 6 weeks postpartum> 6 weeks and ≤ 14 weeks postpartum> 14 weeks and ≤ 52 weeks postpartum> 52 weeks postpartum or no delivery
Women With IUD29777168610775731261114626797

[back to top]

Number of Indicators of a Potentially Difficult Insertion, Overall, by IUD Type and by Menorrhagia Status-first Observed IUD Insertions

To describe the prevalence of indicators of a difficult IUD insertion (e.g., need for cervical dilation, ultrasound guidance, paracervical block, clinician not indicating difficulty, use of misoprostol among all users) (NCT03754556)
Timeframe: Up to 11 years

Interventionindicators (Number)
OverallLNG-IUDCopper IUDWith menorrhagia in the past yearWithout menorrhagia in the past year
Women With IUD29777246664648375426023

[back to top]

Cumulative Incidence of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
Breastfeeding, 1 year of follow-upNot breastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD0.600.351.610.88

[back to top]

Adjusted Incidence Rate Ratio (IRR) for IUD Expulsion-first Observed IUD Insertions

Overall and stratified by breastfeeding status at the time of IUD insertion for IUD expulsion for ≤ 36 weeks postpartum at IUD insertion versus > 36 weeks postpartum or with no recorded delivery, at 1 year and 5 years of follow-up Reference group: > 36 weeks or no delivery (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionadjusted incidence rate ratio (Number)
Overall, 1 year of follow-upOverall, 5 years of follow-upBreastfeeding, 1 year of follow-upNot breastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD1.211.200.601.250.801.23

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing and Uterine Perforation-first Observed IUD Insertions

Adjusted for propensity scores and breastfeeding status, to evaluate whether the risk of uterine perforation among women who had a first observed IUD insertion within different time periods postpartum differs from the risk of uterine perforation among women who had their first observed IUD insertion more than 52 weeks postpartum, including women without a recorded delivery within the past 52 weeks. Reference group: IUD insertion > 52 weeks postpartum (NCT03754556)
Timeframe: Up to 11 years

Interventionajusted hazard ratio (Number)
≤ 6 weeks postpartum> 6 weeks and ≤ 14 weeks postpartum> 14 weeks and ≤ 52 weeks postpartum
Women With IUD6.294.652.94

[back to top]

Crude Incidence Rate of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
≤ 3 days4 days to ≤ 6 weeks≤ 6 weeks postpartum> 6 weeks and ≤ 14 weeks postpartum> 14 weeks and ≤ 52 weeks postpartum> 52 weeks postpartum or no delivery
Women With IUD46.5410.8815.339.2914.3614.93

[back to top]

Adjusted Incidence Rate Difference (IRD) for Uterine Perforation-first Observed IUD Insertions

Propensity score-adjusted incidence rate differences (per 1,000 person-years) for uterine perforation for women ≤ 36 weeks postpartum at IUD insertion compared with those who were > 36 weeks postpartum or with no recorded delivery, 1 year of follow-up and 5 years of follow-up, overall and stratified by breastfeeding status. Reference group: > 36 weeks or no delivery (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionper 1000 person-years (Number)
Overall, 1 year of follow-upOverall, 5 years of follow-upBreastfeeding, 1 year of follow-upNot breastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD3.752.280.633.921.382.33

[back to top]

Crude Incidence Rate of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
LNG-IUDCopper IUD
Women With IUD13.9514.08

[back to top]

Crude Incidence Rate of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
YesNo
Women With IUD39.5611.10

[back to top]

Crude Incidence Rate of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
≤ 6 weeks postpartum> 6 weeks and ≤ 14 weeks postpartum> 14 weeks and ≤ 52 weeks postpartum> 52 weeks postpartum or no delivery
Women With IUD5.143.772.240.68

[back to top]

Adjusted Incidence Rate Difference (IRD) for IUD Expulsion-first Observed IUD Insertions

Adjusted incidence rate differences (per 1,000 person-years) for IUD expulsion for women ≤ 36 weeks postpartum at IUD insertion compared with those who were > 36 weeks postpartum or with no recorded delivery, 1 year of follow-up and 5 years of follow-up, overall and stratified by breastfeeding status Reference group: > 36 weeks or no delivery (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionper 1000 person-years (Number)
Overall, 1 year of follow-upOverall, 5 years of follow-upBreastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 1 year of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD4.282.37-10.79-2.625.112.65

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing and IUD Expulsion-first Observed IUD Insertions

Adjusted for propensity score and breastfeeding status, to evaluate whether the risk of IUD expulsion before and after 49 days of insertion among women who had a first observed IUD insertion within different time periods postpartum differs from the risk of IUD expulsion among women who had their first observed IUD insertion more than 52 weeks postpartum, including women without a recorded delivery within the past 52 weeks Reference group: IUD insertion > 52 weeks postpartum (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Within 49 days, ≤ 6 weeks postpartum (pp)Within 49 days, > 6 weeks and ≤ 14 weeks ppWithin 49 days, > 14 weeks and ≤ 52 weeks ppAfter 49 days, ≤ 6 weeks ppAfter 49 days, > 6 weeks and ≤ 14 weeks ppAfter 49 days, > 14 weeks and ≤ 52 weeks pp
Women With IUD1.930.881.381.321.031.39

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and Uterine Perforation-first Observed IUD Insertions

Adjusted for propensity scores and breastfeeding status, to estimate the risk of uterine perforation among women who had a first observed IUD insertion ≤ 36 weeks postpartum versus women who had a first observed IUD insertion > 36 weeks postpartum, including women without recorded delivery within the past 52 weeks. Reference group: IUD insertion >36 weeks postpartum or with no recorded delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD4.36

[back to top]

Adjusted Incidence Rate Ratio (IRR) for Uterine Perforation-first Observed IUD Insertions

Adjusted for propensity score, overall and stratified by breastfeeding status at the time of IUD insertion for ≤ 36 weeks postpartum at IUD insertion versus > 36 weeks postpartum or with no recorded delivery, at 1 year and 5 years of follow-up. Reference group: > 36 weeks or no delivery (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionadjusted incidence rate ratio (Number)
Overall, 1 year of follow-upOverall, 5 years of follow-upBreastfeeding, 1 year of follow-upNot breastfeeding, 1 year of follow-upBreastfeeding, 5 years of follow-upNot breastfeeding, 5 years of follow-up
Women With IUD4.724.101.116.611.474.86

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and IUD Expulsion-first Observed IUD Insertions

Adjusted for propensity scores, to estimate the risk of IUD expulsion among women who had a first observed IUD insertion ≤ 36 weeks postpartum versus women who had a first observed IUD insertion > 36 weeks postpartum, including women without recorded delivery within the past 52 weeks. Reference group: IUD insertion >36 weeks postpartum or with no recorded delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD0.95

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and Uterine Perforation-first Observed IUD Insertions

Adjusted for propensity scores and breastfeeding status, to estimate the risk of uterine perforation among women who had a first observed IUD insertion early in the postpartum period (i.e., up to 14 weeks postpartum) versus those who had a first observed IUD insertion late in the postpartum period (i.e., more than 14 weeks postpartum, including women without recorded delivery within the past 52 weeks). Reference group: IUD insertion >14 weeks postpartum or with no recorded delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD3.44

[back to top]

Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and IUD Expulsion-first Observed IUD Insertions

Adjusted for propensity scores, to estimate the risk of IUD expulsion among women who had a first observed IUD insertion early in the postpartum period (i.e., up to 14 weeks postpartum) versus those who had a first observed IUD insertion late in the postpartum period (i.e., more than 14 weeks postpartum, including women without recorded delivery within the past 52 weeks). Reference group: IUD insertion >14 weeks postpartum or with no recorded delivery (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD0.88

[back to top]

Adjusted Hazard Ratio (HR) for Menorrhagia Status and Uterine Perforation-first Observed IUD Insertions

Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women using an IUD who have at least one diagnosis code indicating menorrhagia in the 12 months before IUD insertion differs from the risk of uterine perforation among women who do not have this indication (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD1.38

[back to top]

Adjusted Hazard Ratio (HR) for Breastfeeding Status and IUD Expulsion-first Observed IUD Insertions

Propensity score-adjusted to evaluate whether the risk of IUD expulsion among women who were breastfeeding at the time of first observed IUD insertion differs from the risk of IUD expulsion among women who were not breastfeeding at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD0.71

[back to top]

Adjusted Hazard Ratio (HR) for IUD Type and IUD Expulsion-first Observed IUD Insertions

Propensity score adjusted to evaluate whether the risk of IUD expulsion among women with LNG-releasing IUD at the time of first observed IUD insertion differs from the risk of IUD expulsion among women with copper IUD at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD0.69

[back to top]

Adjusted Hazard Ratio (HR) for IUD Type and Uterine Perforation-first Observed IUD Insertions

Propensity score-adjusted hazard ratio to evaluate whether the risk of uterine perforation among women with LNG-releasing IUD at the time of first observed IUD insertion differs from the risk of uterine perforation among women with copper IUD at the time of first observed IUD insertion (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD1.49

[back to top]

Adjusted Hazard Ratio (HR) for Menorrhagia Status and IUD Expulsion-first Observed IUD Insertions

Propensity score adjusted to evaluate whether the risk of IUD expulsion among women using an IUD who have at least one diagnosis code indicating menorrhagia in the 12 months before IUD insertion differs from the risk of IUD expulsion among women who do not have this indication (NCT03754556)
Timeframe: Up to 11 years

Interventionadjusted hazard ratio (Number)
Women With IUD2.79

[back to top]

Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
BreastfeedingNot breastfeeding
Women With IUD4.252.50

[back to top]

Crude Incidence Rate of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
LNG-IUDCopper IUD
Women With IUD1.641.27

[back to top]

Crude Incidence Rate of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
YesNo
Women With IUD1.001.63

[back to top]

Cumulative Incidence of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions

Crude estimates of the cumulative incidence, defined as number of outcomes occurring up to a time point out of the number of IUD insertions (NCT03754556)
Timeframe: At 1 year and 5 years of follow-up

Interventionnumber of outcomes/IUD insertions (%) (Number)
≤ 3 days, 1 year of follow-up4 days to ≤ 6 weeks, 5 years of follow-up≤ 6 weeks postpartum (pp), 1 year of follow-up> 6 weeks and ≤ 14 weeks pp, 1 year of follow-up> 14 weeks and ≤ 52 weeks pp, 1 year of follow-up> 52 weeks pp or no delivery, 1 year of follow-up≤ 3 days, 5 years of follow-up4 days to ≤ 6 weeks, 1 year of follow-up≤ 6 weeks pp, 5 years of follow-up> 6 weeks and ≤ 14 weeks pp, 5 years of follow-up> 14 weeks and ≤ 52 weeks pp, 5 years of follow-up> 52 weeks pp or no delivery, 5 years of follow-up
Women With IUD7.843.872.461.402.332.4910.731.614.813.184.554.88

[back to top]

Crude Incidence Rate of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions

Crude incidence rate was calculated as the number of outcomes occurring during the person-time at risk divided by the total person-time at risk (in person-years) (NCT03754556)
Timeframe: Up to 11 years

Interventionper 1000 person-years (Number)
BreastfeedingNot breastfeeding
Women With IUD10.2314.58

[back to top]

Volume of Distribution (Vd) of LNG

Vd for each participant was calculated from observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Vd using the software package Phoenix WinNonLin (Certara®). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose

InterventionL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)276.70
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)294.92
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)169.05
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)156.31

[back to top]

Time of Minimum Concentration (Tmin) of LNG

Tmin for each participant was time to the minimum observed LNG concentration after the observed dose. (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose

Interventionhours (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)47.07
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)47.95
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)47.61
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)48.00

[back to top]

Oral Clearance (CL/F) of LNG

Apparent oral clearance (CL/F) for each participant was calculated as CL/F = dose/AUC0-24 or CL/F = dose/AUC0-48 of the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine CL/F using the software package Phoenix WinNonLin (Certara®). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose

InterventionL/h (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)12.64
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)15.24
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)4.39
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)12.05

[back to top]

LNG Area Under the Concentration Time Curve (AUC0-48h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants

AUC for each participant was calculated from all available LNG concentrations measured over 48 hours using the linear up/log down version of the trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values < LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose

Interventionhours * ng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)98.95
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)180.25
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)224.81
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)242.68

[back to top]

LNG Area Under the Concentration Time Curve (AUC0-24h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants

AUC for each participant was calculated from all available LNG concentrations measured over 24 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values < LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post-dose

Interventionhours * ng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)81.64
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)153.40
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)157.56
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)213.69

[back to top]

Half-life (T1/2) of LNG

T1/2 for each participant was calculated using regression analysis when possible from the observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine T1/2 using the software package Phoenix WinNonLin (Certara®). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose

Interventionhours (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)12.05
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)11.79
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)24.03
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)8.97

[back to top]

Number and Percentage of Participants Experiencing Either a Serious Adverse Event (SAE) or Adverse Event (AE) Potentially or Definitely Associated With Single Dose LNG Administration.

"Adverse events were Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 and DAIDS AE Grading Table Addendum 1, Female Genital Grading Table for Use in Microbicide Studies, Version 1.0 - November 2007. Relationship of AE to study treatment was determined by the site, study core team, and DAIDS clinical representative.~AEs evaluated in this outcome fulfilled the below criteria:~Potentially or definitely related to LNG dose~Grade 3 or higher AEs~Grade 2 of higher nausea, diarrhea, menorrhagia or metrorrhagia, and ectopic pregnancies" (NCT03819114)
Timeframe: From Day 0 through study Day 28

InterventionParticipants (Count of Participants)
LNG 1.5 mg2
LNG 3.0 mg2

[back to top]

Minimum Concentration (Cmin) of LNG

Cmin for each participant was calculated as the minimum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmin using the software package Phoenix WinNonLin (Certara®). Assay lower limit of quantification for LNG was 0.025 ng/mL; values < LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose

Interventionng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)0.25
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)0.56
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)1.49
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)0.41

[back to top]

Maximum Concentration (Cmax) of LNG

Cmax for each participant was calculated as the maximum observed LNG concentration from LNG PK samples at pre-dose through 48 hours post-dose. Standard noncompartmental techniques were used to determine Cmax using the software package Phoenix WinNonLin (Certara®). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours post-dose

Interventionng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)15.10
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)24.90
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)18.65
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)28.01

[back to top]

LNG Total Area Under the Concentration Time Curve AUCinf (Infinity) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants

AUC for each participant was calculated from all available LNG concentrations measured to infinity hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification for LNG was 0.025 ng/mL; values < LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours pose-dose

Interventionhours * ng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)118.71
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)196.83
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)345.80
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)248.96

[back to top]

LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants

AUC for each participant was calculated from all available LNG concentrations measured over 8 hours using the linear up/log down version of trapezoidal rule (i.e., noncompartmental technique) using the software package Phoenix WinNonLin (Certara®). This version of the trapezoidal rule used linear interpolation between untransformed data up to Cmax, and between log-transformed data from Cmax through Clast. Assay lower limit of quantification (LLOQ) for LNG was 0.025 ng/mL; values < LLOQ were imputed as 0 (if pre-dose) or as 0.0125 (if post-dose). (NCT03819114)
Timeframe: Intensive LNG PK samples at pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours post-dose

Interventionhours * ng/mL (Median)
A: LNG 1.5 mg Among Participants on EFV-based ART (Randomized)52.13
B: LNG 3.0 mg Among Participants on EFV-based ART (Randomized)102.13
C: LNG 1.5 mg Among Participants on DTG-based ART (Assigned)80.50
D: LNG 3.0 mg Among Participants on RIF-INH TB Therapy (Assigned)124.39

[back to top]

Number of Participants With Implant Use at Three Months

(NCT04005391)
Timeframe: Three months

InterventionParticipants (Count of Participants)
Postpartum Contraceptives Offered to Intervention Clusters28
Routine Care Offered to Control Clusters2

[back to top]

Number of Participants With Contraceptive Continuation at Twelve Months

Continuation of any contraceptive method a woman started in the postpartum period assessed by a survey at three and twelve months after study enrollment (NCT04005391)
Timeframe: 12 Months

InterventionParticipants (Count of Participants)
Postpartum Contraceptives Offered to Intervention Clusters73
Routine Care Offered to Control Clusters59

[back to top]

Number of Participants With Any Contraceptive Use at Three Months

Participants actively using any contraceptive method three months after enrollment in the study as assessed by the three-month survey (NCT04005391)
Timeframe: 3 Months

InterventionParticipants (Count of Participants)
Postpartum Contraceptives Offered to Intervention Clusters83
Routine Care Offered to Control Clusters56

[back to top]

Number of Participants With Repeat Pregnancy at Twelve Months

Repeat pregnancy after enrollment in the study, as assessed at the enrollment (baseline) visit and at three and twelve months after study enrollment. (NCT04005391)
Timeframe: 12 Months

InterventionParticipants (Count of Participants)
Postpartum Contraceptives Offered to Intervention Clusters0
Routine Care Offered to Control Clusters4

[back to top]

Contraceptive Satisfaction at Twelve Months

Participant satisfaction with any contraceptive method the woman might be using as determined by a survey question that asks if the woman is very satisfied, satisfied, dissatisfied, or very dissatisfied. (NCT04005391)
Timeframe: 12 Months

,
InterventionParticipants (Count of Participants)
"Very Satisfied or Satisfied""Dissatisfied or Very Dissatisfied"
Postpartum Contraceptives Offered to Intervention Clusters6826
Routine Care Offered to Control Clusters5734

[back to top]